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NEUROPROTECTIVE EFFECTS OF POSTINJURY LITHIUM TREATMENT: 
DETERMINING THE OPTIMAL DOSING PARADIGM AND ASSESSING POTENTIAL 
MECHANISMS OF ACTION 
 
By Katharine Coryell Eakin, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010 
 
 
Major Director:  Robert J. Hamm, Ph.D., 
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Traumatic brain injury (TBI) has a dramatic impact on our society in terms of mortality, 
morbidity, and inherently high financial costs.  Formidable research efforts are being addressed 
to the identification of neuroprotective agents capable of ameliorating the neurological outcome 
after TBI.  Preclinical studies have recently demonstrated lithium to be a promising 
neuroprotective agent for both acute ischemic brain injury and chronic neurodegenerative 
disease.  In light of these encouraging data, we designed a lateral fluid-percussion injury (FPI) 
study aimed at investigating the role of early post-traumatic administration of lithium as a 
strategy for reducing TBI-induced motor and cognitive deficits. The optimal dose of this agent 
and the time window for its administration have been determined on the basis of data derived 
from the assessment of motor and cognitive functioning in experimental animals, as well as from 
xxv 
 
       
 
the stereological quantification of neuronal survival (PID 7) within the CA3 and hilar regions of 
the hippocampus ipsilateral to the FPI.  In addition, we attempted to elucidate the  
mechanisms underlying the neuroprotective properties of this drug via western blot analysis of 
levels of the pro-apoptotic marker caspase-3 (PID 1, 7) and two neuroplasticity markers, growth 
associated protein-43 (GAP-43) and brain-derived neurotrophic factor (BDNF) (PID 1, 7, 21).   
Our findings indicate that low-dose lithium chloride (0.125 or 0.25 mmol/kg), given 
either 30 min or 8 hr after lateral FPI significantly ameliorates injury-induced cognitive and 
motor impairment.  Specifically, cell survival in the CA3 region of the hippocampus of the 
injured lithium-treated animals (but not in the hilus) was significantly increased compared to 
injured vehicle-treated animals.  Western blot analyses revealed a significant increase in GAP-43 
levels on PID 7 in injured animals when treated with lithium, indicating a possible mechanism 
for lithium-induced neuroprotection.  In contrast, BDNF levels were relatively unchanged until 
PID 21, and caspase-3 activation was not observed at all, suggesting that these proteins play less 
significant roles in the observed neuroprotective effects of lithium treatment after lateral FPI.  
Early administration of lithium, within 8 hours after TBI, holds promise as an effective therapy 
to ameliorate postinjury neurobehavioral deficits and warrants further investigation in clinical 
TBI studies. 
Keywords: lithium, traumatic brain injury, TBI, cognitive function, vestibulomotor 
function, depression, forced swim test, beam walk, neuroprotection, hippocampus, CA3, hilus, 
BDNF, GAP-43, caspase-3, preclinical, translational research, Morris water maze, MWM.
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Neuroprotective Effects of Postinjury Lithium Treatment: Determining the Optimal Dosing 
Paradigm and Assessing Potential Mechanisms of Action 
 
 
Traumatic Brain Injury 
 Epidemiology.  TBI represents a major public health problem in the United States.  TBI 
is one of the leading causes of preventable mortality and morbidity among children, young adults 
and the elderly (Langlois, Rutland-Brown, & Thomas, 2004; Sosin, Sniezek, & Thurman, 1996; 
Thurman et al., 1999). 
 According to the Centers for Disease Control and Prevention (CDC), approximately 1.4 
million Americans sustain a TBI each year.  To put the magnitude of this number into 
perspective, there are more new cases of TBI each year than breast cancer (212,920) (American 
Cancer Society) and HIV/AIDS (43,700) combined.   Of these 1.4 million, approximately 1.1 
million will receive care from an emergency department (ED), 230,000 will require 
hospitalization, and 50,000 will die.  The most common causes of TBI are falls (28%), motor 
vehicle accidents (20%), “struck by/against” events (19%), and assault (11%) (Langlois et al., 
2004). 
Incidence of TBI is highest in children (0-4 years), young adults (15-19 years), and older 
adults (>75 years).  In almost every age group, males are about 1.5 times more likely than 
females to incur TBI, possibly due to a higher incidence of motor vehicle accidents, use of 
firearms, and risk-taking behavior among males (Langlois et al., 2004). Additionally, in the 
young adult population (15-24 years), mortality rates for males are 3.6 times higher than for 
females. 
TBI survivors may suffer enduring physical, emotional, cognitive and behavioral changes 
that significantly interfere with daily functioning.  Recent epidemiologic data from the CDC 
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indicate that 80,000-90,000 individuals become disabled from TBI each year.  A conservative 
estimate is that 5.3 million Americans currently live with long-term disabilities due to TBI, 
accounting for 2% of the total population (Langlois et al., 2004; Thurman, Alverson, Dunn, 
Guerrero, & Sniezek, 1999).  Functional impairment may also occur following mild brain injury, 
and it is estimated that 25% to 35% of individuals will continue to present cognitive and 
emotional difficulties when re-evaluated at 3 and 6 months from the time of injury. 
  In addition to the physical, psychosocial and vocational disabilities caused by TBI, the 
related long-term morbidity may place a dramatic financial burden on the individual, his or her 
family, workplace, and society.  The direct and indirect costs associated with TBI in the U.S. are 
estimated to be $60 billion annually (Finkelstein E, Corso P, Miller T and associates.  The 
Incidence and Economic Burden of Injuries in the United States. New York (NY): Oxford 
University Press; 2006.), and the lifetime cost for one person surviving a severe TBI can reach 
$4 million  (Langlois et al., 2004).   
Biomechanics of TBI.  TBI can result from rapid acceleration or deceleration of the head 
and neck, blunt trauma to the head caused by an object striking the head, or an object penetrating 
the skull (McIntosh et al., 1996; Povlishock & Christman, 1994).  Holbourn (1943) was the first 
to describe the effects of shearing strains, specifically rotational acceleration forces, as a primary 
cause of predictable injury in the brain.  The effect of acceleration or deceleration forces on the 
brain is varied and largely depends on the presence of rotational forces applied to the head and 
neck.  Individuals who sustain a sagittal (front to back) injury have the greatest likelihood of 
recovery, lateral (side to side) injuries have the worst percentage for recovery, and oblique injury 
outcomes are somewhere in between (McIntosh et al., 1996).  These forces are sufficient to 
produce brain injury without any accompanying contact injury.     
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The mechanical forces that produce TBI can be attributed to either static or dynamic 
loading.  In order to assess the severity of a TBI resulting from dynamic loading, it is important 
to account for inertial, acceleration and impact forces.  The greater the force acting on the head 
and neck, the more damage is inflicted (Gaetz, 2004; Ommaya & Gennarelli, 1974).  By 
understanding the biomechanical events associated with TBI, researchers are better able to 
replicate injuries in animal models, and this might ultimately lead to the development of new 
treatments for TBI.   
 Static loading.  Static loading occurs when forces are applied to an unmoving head over 
an extended time course (greater than 200 ms) and generally produces multiple, comminuted, or 
eggshell fractures of the skull.  This type of mechanical force does not normally produce the 
characteristic symptoms commonly associated with TBI, and neurological signs such as coma 
are not generally seen unless the force is sufficient to cause deformation of the skull and brain 
tissue (Graham, McIntosh, Maxwell, & Nicoll, 2000).  
 Dynamic loading.  Dynamic loading is the mechanical force that is most commonly 
associated with the typical sequelae of TBI.  Dynamic loading generally occurs in a much faster 
timeframe compared to static loading (less than 50 ms).  Dynamic loading can be further 
classified as either impact or impulsive (Graham et al., 2000; McIntosh et al., 1996).   
 Impact loading.  Impact loading occurs when a blunt object strikes the head, typically 
producing both contact- and inertial-related injuries.  The amount of damage produced is directly 
related to the amount of force applied to the skull.  Contact forces can generate stress waves that 
radiate through the skull and can cause additional skull fractures distant from the point of impact 
(Graham et al., 2000; McIntosh et al., 1996).   
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 Impulsive loading.  Impulsive loading occurs when the head is set into motion or when a 
moving head is suddenly stopped, either without striking anything or by contact with an object.  
This type of injury can be produced when the head moves indirectly as a result of impact to 
another part of the body (McIntosh et al., 1996).  Primary damage to the brain parenchyma is 
caused by non-uniform distribution of pressure and strain (Graham et al., 2000; McIntosh et al., 
1996).  Biological tissue is more resilient to slower strains as compared to fast strains (Graham et 
al., 2000).   
Primary and secondary brain injury.  Historically, the pathophysiology of TBI has 
been characterized by two distinct phases: primary and secondary injury.  Primary injury consists 
of the immediate craniocerebral damage (i.e., injury to the skull, brain or both) that occurs at the 
moment of the initial impact, and is classically distinguished into two components, focal 
(cerebral contusion, laceration, rupture of intracranial vessels) and diffuse (traumatic axonal 
injury (TAI), diffuse microvascular injury) (Graham et al., 2000; McIntosh et al., 1996; 
Povlishock & Becker, 1985), although both may coexist to varying degrees (Graham et al., 2000; 
Povlishock & Katz, 2005). 
Secondary injury can be described as a dynamic process of neuronal dysfunction 
eventually culminating in cell death, triggered by the activation of a cascade of complex and 
interrelated neurochemical events that initiate in the immediate post-traumatic period.  This 
process, which evolves in the hours and days following the initial traumatic event, is responsible 
for progressive neurological impairment and may significantly alter prognosis.  Therefore, an 
understanding of the biomolecular mechanisms underlying this secondary process of neuronal 
demise and the development of effective therapeutic strategies capable of arresting it has become 
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a focus of intense research activity over the last two decades, both in the clinical and preclinical 
setting. 
One of the most important concepts emerging from this research is that a lack of oxygen 
supply to the brain (i.e., hypoxia) is the key factor initiating the cascade associated with the 
development of the secondary brain injury.  Therefore, prevention or prompt recognition and 
treatment of factors such as hypotension and increased intracranial pressure (ICP) that lead to 
decreased oxygen delivery to the injured brain appear to be crucial to a good neurological 
outcome.  Increase in intracranial pressure is related to several factors such as brain edema (both 
cytotoxic and vasogenic), hydrocephalus, and intracranial mass (brain contusion or 
intraparenchymal hematoma).  Hypoxic events lead to the production of free radicals, disruption 
of intracellular calcium, release of cytochrome c from mitochondria, and initiation of apoptotic 
cascades(Gaetz, 2004; McIntosh et al., 1996; Merenda & Bullock, 2006).   
Focal injury.  Primary focal injury such as a missile (e.g., gunshot wound) or penetrating 
wound is characterized by the presence of contusions or direct disruption of brain tissue and can 
include hemorrhage and hematomas in the epidural, subdural, subarachnoid, and 
intraparenchymal areas (Gaetz, 2004; Gennarelli, 1993).  Secondary damage from focal injuries 
includes delayed neuronal injury to neighboring regions, microvascular injury, focal ischemic-
hypoxic injury, herniation, and regional and diffuse hypometabolism.  Focal injuries produce 
regions of significantly reduced cerebral blood flow creating ischemic conditions that promote 
inflammation and cytotoxicity in addition to neuronal necrosis (Bullock, Maxwell, Graham, 
Teasdale, & Adams, 1991; Gaetz, 2004).  
 Contusions.  The presence of a contusion is extremely common in patients with focal 
TBI; however, TBI can occur without contusion.  Contusions cannot be used as an explanation 
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for loss of consciousness at the time of injury or as a factor in the maintenance of a comatose 
state, but they are linked to focal seizures and/or functional deficits in the language centers of the 
brain (Povlishock & Christman, 1994; Ribas & Jane, 1992).  In most cases, contusions are the 
byproduct of hemorrhagic lesions within the gray matter or at the gray-white interface and 
contribute to neuronal damage and ischemia (Povlishock & Katz, 2005).  Contusions are most 
commonly located on the frontal and temporal poles, the lateral and inferior surfaces of the 
frontal and temporal lobes, and above the Sylvian fissure (Gaetz, 2004; Gennarelli & Graham, 
1998; Gurdjian, 1976; McIntosh et al., 1996; Povlishock & Christman, 1994).  They are 
commonly seen at the apex of gyri and can appear as punctate hemorrhages or streaks of 
hemorrhage usually accompanied by progressive bleeding into adjoining white matter 
(Gennarelli & Graham, 1998).   
There are several types of contusions, including coup contusions that occur directly 
beneath skull fractures, contracoup contusions that occur some distance (not always directly 
opposite) from the fracture, and gliding contusions.  Gliding contusions are most likely to be 
associated with diffuse brain injury and are produced by cortical gray matter moving in 
opposition to the underlying white matter causing shearing strains that damage the penetrating 
vessels located at the gray/white interface, producing hemorrhagic lesions in the parasagittal 
cortex (Adams, Doyle, Graham, Lawrence, & McLellan, 1986; Povlishock & Christman, 1994).  
In addition, nonhemorrhagic contusions may be identified using MRI.  These lesions are not 
associated with hemorrhage but are located on the cortical surface where one would expect to see 
“traditional” contusions.  Another type of nonhemorrhagic contusion is identified within the 
subcortical white matter, leaving the superficial cortex unharmed.  These lesions are associated 
with shearing forces and diffuse axonal injury (Povlishock & Christman, 1994).  
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 Hematomas.  There are several kinds of hematomas, including intraparenchymal 
hematoma, epidural hematoma, and acute subdural hematoma (Gaetz, 2004; Gennarelli & 
Graham, 1998; Povlishock & Christman, 1994).  One possible explanation for the formation of 
hematomas is the rupturing of cerebral arterioles caused by the shearing and tensile forces 
generated by the injury (Povlishock & Christman, 1994).  Intraparenchymal hematomas are 
located deep within the parenchyma and are associated with rupture of a blood vessel.  Epidural 
hematomas are most commonly associated with a skull fracture.  Acute subdural hematomas are 
caused by the rupturing of bridging veins beneath the dura or cortical arteries (Gennarelli & 
Graham, 1998).  Cerebral hematomas are usually formed at the time of injury; however, there is 
evidence that delayed hematoma formation may occur in patients with injuries ranging from mild 
to severe (Povlishock & Christman, 1994; Soloniuk, Pitts, Lovely, & Bartkowski, 1986).  
Hematoma and contusion are associated with secondary ischemic damage and subsequent 
necrosis from mass effect from blood that affects the adjacent tissue (Gennarelli & Graham, 
1998).   
 Diffuse injury.  Primary diffuse injury consists of diffuse axonal injury (DAI) and 
petechial white matter hemorrhage.  Secondary diffuse injury is associated with delayed neuronal 
injury, microvascular injury, diffuse hypoxic-ischemic injury (HII), and diffuse hypometabolism 
(Povlishock & Katz, 2005).  In addition to secondary injuries, delayed pathology resulting from 
brain injury can lead to DAI, which is characterized by axonal swelling and degradation 
followed by axonal separation from its downstream segment and characteristic formation of a 
retraction bulb (Povlishock & Christman, 1995).  Diffuse cell death is among the sequelae 
commonly observed following TBI and can be attributed to one of two morphologically distinct 
processes: apoptotic and necrotic.      
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Necrosis.  Necrotic cell death occurs following degradation of the cell membrane and 
disruption of ionic homeostasis leading to the rapid destruction of the cytoskeleton and 
cytoplasmic components (Povlishock & Katz, 2005).  Rapid cell death is linked to the activation 
of the cysteine proteases calpain and caspase, causing degeneration and increased porosity of the 
plasma membrane and leakage of cell contents into the extracellular space (Rowe & Chuang, 
2004).   
Apoptosis.  Apoptosis is programmed cell death from internal mechanisms.  Unlike 
necrosis, apoptosis does not require disruption of the cell membrane.  Apoptotic events are 
mediated by internucleosomal DNA strand breaks with nuclear condensation that cause the cell 
to slowly die (Povlishock & Katz, 2005).  Apoptotic cells are characterized by dense packing of 
cellular material into apoptotic bodies that are subsequently phagocytized (Rowe & Chuang, 
2004).  Trauma-induced apoptosis has many mitigating factors, including excessive 
neuroexcitation via excitatory amino acids (EAA) (e.g., glutamate, aspartate, NMDA, AMPA), 
decreased ATP level, radical-mediated injury, ionic imbalance (e.g., dysregulation of calcium 
homeostasis), aberrant proteolytic enzyme activity, dysregulation of pro-apoptotic genes (e.g., 
Bcl-2), and traumatic axonal injury (Ansari, Roberts, & Scheff, 2008; Povlishock & Katz, 2005; 
Raghupathi, 2004; Raghupathi, Graham, & McIntosh, 2000; Yakovlev & Faden, 2004).   
 Traumatic axonal injury / diffuse axonal injury.  DAI was first described by Strich in 
1956.   Originally, the pathogenesis was assumed to be tearing of axons throughout the brain 
caused by shearing forces generated at the time of injury.  This hypothesis was based on the 
observation that the injured axons appear reactive and swollen when visualized postmortem 
using histological techniques (Adams, Graham, Murray, & Scott, 1982; Strich.S.J., 1956).  
However, subsequent research has shown that DAI is not the result of immediate shearing of 
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axons, since reactive axons are undetectable using histological techniques unless the patient 
survives for a minimum of 12 hours postinjury (Pilz, 1983).  Instead, DAI is a dynamic and 
evolving process that can continue for months postinjury.  DAI is characterized by disruption of 
the neurofilament and cytoskeletal network allowing accumulation of typically excluded ions 
and neurofilament compaction, in addition to damaged mitochondria within the axon.  All of this 
leads to Wallerian degeneration, the reactive swelling and detachment of the axon segment 
downstream from the point of injury forming characteristic retraction bulbs.  Damaged axons can 
be found throughout the subcortical white matter, basal ganglia, diencephalon, and all areas of 
the brainstem.  Interestingly, these damaged neurons are typically observed next to healthy axons 
and can also be found running along healthy microvessels.  However, damaged axons can also be 
found in foci of petechial hemorrhaging or in the area surrounding a hematoma (Povlishock & 
Christman, 1994).  Other aspects commonly associated with DAI are edema, petechial 
hemorrhages, non-hemorrhagic macroscopic white matter lesions, and small subarachnoid and 
intraventricular hemorrhages (Povlishock & Katz, 2005).   
 Generalized changes.  In addition to the characteristic changes of focal and diffuse brain 
injury, there a number of generalized changes that occur following TBI, including alterations in 
the permeability of the blood brain barrier (BBB), neurotransmitter responses, carbon dioxide 
(CO2) levels, and cerebral blood flow (Povlishock & Christman, 1994).   
Findings from clinical studies have found elevated neurotransmitter levels in the cerebral 
spinal fluid (CSF) of brain-injured patients.  Studies have also shown that increases in the levels 
of EAAs such as glutamate and aspartate in the extracellular fluid surrounding the contusion area 
can remain elevated for as many as four days after injury (Povlishock & Christman, 1994).  EAA 
release is determined by the severity of the initial injury combined with any secondary events 
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that may have occurred prior to stabilization at a hospital (Zauner & Bullock, 1995).  Most of the 
research supporting the presence of generalized changes comes from preclinical studies and will 
be discussed in greater detail in the experimental TBI section. 
Neurotransmitters involved in TBI pathology.  Following TBI, multiple 
neurotransmitter systems are affected and changes can persist for years following the insult.  A 
brief discussion of each of the neurotransmitters involved in TBI pathology follows, as well as a 
description of the effects of lithium treatment.  The neurotransmitters that are affected by both 
TBI and lithium include: serotonin (5-HT), glutamate, γ-aminobutyric acid (GABA), 
norepinephrine (NE), dopamine (DA), and acetylcholine (ACh) (Faden, Demediuk, Panter, & 
Vink, 1989; Fonseca, Sierra, Geraldes, Cerdan, & Castro, 2009; Hamill, Woolf, McDonald, Lee, 
& Kelly, 1987; Hayes, Jenkins, & Lyeth, 1992; O'Dell, Gibson, Wilson, DeFord, & Hamm, 
2000; Rowe & Chuang, 2004; Shaldubina, Agam, & Belmaker, 2001; Verbois, Sullivan, Scheff, 
& Pauly, 2000). 
 Serotonin.  5-HT is released by presynaptic serotonergic neurons and activates specific 
postsynaptic receptors, mostly affecting the 5-HT2 subgroup of 5-HT receptors.  5-HT also 
activates presynaptic autoreceptors.  These subgroups of receptors are known as 5-HT1A or 5-
HT1B and they decrease the amount of 5-HT released per nerve impulse via an inhibitory 
feedback loop.  5-HT1A autoreceptors are localized on the soma and dendrites of serotonergic 
neurons and 5-HT1B autoreceptors are located on the terminal boutons of presynaptic 
serotonergic neurons.  Levels of this neurotransmitter can be modulated by preventing the 
breakdown of 5-HT via monoamine oxidase inhibition or by preventing the reuptake of 5-HT 
from the synaptic cleft via blockade of autoreceptors on the presynaptic neuron.  The discovery 
of the therapeutic benefits of 5-HT modulation in the treatment of mental illness has lead to 
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intensive study and subsequent discovery of its involvement in brain activity for sleep regulation, 
sexual activity, depression, and anxiety, as well as the perception of hunger and satiety (Zafonte, 
Cullen, & Lexell, 2002). 
There is substantial evidence that 5-HT plays a significant role in the pathogenesis of 
TBI.  Pharmacological treatments that target 5-HT have been shown to significantly improve 
outcome following TBI.  Reduction in the metabolites of 5-HT have been found in the CSF of 
patients with TBI (Markianos, Seretis, Kotsou, & Christopoulos, 1996; Zafonte et al., 2002).  
Major depression is one of the most prevalent co-morbid conditions reported by individuals 
following TBI (Rosenthal, Christensen, & Ross, 1998).  A study by Kreutzer, Seel, and Gourley 
(2001) investigating the prevalence of depression following TBI reported that 42% of individuals 
met the American Psychiatric Association’s requirements for diagnosis with depression, as 
outlined in the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV, 1994) (4th 
ed.; DSM–IV; American Psychiatric Association, 1994).  In clinical studies, selective 
serotonergic reuptake inhibitors (SSRI) were administered to patients diagnosed with depression 
resulting from a TBI, and improvements were found in neuropsychological assessment of 
psychomotor speed, recent verbal memory, recent visual memory, and general cognitive 
efficiency (Fann, Uomoto, & Katon, 2001; Zafonte et al., 2002), as well as normalization of 
mood swings (e.g., crying or laughing spells) (Nahas, Arlinghaus, Kotrla, Clearman, & George, 
1998; Zafonte et al., 2002).  
Glutamate.  Glutamate is the primary excitatory neurotransmitter in the brain.  It is 
important in synaptic plasticity, neuronal migration during development, neuronal viability, and 
long-term potentiation (LTP) (Lu, Roder, Davidow, & Salter, 1998; Schumann, Alexandrovich, 
Biegon, & Yaka, 2008).   In the acute phase following TBI, increases in extracellular glutamate 
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have been observed both in animal models and in human patients (Bullock et al., 1995; 
Schumann et al., 2008).  Release of glutamate activates ionotropic and metabotropic receptors, 
particularly the ionotropic N-methyl-D-aspartate (NMDA) receptor with its NR2A and NR2B 
subunits.  In non-injured brains, the NMDA receptor is crucial for the initiation of LTP in both 
the hippocampus and the cortex (Lu et al., 1998; Rosenblum, Dudai, & Richter-Levin, 1996; 
Schumann et al., 2008).  Injury-induced hyperactivation of NMDA receptors allows calcium 
levels to reach toxic levels, and calcium is among the key mediators of cell death initiated by 
secondary injury.   
γ-Aminobutyric acid (GABA).  GABA is the primary inhibitory neurotransmitter in the 
brain and is responsible for maintaining control over excitatory feedback loops.  Following TBI, 
modulation of GABA receptors can produce markedly different outcomes depending on the time 
point and duration of postinjury treatment.  In a rat weight-drop model of diffuse brain injury, 
levels of GABA metabolites were significantly increased at 24 and 48 hours postinjury (Pascual 
et al., 2007), corresponding to the timeframe of the hypofunctional state in the biphasic 
hypothesis of secondary brain injury.  The drug diazepam, a benzodiazepine and indirect 
GABAA agonist, has been found to significantly impair motor recovery following daily short-
term administration beginning 12 hours post-lesion (Schallert, Hernandez, & Barth, 1986).  
However, administration of diazepam either 15 min prior to or 15 min after central fluid 
percussion injury was found to reduce mortality rates and improve performance in the Morris 
water maze (MWM) compared to untreated injured animals (O’Dell, Gibson, Wilson, DeFord, & 
Hamm, 2000).  Likewise, administration of the GABAA antagonist bicuculline 15 min after TBI 
significantly increased the latency to reach the goal platform as compared to injured saline-
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treated animals (O'Dell et al., 2000).  These studies show that increasing the activity of inhibitory 
pathways may be neuroprotective in the acute phase of secondary injury.  
Norepinephrine.  Catecholamines are important in the normal functioning of the 
prefrontal cortex (PFC), particularly in the case of working memory (Goldman-Rakic, Muly, III, 
& Williams, 2000).  In clinical studies, serum levels of NE have been correlated with injury 
severity, with higher concentration of NE corresponding to a greater severity of injury (Clifton, 
Ziegler, & Grossman, 1981; Hamill et al., 1987).  NE levels were found to be increased in the 
hypothalamus at 1 hr and 1 week after fluid-percussion injury (FPI) (McIntosh, Yu, & 
Gennarelli, 1994).  Additionally, using the CCI impact model, NE levels were increased in the 
medial PFC (MPFC) at 7 and 14 days postinjury (Kobori, Clifton, & Dash, 2006).   
Dopamine.  DA is a key mediator in neurological functioning following TBI.  DA 
agonists administered in the hypofunctional chronic phase postinjury have been shown to 
improve cognitive outcome following TBI in experimental and clinical settings (Gualtieri, 1988; 
Kline, Yan, Bao, Marion, & Dixon, 2000; Whyte, Vaccaro, Grieb-Neff, & Hart, 2002).  Both the 
D1-R and D2-R subtypes are involved in memory dysfunction following brain injury.  Long-
term memory dysfunction has been attributed to depleted dopamine levels in the hippocampus 
(Tang, Noda, Hasegawa, & Nabeshima, 1997).  Catecholamines in the PFC are necessary for 
regulating aspects of cognitive functioning such as working memory and attention (Goldman-
Rakic et al., 2000).  The PFC is known to be particularly vulnerable to TBI and injury-induced 
disturbances to the DA system are related to impaired cognitive functioning (Massucci, Kline, 
Ma, Zafonte, & Dixon, 2004; Mattson & Levin, 1990; McDowell, Whyte, & D'Esposito, 1997; 
Sawaguchi & Goldman-Rakic, 1991).   
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Acetylcholine.  The medial PFC and hippocampus are innervated by the cholinergic 
basal forebrain complex and are involved in cortical arousal, consciousness, memory and 
learning (Brand, Groenewald, Stein, Wegener, & Harvey, 2008; Picciotto, Brunzell, & 
Caldarone, 2002; Sarter & Bruno, 2000).  The involvement of ACh in TBI has been well 
established.  Regional and temporal changes in ACh levels and its synthesizing enzyme choline 
acetyltransferase (ChAT) have been reported following TBI (Donat et al., 2008; Saija et al., 
1988).  Fluctuations in ACh levels of up to 50% have been reported immediately postinjury.  In 
the hippocampus there is a significant decline in cholinergic activation at 1 hour, persisting for 
up to 21 days postinjury (Verbois et al., 2000). 
Human TBI outcome.  Individuals who have sustained a TBI are likely to suffer 
cognitive and/or behavioral impairments following the injury.  In minor head injuries, accounting 
for 75% of the total number of TBI’s per year, the most common clinical syndrome seen after 
injury is brain concussion.  Many patients with mild TBI develop what is known as post-
concussion syndrome, marked by disabilities due to cognitive impairment or psychological 
sequelae for variable periods of time.  TBI patients who suffer a moderate to severe injury 
usually experience unconsciousness and/or post-traumatic amnesia (PTA) following TBI 
(Povlishock & Katz, 2005).  PTA is commonly observed following moderate and severe injury, 
but individuals with mild injury may also experience PTA.  PTA is associated with two types of 
memory impairment: retrograde and anterograde amnesia.  Permanent memory loss is associated 
with severe head injuries. 
Retrograde amnesia.  Retrograde amnesia is the inability to recall events prior to the 
traumatic event.  Most retrograde amnesia cases follow Ribot’s law, which states that the closer 
temporally a memory is to the traumatic event, the more susceptible it is to disruption by TBI.  
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Recovery from retrograde memory loss begins with more remote memories and typically only 
the moments immediately prior to injury remain lost.  Usually the period of permanent memory 
loss can be measured in minutes, although in rare cases memory loss of 2 or more days prior to 
the traumatic event can occur (Capruso & Levin, 1992).      
Anterograde amnesia.  Anterograde amnesia is the inability to form new memories 
following the traumatic event.  In severe head injury, typically following recovery from coma, 
individuals may experience a confusional state accompanied by anterograde amnesia.  The 
hallmark of anterograde amnesia is disorientation.  Individuals with this type of memory loss can 
also exhibit other symptoms of confusion such as deficits in attention, agitation, combativeness, 
hypokinetic or hyperkinetic behavior, inappropriateness, disinhibition, and severe perseveration.  
Recovery from anterograde amnesia typically follows a set sequence: first, orientation to person; 
second, orientation to place; and third, orientation to time (Capruso & Levin, 1992).      
The frontal cortex is highly susceptible to TBI-induced pathology.  Executive functioning 
(e.g., information processing, memory, and attention), controlled by the dorsolateral PFC 
(DLPFC) is frequently impaired, even following mild injury (Lipton et al., 2009).  In a recent 
study, diffusion-tensor imaging was used to evaluate the relationship between post-TBI structural 
changes and performance on neuropsychological assessment in the continuous performance and 
executive maze tasks.  Patients with mTBI performed worse compared to healthy controls in 
overall performance on both tests.  Additionally, lower fractional anisotrophy, an indicator of 
axonal injury, was predictive of poorer performance on measures of executive functioning 
(increased errors of omission in the continuous performance task and increased number of trials 
and errors in the executive maze) in mTBI patients (Lipton et al., 2009).  The frontal cortex 
oversees and regulates many important aspects of life such as motivation for self-initiated 
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behavior and the regulation, initiation, and planning of behavior.  Long-term attentional deficits 
after TBI are reported to be a significant problem by both individuals with TBI and their families 
as a significant problem.  TBI patients have difficulty in tasks requiring vigilance and focused 
attention.  They generally can perform untimed tasks of immediate attentional span (e.g., digit 
span) as well as uninjured individuals, but if a task requires switching focus, decision making, or 
speed of processing, TBI patients are often significantly impaired. 
Psychological disease.  An individual’s outcome following TBI is related to several 
factors, including age, preinjury abilities, personality, and injury severity (Capruso & Levin, 
1992).  Acute confusional states are most commonly observed during the first few weeks 
following a TBI (Jorge, 2005).  Post-traumatic agitation is another common symptom and 
typically resolves within 10 days (Jorge, 2005; Kadyan et al., 2004).  Patients frequently report 
slowed or diminished cognitive abilities after TBI.  Memory is the most susceptible of cognitive 
functions following TBI.  TBI can also bring about psychiatric conditions, and the frequency of 
mood disorders such as major depression, bipolar disorder, and anxiety are significantly greater 
in TBI populations.  Post-traumatic stress disorder (PTSD) is commonly associated with TBI as 
well, and there is a correlation between the presence of neuropsychiatric disorders and difficulty 
with psychosocial adjustment and ability to return to work following TBI (Jorge & Robinson, 
2002).  Given the profound impact of TBI on the individual as well as his or her family, co-
workers and friends, it is important to evaluate therapeutic measures that may be able to prevent 
these cognitive sequelae from occurring.   
Experimental Traumatic Brain Injury.  Experimental brain injury models must 
generate similar injuries to those observed following human TBI.  Regardless of the 
physiological, behavioral, or anatomical outcome measure, it is important that the results be 
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reproducible and quantifiable, clinically relevant, and produce a continuum of injury severities 
(Lighthall, Dixon, & Anderson, 1989).  No single model can replicate the complex mechanisms 
that occur following human TBI, but several preclinical models of TBI have been developed and 
implemented to properly characterize its underlying pathology.   
Models and mechanics of experimental TBI.  There are four models that have been used 
to investigate the effects of TBI: physical, computational, cell culture, and animal.  All of these 
models have provided important data for the understanding and treatment of TBI.  However, to 
date, only animal models are able to fully represent how a living organism responds to trauma.  
There are a number of animal models that reliably reproduce the sequelae associated with human 
TBI.  Animal models of injury include dynamic closed head injury, penetration, ablation, 
lesioning, and quasistatic injury.  Since the present study utilizes a closed head model of head 
injury, other models of TBI will not be discussed further.  One aspect that must be taken into 
consideration when evaluating experimental data is the time course of events following trauma.  
The pathophysiological mechanisms that occur following experimental injury in animal models 
occur over a faster timeframe than that which is observed following human TBI (Zauner & 
Bullock, 1995).  This is also important when evaluating the effects of pharmacological 
treatments in animal models of injury, such as the rate of metabolism of the selected drug.   
 Fluid-percussion injury.  FPI is the most commonly used rodent model of TBI.  The 
model requires a small-diameter (4.8 mm) craniotomy to expose the dura mater, and the injury is 
produced by applying a brief fluid pulse directly to the surface of the dura.  The injury can be 
delivered either centrally or laterally.  Central FPI delivers the fluid pulse along the central suture 
midway between bregma and lambda.  Lateral FPI delivers the injury to the parietal lobe midway 
between the coronal and lambdoid sutures.  The FPI model is able to replicate the cognitive and 
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histological changes seen in human head injury (Dixon et al., 1987).  In rodent models, FPI has 
been shown to produce cognitive deficits that can last for weeks or months postinjury (Hamm, 
Lyeth, Jenkins, O'Dell, & Pike, 1993).  Other aspects of human TBI are also generated following 
FPI, such as hemorrhage at the gray/white interface, acute hypertension, bradycardia, increased 
plasma glucose levels, and suppression of electroencephalogram amplitude that is related to the 
magnitude of the head injury (Cortez, McIntosh, & Noble, 1989; Dixon, Lighthall, & Anderson, 
1988).   
Both central and lateral FPI models are capable of producing cognitive deficits via 
damage to the hippocampus, a region of the brain known to be selectively vulnerable in human 
TBI.  The two models differ in the type of damage inflicted on the hippocampus.  Central FP 
does not produce the same magnitude of cell loss that is typically seen following lateral FP, but it 
does produce hippocampal damage (Hamm et al., 1993; Lyeth et al., 1990).  The memory 
impairment observed following central FPI is not believed to be due to cell death but instead due 
to neuronal dysfunction in the hippocampus (Hayes et al., 1992; Lyeth et al., 1990).  Lateral FPI 
is known to cause significant cell death in the CA3 region of the hippocampus as well as bilateral 
cell loss in the hilus (Cortez et al., 1989; Hicks, Smith, Lowenstein, Saint, & McIntosh, 1993; 
Smith, Okiyama, Thomas, Claussen, & McIntosh, 1991).  Memory dysfunction observed 
following lateral FPI is directly related to the amount of cell death in the dentate hilar region 
(Smith, Lowenstein, Gennarelli, & McIntosh, 1994).   
The lateral FPI model of TBI was selected for use in the present study because it reliably 
produces aspects of both focal (cortical contusion) and diffuse (impaired functioning of 
subcortical structures) brain injury, resulting in motor and cognitive deficits typical of human 
TBI (Hallam et al., 2004; Hicks, Soares, Smith, & McIntosh, 1996; Nahas et al., 1998; Nolan et 
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al., 1997).  Lateral FPI produces alterations in regional cerebral blood flow, BBB permeability 
(Cortez et al., 1989; Yamakami & McIntosh, 1991), metabolic functioning, and 
electroencephalographic activity (Hovda et al., 1995; Kokiko-Cochran, Michaels, & Hamm, 
2008; McIntosh et al., 1989), all of which are known to occur following human head trauma.  
Neurochemical changes detected in human patients have been reported in animal models using 
lateral FPI, including neurotoxicity from glutamate over-expression, alteration in the expression 
of neurotrophic factors and stress-induced proteins, and compromised integrity of cytoskeletal 
architecture (Di, Gordon, & Bullock, 1999; Hallam et al., 2004; Hicks, Martin, Zhang, & 
Seroogy, 1999; Huh, Raghupathi, Laurer, Helfaer, & Saatman, 2003; Raghupathi, McIntosh, & 
Smith, 1995).  Because it is able to closely approximate the injuries observed following human 
TBI, the lateral FPI model was selected for use in the present study.   
Controlled cortical impact.  Controlled cortical impact (CCI) uses either a pneumatic or 
magnetically driven piston to strike exposed brain tissue.  The advantage of this model is that the 
biomechanical events contributing to the injury can be precisely quantified, and force, velocity, 
and tissue deformation can be correlated to the amount of tissue damage and/or functional 
impairment.  The CCI model has been shown to produce cognitive deficits similar to those 
observed following human TBI (Hamm et al., 1992).  Moreover, CCI is able to simulate the 
neuropathology of severe human head injury more effectively than FP injury (Dixon, Clifton, 
Lighthall, Yaghmai, & Hayes, 1991).  Hoffman and colleagues developed a bilateral model of 
frontal cortical contusion that was able to reproduce deficits typically observed after frontal lobe 
damage in humans (Hoffman, Fulop, & Stein, 1994).  This model uses a pneumatically-
controlled cortical impactor to create bilateral contusions of the medial prefrontal cortex in male 
Sprague-Dawley rats.  Both CCI models were able to produce cognitive deficits as measured by 
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the Morris water maze (MWM) in addition to producing neurological, histological, and 
physiological deficits (Hamm et al., 1992; Hoffman et al., 1994).  CCI can also cause direct 
hemorrhage within the cortical gray matter and produce significant edema and damage to the 
BBB (Beaumont et al., 2000). 
Weight drop model.  First described by Foda and Marmarou (1994), this model induces 
diffuse TBI using a free-falling brass weight dropped from a predetermined distance onto a 
stainless steel disk cemented onto the animal’s skull.  The stainless steel disk prevents skull 
fractures, allowing for greater impact-acceleration levels and increased range of brain injury 
severity (Foda & Marmarou, 1994).  Postinjury apnea, convulsions, subarachnoid hemorrhage, 
and intraventricular hemorrhage are common after this type of injury.  In severely injured 
animals, there is also evidence of petechial hemorrhage.  Foda and Marmarou (1994) used this 
model to show that brainstem damage is not a necessary component of severe head injury as 
previously thought.  Irrespective of the severity of the brain injury (mild, moderate, severe), this 
model produces microscopic damage to neurons, axons, astrocytes, and small blood vessels.  
However, the extent of these changes is directly proportional to the severity of the TBI.   
Pathobiology of experimental TBI. 
Focal.  The FPI (Dixon et al., 1987) and CCI (Lighthall et al., 1989) mechanisms of 
injury are capable of eliciting focal contusion and hemorrhage in various animal models 
including primates, rodent and non-rodent models.  In the most severe injuries, hemorrhage can 
lead to further destruction of the cortical gray matter followed by the formation of a cystic cavity 
surrounded by glial cells.  Precontusional changes observed in animal models of TBI correlate 
with nonhemorrhagic contusions observed in human TBI.  Hemorrhage in injured cortical areas 
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can expand over time and produce a larger hemorrhagic mass that can facilitate secondary 
ischemia and infarction (Povlishock & Christman, 1994).   
Intraparenchymal hemorrhage can be generated following FPI and is typically seen only 
following severe injury.  As in human TBI, the presence of a contusion is not always associated 
with mortality, nor does the presence of a contusion necessarily have a direct correlation with 
behavioral pathologies.  Only when the contusion spans a large area of nervous tissue and/or 
involves a discrete functional area does it have a direct relationship to behavioral outcome 
(Povlishock & Christman, 1994).   
Diffuse.  Not all animal models of TBI are able to mimic the pathology of diffuse axonal 
injury.  FPI and CCI models are only able to produce focally confined axonal damage, but these 
models have nevertheless been used to obtain the majority of data regarding traumatically-
induced DAI (Povlishock & Katz, 2005).  The model that most closely replicates the pathology 
associated with DAI was described in a study by Gennarelli et al. (1982).  In this study, 
nonhuman primates sustained DAI as a result of rapid acceleration of the head in one of three 
directions (sagittal, oblique, or lateral) without impact (Gennarelli et al., 1982).  Due to the 
difficulty and expense associated with nonhuman primate studies, new models utilizing optic 
nerve stretch have been developed to study DAI (Maxwell, Povlishock, & Graham, 1997).   
 The nature of DAI was not fully investigated until adequate animal models were 
developed.  Povlishock and colleagues used anterograde tracers in the major conducting 
pathways prior to applying varying levels of experimental injury to determine if the axons were 
disconnecting at the time of injury or if there was another process occurring within the axon that 
was facilitating axonal degradation.  These experiments showed that there was a change in axon 
length within 1-2 hours postinjury and an accumulation of the anterogradely transported tracer, 
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which caused local swelling of the axon.  Within 3- to 6-hours postinjury, the axonal swelling 
increased to form a retraction bulb and ultimately resulted in axonal separation (Cheng & 
Povlishock, 1988; Povlishock & Becker, 1985; Povlishock & Kontos, 1985).  This demonstrated 
that axonal injury is not caused by tearing of the axon by external forces at the time of injury, but 
rather is the result of injury-induced changes within the axon.  In their 2005 review article, 
Povlishock and Katz noted that while previous research had focused on investigating the effects 
of injury on large caliber myelinated axons, more recent findings have shed light on the 
importance of injury to myelinated and unmyelinated fine caliber fibers.  This aspect of injury 
may be more important to outcome following TBI (Reeves, Phillips, & Povlishock, 2005).     
Generalized.  FPI produces an immediate increase in extracellular release of 
neurotransmitters, including catecholamines, acetylcholine, and glutamate (Faden et al., 1989; 
Hayes et al., 1992; Zauner & Bullock, 1995).  Shearing injuries can initiate widespread changes 
in neurotransmitter functioning and ionic homeostasis.  These changes set off widespread 
depolarization of cells allowing influx of sodium and calcium ions into the cell and efflux of 
potassium ions to the extracellular space (Katayama, Becker, Tamura, & Hovda, 1990).  These 
cellular changes are related to neuronal and glial swelling that can lead to edema and increases in 
intracranial pressure (ICP) (Zauner & Bullock, 1995).  A hallmark feature of experimental brain 
injury is excessive release of EAA’s (Katayama et al., 1990; McIntosh et al., 1989).  Although 
there are several excitatory neurotransmitters that are associated with TBI-induced neurotoxicity, 
glutamate appears to be the most important (Rothman & Olney, 1986).  Increased release of 
EAA’s such as glutamate and aspartate from the hippocampus is seen following moderate to 
severe TBI, and amount of neurotransmitter release seems to correlate with injury severity 
(Hayes & Dixon, 1994).  Animal studies have confirmed that multiple agonist-receptor 
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interactions are involved in TBI pathologies, and this is the basis of the strategy of treatment 
with receptor antagonists as a method of neuroprotection after TBI.  Povlishock and Christman 
(1994) discuss several studies that have used EAA antagonists to elicit a neuroprotective effect.  
When multiple EAA antagonists are combined they offer even greater neuroprotection than when 
used individually (Jenkins et al., 1988).  
In brain tissues affected by moderately reduced regional cerebral blood flow (rCBF), 
glutamate excitotoxicity may be responsible for secondary ischemic damage.  Hypoxia-related 
neuronal depolarization is caused by increased extracellular levels of glutamate due to increased 
release and decreased reuptake of glutamate.  High levels of glutamate can cause depolarization 
of cell membranes and activation of voltage-gated calcium channels that in turn activates the 
release of more glutamate via a positive feedback loop, resulting in glutamate neurotoxicity and 
ultimately cell death (Gennarelli, 1993).  Other amino acid neurotransmitters such as glycine are 
reported to be involved in seizure activity and toxicity from secondary damage (Nilsson et al., 
1994).  Glutamate antagonists have been found to be effective in reducing intracranial pressure 
produced by edema (Schroder, Muizelaar, Bullock, Salvant, & Povlishock, 1995). 
Edema is the accumulation of serous fluid within a body cavity or tissue and is a 
significant factor related to secondary injury.  Edema can be caused by a multitude of events and 
is the endpoint of several pathological processes.  There are two primary types of edema: 
vasogenic and cytotoxic.  Vasogenic edema is a common element in clinical and experimental 
TBI.  The breakdown of the BBB occurs at the tight junctions of endothelial cells, resulting in 
vascular permeability to water and plasma proteins (Tanno, Nockels, Pitts, & Noble, 1992b) 
allowing passage of neurotoxic vascular components into the parenchyma (McIntosh et al., 
1996).  Cytotoxic edema is produced by acute ischemic events and characterized by swelling of 
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neurons, glia, and endothelial cells.  Lack of oxygen prevents adenosine triphosphate (ATP)-
dependent sodium and potassium ion transport.  ATP levels can be disrupted by ischemic 
reduction in cerebral blood flow or mitochondrial dysfunction.  Sodium accumulates within cells, 
disrupting osmotic equilibrium and allowing excessive amounts of water into the cell.  
Intracellular calcium levels are also increased and lead to the activation of phospholipases and 
the subsequent release of arachidonic acid followed by the release of oxygen-derived free 
radicals and infarction (Kandel, 2000).   
Disruption of the BBB may be exacerbated by the occurrence of a secondary insult such 
as hypoxia or ischemia (Tanno, Nockels, Pitts, & Noble, 1992a; Tanno et al., 1992b).  Mild and 
moderate focal TBI have been linked to alterations in the permeability of the BBB that has been 
shown to persist for up to 15 hours postinjury (Cortez et al., 1989).  In another study, lateral FPI 
was combined with a secondary ischemic insult, and the combined injuries were associated with 
transient breakdowns of the BBB that spanned from 1-72 hr post-TBI.  The re-establishment of 
the BBB occurred in stages; brain regions farther away from the injury site recovered more 
quickly, some within 1 hr, while the region directly below the injury site demonstrated BBB 
disruption that lasted up to 72 hr after injury (Tanno et al., 1992a; Tanno et al., 1992b).  
Hypertensive responses following moderate or severe injury are also known to disrupt the BBB 
(Hayes & Dixon, 1994).   
Vascular abnormalities in preclinical research are very similar to those seen following 
human TBI and include impairment or loss of autoregulation (Lewelt, Jenkins, & Miller, 1980), 
impaired physiologic cerebral vascular responsiveness to changes in arterial blood gases (Wei, 
Dietrich, Povlishock, Navari, & Kontos, 1980), and altered cerebral blood flow (DeWitt et al., 
1986; Povlishock & Christman, 1994).  Abnormally low levels of carbon dioxide in the blood 
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stream have been found following experimental TBI.  It is hypothesized that shear and tensile 
strains may produce functional and structural changes in cerebral blood vessels (Povlishock & 
Christman, 1994).  
Biphasic Hypothesis 
Remote Functional Depression (RFD) is a hypothesis proposed by Feeney (1991) to 
explain the apparent biphasic condition associated with the brain’s response to trauma-induced 
injury.  RFD is derived from the idea of diaschisis, first proposed by von Monakow in 1914 
which postulates that a focal injury to one area of the brain can produce damage to a 
morphologically separate area via common neural pathways.  Von Monakow attributed the 
remote damage to a loss of excitatory input from the injured area.  It was speculated that 
spontaneous recovery from this state was due to the resolution of the dysfunctional signaling 
pathway (von Monakow, 1914, translated to English in 1969).   
The biphasic model of brain injury deals with the sequelae associated with secondary 
injuries and is divided into acute and chronic phases.  In the acute phase, marked cerebral 
hypermetabolism leads to increases in the extracellular release of several neurotransmitters 
leading to neurotoxicity.  The chronic phase is characterized by a hypofunctional state with 
delayed cell loss in selectively vulnerable brain regions, leading to cerebral atrophy on 
neuroimaging  and decreased cerebral metabolism.  These are associated with neuronal loss and 
inflammation that is observed via magnetic resonance spectroscopy (MRS) and which can persist 
for months following TBI in humans.  Experimental therapies to treat TBI are designed to target 
either the acute or chronic phase.  It is within these two time points that treatments can be 
implemented.  Typically, treatments that are effective in the excitotoxic acute phase are 
ineffective when administered during the hypofunctional chronic phase, and vice versa.  The 
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time-sensitive nature of treatment intervention can make the translation from acute treatments in 
preclinical models to clinical use extremely difficult.   
In the proposed study, postinjury treatment with lithium is theorized to be beneficial in 
ameliorating the pathobiology associated with both the acute and chronic phases following TBI.  
Due to the known mechanisms of lithium’s action, it is hypothesized that lithium will be able to 
attenuate the excitotoxic processes associated with the acute postinjury phase and prevent 
apoptotic events as well as enhance neuronal regeneration in the chronic postinjury phase (Ren, 
Senatorov, Chen, & Chuang, 2003). 
Lithium 
Background.  Lithium is the third element on the periodic table and a member of the 
alkali metal group.  Lithium has many remarkable therapeutic applications, most notably its 
ability to treat both the manic and depressive phases of bipolar affective disorder (BAD) 
(Shaldubina et al., 2001).  This drug has been also used to alleviate aggressive behavior, 
migraines, cluster headaches, the inappropriate secretion of anti-diuretic hormone, and 
chemotherapy-induced leucopoenia (Shaldubina et al., 2001).  More recently, the evidence that 
this simple cation may exert beneficial effects in various models of brain injury has brought 
renewed interest in the therapeutic potential of this drug.  The following sections will outline the 
general effects of the clinically relevant doses of lithium in the brain that are related to lithium’s 
effectiveness as a therapy for BAD and factors related to learning and memory, followed by an 
in-depth review of lithium’s role in neuroprotection, neuroplasticity, and neurogenesis.   
Lithium has a multitude of effects in the brain, not all of which are relevant to this thesis.  
In the following section, a short synopsis of some of the prominent aforementioned effects 
produced by clinically relevant doses of lithium will be discussed.  These lithium-induced effects 
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include inositol monophosphatase (IMPase), glucose metabolism, enzymes, and the 
neurotransmitters 5-HT, ACh, and NE. 
Inositol monophosphatase (IMPase).  Lithium is speculated to inhibit IMPase and 
thereby hinder the functioning of the cycle of the second-messenger phosphatidylinositol (PI) 
(Shaldubina et al., 2001).  Allison and Stewart (1971) showed that lithium decreases free inositol 
concentration and increased inositol monophosphate (IP) concentration in the brain (Allison & 
Stewart, 1971; Shaldubina et al., 2001).  Allison and Bilsner, using a rat model, found that 
therapeutic doses of lithium inhibited brain inositol monophosphatase, providing an explanation 
for the reduction in inositol and accumulation of inositol monophosphate (Allison & Blisner, 
1976).  Lithium inhibits the dephosphorylation of IP by inositol monophosphatase, thus 
preventing the release of inositol.  Other mood stabilizers (e.g., valproic acid and carbamazepine) 
also inhibit inositol.  A common mechanism of action for these drugs is the depletion of inositol, 
thereby suggesting that it may have a role in the clinical effectiveness of these therapies (Teo et 
al., 2009).  
Glucose metabolism.  Regional cerebral metabolic rate for glucose (rCMRglc) is an 
imaging technique that can be utilized to determine areas of brain activity in vivo (Basselin, 
Chang, & Rapoport, 2006).  It was determined that chronic (6-week) lithium treatment, within 
the therapeutic range used to treat BAD, produced an increase in regional brain glucose 
metabolism in 30 of 81 brain regions examined.  The increased activity was observed in auditory 
and visual areas as well as in the frontal cortex, amygdala, hippocampus, nucleus accumbens, 
caudate-putamen, interpeduncular nucleus, and substantia nigra (Basselin et al., 2006).    
Serotonin.  Lithium treatment downregulates the expression of 5-HT1B autoreceptors and 
thereby increases 5-HT levels in the brain (Odagaki, Koyama, Matsubara, Matsubara, & 
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Yamashita, 1990; Redrobe & Bourin, 1999).  In vitro studies report that administration of 
therapeutic levels of lithium caused specific inhibition of 5-HT1B receptor binding in membrane 
preparations (Massot et al., 1999; Shaldubina et al., 2001).  In support of this effect, in vivo 
studies revealed that lithium is able to prevent behaviors mediated by 5-HT1B (Massot et al., 
1999; Shaldubina et al., 2001).  Lithium-induced actions at 5-HT neurons were correlated with 
management of hyperactive behavior in rats (Grahame-Smith & Green, 1974; Redrobe & Bourin, 
1999).  Short-term, two-day, treatment with lithium was found to increase 5-HT levels without 
altering 5-HT firing rate or alteration in the number of spontaneously active neurons, which 
indicates that short-term lithium treatment inhibits presynaptic 5-HT receptors (Blier & De 
Montigny, 1985; Redrobe & Bourin, 1999).  
Lithium’s observed effect of inhibiting 5-HT1B may have beneficial effects in learning 
and memory.  Research indicates that antagonists of 5-HT1B receptors can prevent memory 
impairment and facilitate learning during tasks that require a high cognitive demand (Zafonte et 
al., 2002).  In support of this finding, agonists of 5-HT1B receptors produced deficits in learning 
(Zafonte et al., 2002).  Additionally, lithium’s actions may help to reduce aggressive behavior in 
TBI patients.  However, due to potential lithium-induced toxicity, it is recommended that less 
toxic treatment options be considered first (Levy et al., 2005).    
Acetylcholine.  Some of lithium’s effects on memory may be related to its effects on 
ACh.  ACh is known to be involved in memory formation in both humans and animals (Hogg, 
Raggenbass, & Bertrand, 2003; McNamara & Skelton, 1993).  Lithium was found to increase the 
synthesis and release of ACh in the hippocampus, mediated by 5-HT1A receptor-mediated 
pathways (Fujii, Nakai, Nakajima, & Kawashima, 2000).  A time- and concentration-dependent 
increase in the expression of the muscarinic ACh receptor was reported following lithium 
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administration.  Additionally, lithium prevented agonist-induced downregulation of the 
muscarinic receptor (Liles & Nathanson, 1988).  ChAT activity was also reported to be 
influenced by lithium administration (Giovanni, Scali, Prosperi, Bellucci et al., 2002).  Lithium 
was found to reduce memory deficits related to the drug, H-89, a PKAII agonist, in part by 
increasing the activation of cholinergic markers (Sharifzadeh et al., 2007).   
Norepinephrine.  Lithium is reported to enhance the reuptake of NE in both 
synaptosomes and brain slices.  The ability of lithium to decrease the activity of NE is reported 
to likely contribute to the acute antimanic and prophylactic effects of the drug.  In a study by 
Katz and Kopin (1969), lithium administration decreased the amount of the [3H]NT released 
following electrical stimulation of brain slices but did not affect the spontaneous release of NE.  
Another study reported that lithium treatment reduced yohimbine-induced increases in NE levels 
in the cerebral cortex, possibly by reducing NE release (Swann, 1988).      
Enzymes.  Numerous enzymes are affected by lithium; however, only few are 
significantly inhibited at therapeutic serum concentrations.  Clinically relevant serum levels of 
lithium (0.5 – 1 1.2 mM) are known to have direct effects on the metabolic enzyme 
phosphoglucomutase and on a superfamily of structurally related phosphomonoesterases.  Of this 
family, the enzymes IMPase, polyphosphate 1-phosphatase (IPPase), fructose 1,6-
biophosphatase (FBPase), and bisphosphate nucleotidase (BPNase) have been shown to have a 
magnesium ion binding site within the active site of the enzyme (Atack, Broughton, & Pollack, 
1995b; Gould, Quiroz, Singh, Zarate, & Manji, 2004; Harwood & Agam, 2003).  Lithium has an 
ionic radius similar to magnesium and as such can substitute for magnesium through 
uncompetitive inhibition, binding to the active site and preventing product release and trapping 
products in the active site (Atack, Broughton, & Pollack, 1995a; Harwood & Agam, 2003).   
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  Pharmacokinetics of lithium.  Lithium has the narrowest therapeutic window of any 
drug routinely prescribed in psychiatric medicine (Kilts, 1998).   The therapeutic range for 
human serum concentrations of lithium was determined to be 0.6 – 1.2 mEq/L (Feldman, Meyer, 
& Quenzer, 1997; Kilts, 1998; Komoroski & Pearce, 2004).  Serum levels that fall below 0.6 
mEq/L have been associated with increased rates of relapse of symptoms and poorer 
psychosocial functioning in BAD patients (Gelenberg et al., 1989; Kilts, 1998; Solomon et al., 
1996).  Serum levels above 1.5 mEq/L are associated with adverse side effects and levels above 
3.5 mEq/L are associated with life-threatening lithium intoxication.  It is very important for 
individuals prescribed lithium to have routine monitoring of serum lithium concentrations to 
prevent aversive effects.  If serum levels go beyond 2.0 mEq/L, lithium is known to have toxic 
effects that include vomiting, diarrhea, nephrogenic diabetes insipidus (including polyuria and 
polydipsia), bone loss, hypercalcaemia, ataxia, tremor, fatigue, irritability, seizures, coma, and 
death (Feldman et al., 1997; Schou, 2001).  Due to the side effects of lithium it is estimated that 
over one third of patients are poorly able to tolerate its effects.  Lithium also has reported 
teratogenic effects.  In humans, there is an increased risk for cardiovascular malformations, 
particularly Ebstein’s anomaly, a congenital heart defect, when lithium is taken during the first 
trimester of pregnancy (De Santis et al., 2008). 
Lithium is the smallest of the alkali cations, with an ionic radius of 0.60 Å.  The 
structural similarity of lithium to sodium (0.95 Å) and potassium (1.4 Å), all members of group 
1A in the periodic table, allows lithium to substitute for these cations in various cellular 
processes.  However, the differences in ionic radii alter the effectiveness of lithium to carry out 
these processes to the same degree as the other cations (Ehrlich & Diamond, 1980).   For 
example, in the brain, lithium can replace sodium in extracellular fluid and is easily drawn into 
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neurons during an action potential.  However, it is not easily removed by the sodium-potassium 
pump, and thereby prevents potassium from reentering the cell.  The resulting imbalance in 
electrolytes prevents the cell from repolarizing properly and inhibits conduction and thereby 
neuronal excitability (Grafe, Reddy, Emmert, & ten, 1983).  Lithium can also substitute for the 
divalent cations, calcium and magnesium.  Calcium and lithium have a similar charge density, 
and magnesium and lithium have a very similar ionic radius, 0.65 and 0.60 Å respectively.  It is 
the similarity between lithium and the afore mentioned divalent cations that is physiologically 
relevant because of their regulatory actions in cellular functioning (e.g., enzymes, kinetics, and 
synaptic events) (Ehrlich & Diamond, 1980).    
 Lithium negligibly binds to plasma proteins and it is not metabolized or biotransformed 
in any appreciable way.  Lithium is excreted by the kidneys in its intact form and is reabsorbed 
in the proximal renal tubules (Feldman et al., 1997; Janicak & Munson, 1998; Kilts, 1998).  
Lithium has high energy of hydration and its hydrated ionic radius (310 pm) is similar to sodium 
with its hydration coat (340 pm).  Because of this ionic radius, lithium can substitute for sodium 
in many of the active sodium transport mechanisms.  In periods of dehydration or sodium 
depletion, both sodium and lithium retention is increased, necessitating adequate hydration prior 
to initiating lithium treatment to prevent excessive build-up of lithium in the body (Janicak & 
Munson, 1998). 
As previously mentioned, the similarities between sodium and lithium allow for lithium 
to replace it in sodium transport mechanisms, such as: the sodium-potassium pump, sodium-
lithium countertransport, bicarbonate-sensitive pathway, voltage-dependent sodium channel, and 
leak (i.e., passive diffusion).  However, under physiological conditions, the affinity of lithium 
relative to other cations in the various transport mechanisms precludes the likelihood for certain 
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mechanisms to be important in the transport of lithium across a particular membrane.  For 
example, the transport of lithium across the membrane of a red blood cell (RBC) occurs through 
leak and bicarbonate-sensitive pathways, whereas sodium-lithium countertransport is important 
for the removal of lithium from the cell.  The influx of lithium into excitable cells (i.e., nerve and 
muscle cells) is primarily through via voltage-dependent sodium channels and to a lesser extent, 
passive diffusion.  Similar to RBCs, the removal of lithium from excitable cells is largely via 
sodium-lithium countertransport (Ehrlich & Diamond, 1980). 
Lithium enters the brain via the blood-CSF barrier (Ehrlich & Wright, 1982).  The 
authors reported that lithium is passively transported across tight junctions formed by the 
epithelial cells of the choroid plexus via sodium-lithium countertransport (Ehrlich & Wright, 
1982).  In this mechanism, one lithium ion is transported out of the cell in exchange for one 
external sodium ion, which goes into the cell.  Once across the choroid plexus, lithium enters the 
brain through the CSF, which is continuous with the interstitial fluid that surrounds the cells of 
the brain.     
In humans, lithium (typically lithium carbonate) is easily absorbed and reaches peak 
plasma levels in 1 – 2 hours for standard release formulations and 4 – 5 hours for sustained 
release formulations (Grandjean & Aubry, 2009).  The effect of lithium administration on serum 
levels can vary greatly among human subjects depending on factors like weight and age.  The 
half-life of lithium is 18 – 20 hours in healthy young adults and up to 36 hours in elderly patients 
(Janicak & Munson, 1998).  The elimination half-life of lithium is between 18 – 36 hours.  In 
humans, the difference between brain and plasma lithium concentrations is significant.  Brain 
concentrations are approximately half of serum levels (Komoroski & Pearce, 2004; Pearce, 
Lyon, & Komoroski, 2004).  In one study, it was reported that brain concentrations of lithium are 
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better correlated with effective treatment of mania as compared to serum concentrations (Kilts, 
1998).  Similarly, (Gould et al., 2008), using a mouse model of depression, found that the 
observed antidepressant-like effects of lithium were due to its action in the brain, and not to any 
peripheral effects of the drug (Gould et al., 2008).   However, MRI studies show that among 
animals there is less variability between brain and serum concentrations of lithium (Komoroski 
& Pearce, 2004; Pearce et al., 2004).  Indeed, in rodents, following long-term treatment with 
lithium, whole brain and serum lithium concentrations were found to be equivalent 
(Ghoshdastidar, Dutta, & Poddar, 1989; Gould et al., 2008; Gould, O'Donnell, Picchini, & 
Manji, 2007).   
The distribution and retention of lithium in the blood and brain of male mice was 
evaluated following single-dose and chronic (21 day) lithium treatment.  A single-dose of lithium 
(0.5 mmol/kg) produced peak plasma levels at 8 hours post-injection and peak brain 
concentration at 12 hours post-injection.  Chronic daily administration of this dose showed no 
change in overall lithium concentration in the whole brain or the following brain regions: 
cerebral cortex, striatum, hippocampus, diencephalon, brain stem and cerebellum (Messiha, 
1976).  Lambert and colleagues also reported steady brain levels of lithium following both acute 
and chronic lithium dosing (Lambert, McGirr, Ely, Kilts, & Kuhar, 1999).   
Serum lithium levels in rats were assessed after acute (single-dose) and chronic (30 day) 
dosing with 2.0 mmol/kg lithium chloride, administered via intraperitoneal injection (Tsaltas, 
Kyriazi, Poulopoulou, Kontis, & Maillis, 2007).   The serum concentrations were evaluated to 
ensure that daily lithium administration did not result in accumulation of the drug, which might 
cause increased serum levels over days and possibly affect the health of the animals.  Serum 
concentrations were assessed at 1, 12, or 24 hours following the last lithium injection.  The 
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findings from this study show that there was no difference in the serum lithium levels of 
chronically or acutely treated rats at any of the time points.  Thus, the authors concluded that 
daily intraperitoneal injections of lithium are not likely to produce excess lithium accumulation 
over time (Tsaltas et al., 2007).  However, there was a significant difference in the serum levels 
of lithium over the three post-injection time points (1, 12, and 24 hours), irrespective of the 
duration of treatment.  The 2.0 mmol/kg (84.7 mg/kg, ip) dose of lithium produced peak serum 
concentrations (1.7 ± 0.4 mEq/L) at 1 hour post-injection.  Serum concentrations decreased at 12 
hours (0.5 ± 0.4 mEq/L) and were almost absent by 24 hours (0.4 ± 0.4 mEq/L) post-injection 
(Tsaltas et al., 2007).  In another study, single dose of 5.0 mmol/kg administered to rats produced 
a maximum brain concentration of 1.5 mmol/kg between 9 and 24 hours, and the half-life was 
determined to be 12 hours (Wraae, 1978).  These animal findings are in accord with the decline 
in serum concentrations observed in human pharmacokinetic studies (Tsaltas et al., 2007).   
Lithium is neuroprotective.  There is compelling evidence to state that lithium is 
neuroprotective.  Supporting data comes from in vitro, in vivo and clinical studies employing 
vastly diverse methodologies and parameters (Rowe & Chuang, 2004).   
In vitro.  In studies using both rodent and human cell lines, (e.g., cerebellar granule cells 
(CGC), cerebral cortical cells, hippocampal neurons, PC12 cells, and neuroblastoma cells) 
lithium has been found to be neuroprotective against a variety of insults (e.g., β-amyloid peptide 
(Aβ), potassium deprivation, staurosporine and heat shock, oubain, β-bungarotoxin, and 
glutamate excitotoxicity (Alvarez et al., 1999; Bijur, De Sarno, & Jope, 2000; Bournat, Brown, 
& Soler, 2000; Hennion, el-Masri, Huff, & el-Mailakh, 2002; Mora et al., 2001; Nonaka, Hough, 
& Chuang, 1998; Nonaka, Katsube, & Chuang, 1998; Rowe & Chuang, 2004; Wei et al., 2000).   
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 In an animal model of Alzheimer’s disease, primary cultures of rat cortical neurons were 
treated with Aβ, known to induce cell death in cultured neurons.  Lithium treatment (10 mM and 
2 mM), was found to prevent Aβ-induced tau hyperphosphorylation in addition to providing 
significant neuroprotection to cortical neurons (Alvarez et al., 1999).  These effects are 
hypothesized to involve lithium-induced inhibition of GSK-3β, a kinase known to phosphorylate 
a wide range of substrates including tau.  The 10 mM dose of lithium was protective against Aβ; 
however, this dose resulted in lithium-induced toxicity and cell death after 4 days of treatment.  
The lower dose of lithium did not have the same toxic effects.  Therefore, it was speculated by 
the authors that low doses of lithium, similar to those used in the treatment of BAD, may be 
beneficial in treating Alzheimer’s disease, as well as other neurodegenerative disorders (Alvarez 
et al., 1999).   
When cells in culture are deprived of potassium, the result is increased activated caspase-
3 levels, in addition to promoting the phosphorylation of PKB and GSK-3.  Granule cells 
subjected to potassium deprivation, in the presence of 5 mM lithium chloride, were completely 
protected against potassium-induced apoptosis.  Additionally, the protective effect was observed 
for up to 48 hours after lithium treatment.  These findings indicate that the neuroprotective 
actions of lithium are effective for a period of time after lithium treatment has ended (D'Mello, 
Anelli, & Calissano, 1994).  In another study, Mora and colleagues also examined the effects of 
potassium deprivation in cerebellar granule cells, with the aim to elucidate a potential 
mechanism of action for lithium-induced neuroprotection (Mora, Gonzalez-Polo, Fuentes, Soler, 
& Centeno, 1999).  Caspase-3 is an effector caspase and has been established as a biochemical 
marker of apoptosis (Bijur et al., 2000).  In CGC’s, 5 mM lithium, co-incubated with low 
potassium, significantly decreased the levels of activated caspase-3 protein.  Lithium was found 
 
 
36 
 
to prevent the cleavage of procaspase-3, and not the activity of the active form of capase-3 (Mora 
et al., 2001).  The authors speculate that the phosphorylation state of PKB and GSK-3β are 
related to lithium’s effects.   
 Staurosporine is used to experimentally induce apoptosis in all cell types and thereby 
increase activation of caspases-3 and -9 (Bijur et al., 2000).  Human neuroblastoma SH-SY5Y 
cells were subjected to staurosporine or heat shock in the presence of GSK-3β over-expression.  
GSK-3β alone was not sufficient to induce apoptosis.  However, over-expression did confer 
greater vulnerability to caspases-3 activation and apoptosis when combined with staurosporine or 
heat shock (Bijur et al., 2000).  Lithium treatment was able to significantly reduce the apoptotic 
effect.  It was proposed that lithium’s activation of the phosphoinositide 3-kinase/Akt (PI3k/Akt) 
pathway may partially contribute to these protective effects via PI3-K inhibition of GSK-3β.  
Additionally, lithium-induced inhibition of GSK-3β prevents degradation of β-catenin.  
Decreased β-catenin has been linked to increased cell death (Bijur & Jope, 2000).  Contrary to 
these findings, another study, using CGCs exposed to staurosporine, and then treated with 
lithium, failed to find neuroprotection (Nonaka et al., 1998).  Because lithium’s neuroprotective 
effects against other insults in cerebellar granule cells has been well documented in the literature, 
these findings indicate that lithium neuroprotection may be specific to particular initiators of 
apoptosis, i.e., GSK-3β (Bijur & Jope, 2000; Nonaka et al., 1998).    
 Oubain is a toxic agent used to experimentally mimic the neurochemical changes 
observed following manic episodes in individuals with BAD.  Mania is associated with increased 
sodium retention, increases in intracellular sodium and calcium, and decreased activity of the 
sodium-potassium pump (Hennion et al., 2002).  Low dose lithium treatment for 72 hours prior 
to oubain exposure was protective against oubain-induced toxicity.  However, if lithium was 
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administered 24 or 48 hours prior to exposure, the protective effect was not observed.  This 
finding indicates that for some of the beneficial effects of lithium, a loading period is required.  
Indeed, in the treatment of BAD, the mood stabilizing effects are not observed for a period of 
time following initiation of treatment (Hennion et al., 2002).      
Cultured cerebellar granule cells exposed to the neurotoxin β-bungarotoxin, a NMDA 
receptor and L-type calcium channel agonist, results in increased neuronal calcium influx.  
Lithium pre-treatment, ranging from 2 – 7 days, was found to be dose and time-dependent.  
Maximum effectiveness was observed following pretreatment with 1.2 mM lithium for 3 days.  
This dose and duration of pre-treatment attenuated the β-bungarotoxin-induced increase in 
reactive oxygen species (ROS) and superoxide anion.  However, pre-incubation for 6 – 7 days 
using the same dose (1.2 mM) of lithium resulted in suboptimal levels of neuroprotection.  A 
higher concentration of lithium (3.0 mM) was also found ineffective in preventing β-
bungarotoxin neurotoxicity, in addition to being slightly toxic to the cells (Tseng & Lin-Shiau, 
2002).  The dose of lithium found to be most effective against this neurotoxin is in accordance 
with the therapeutic serum levels of lithium used in human patients (between 0.5 and 1.2 mM) 
(Hopkins & Gelenberg, 2000; Tseng & Lin-Shiau, 2002). 
Several studies have reported on lithium’s neuroprotective effects against glutamate-
induced neurotoxicity in cultured CGCs (Chen & Chuang, 1999; Kopnisky, Chalecka-Franaszek, 
Gonzalez-Zulueta, & Chuang, 2003; Manji, Moore, & Chen, 1999; Nonaka et al., 1998).  
Glutamate excitotoxicity leads to initiation of pro-apoptotic pathways and is known to play a role 
in TBI pathology.  Cerebellar granule cells pre-treated (7 – 9 days) with lithium (0.5 – 5.0 mM) 
showed significant protection against glutamate-induced neurotoxicity by modulation of NMDA 
receptor mediated calcium influx (Nonaka et al., 1998).  Lithium is able to protect against not 
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only NMDA receptors mediated calcium influx, but also suppresses apoptotic mechanisms 
initiated by excitotoxic calcium influx.   
Lithium’s involvement in preventing apoptosis was assessed via examination of gene 
expression and protein levels of pro-apoptotic (p53 and Bax), and cytoprotective (Bcl-2) (Chen 
& Chuang, 1999; Manji et al., 1999).  CGCs pre-treated with lithium (3 mM) for 7-days 
prevented glutamate-induced increases in p53 and Bax mRNA levels, and at the same time, 
sustained lithium-induced increases in Bcl-2 mRNA (Chen & Chuang, 1999).  Indeed, lithium 
also increased the ratio of Bcl-2 protein levels over Bax protein.  These findings are further 
supported by both in vitro and in vivo studies, where chronic lithium treatment increased the 
expression of Bcl-2 and decreased the expression of p53 and Bax (Manji et al., 1999).  Bax and 
Bcl-2 are both involved in modulating cytochrome c release by mitochondria.  Pre-treatment 
with lithium for 7 days was found to block glutamate-induced cytochrome c release by 
mitochondria, thereby preventing the release of cytochrome c into the cytosol (Chen & Chuang, 
1999).   
 Cyclic AMP-responsive element binding protein (CREB) is a signaling system involved 
in cell survival and increases in CREB are associated with synaptic plasticity and neuronal 
reorganization in hippocampal mossy fiber cells following TBI (Finkbeiner, 2000; Hu et al., 
2004).  Additional supporting evidence for its beneficial effects in cell survival is from data 
showing phosphorylated CREB (pCREB) directly regulates the CRE-dependent transcription of 
the BDNF and Bcl-2 (Kopnisky et al., 2003; Tao, Finkbeiner, Arnold, Shaywitz, & Greenberg, 
1998).  CGCs exposed to glutamate for 8 days revealed a dose- and time-dependent change in 
pCREB at Ser133.  Decreases in pCREB due to glutamate exposure were completely blocked by 
treatment with MK-801 (a potent NMDA receptor antagonist), indicating that the glutamate-
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induced changes in pCREB are related to the activation of NMDA receptors (Kopnisky et al., 
2003).  Lithium pre-treatment for 7 days prior to glutamate exposure suppressed glutamate-
induced decreases in pCREB, whereas lithium treatment for 30 minutes, 4 hour and 24 hours did 
not affect pCREB levels.  Increased protein phosphatase-1 (PP-1) activity is reported to be 
involved in glutamate-induced decreases in pCREB.  It was found that lithium treatment 
prevented glutamate-induced increases in PP-1 activity (Kopnisky et al., 2003).  In addition to 
PP1, the MEK/ERK pathway also regulates pCREB and is increased following lithium 
administration (Kopnisky et al., 2003).   
Cerebral cortical neurons exposed to toxic levels of glutamate can be protected by 
NMDA receptor antagonists (e.g., MK-801).  However, non-NMDA receptor antagonists were 
not effective.  Again, this indicates that glutamate toxicity in these neurons is mediated by 
NMDA receptors (Hashimoto, Hough, Nakazawa, Yamamoto, & Chuang, 2002).  Lithium 
treatment, at therapeutic levels, generates plasma levels within the range of 0.6 – 1.2 mM 
(Hashimoto et al., 2002; Hopkins & Gelenberg, 2000).  Doses of lithium between 0.1 mM – 1.0 
mM showed significant neuroprotective effects when administered 6 days prior to excitotoxicity.  
These data indicate that lithium at therapeutic and sub-therapeutic concentrations is 
neuroprotective in cerebral cortical neurons (Hashimoto et al., 2002).  Additionally, the duration 
of lithium pre-treatment was critical for its neuroprotective effects.  The minimum duration for 
pre-treatment to achieve neuroprotection was at least 2 days.  Maximum neuroprotection was 
attained after 5 – 6 days (Hashimoto et al., 2002).   
   In vivo.  In vivo studies have also demonstrated the neuroprotective effects of lithium 
in several animal models (e.g., transient and focal ischemia-induced brain damage, striatial 
infusion of quinolinic acid to produce an excitotoxic model of Huntington’s disease, excitotoxic 
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lesions of the cholinergic system, kainic-acid-induced brain lesions, and irradiation)  (Inouye et 
al., 1995; Rowe & Chuang, 2004).  Manji, Moore, & Chen, (1999), reported that in both in vitro 
and in vivo studies, chronic lithium treatment increased the expression of the anti-apoptotic 
protein Bcl-2 and decreased the expression of pro-apoptotic proteins p53 and Bax.  
Compelling evidence for lithium’s efficacy as a treatment against secondary injuries 
associated with TBI comes from an experimental model of stroke that produces transient focal 
cerebral ischemia via middle cerebral artery occlusion (MCAO) (Ren et al., 2003; Xu, Culman, 
Blume, Brecht, & Gohlke, 2003; Yan, Wang, Hou, Ji, & Zhou, 2007).   MCAO is characterized 
by ischemia-induced infarct, damage to the basal ganglia (i.e., striatum, subthalamic nucleus, and 
substantia nigra), in addition to sensory, motor and behavioral deficits (Borlongan, Cahill, & 
Sanberg, 1995).    
Heat shock proteins (HSP) (e.g., HSP-70 & HSP-71) are molecular chaperones that 
protect the cell from thermal and oxidative stress.  Additionally, HSPs protect neurons by 
antagonizing apoptosis-inducing factor (AIF) (Ravagnan et al., 2001).  HSP-70 is a stress-
induced protein that acts to protect unfolded or malfolded proteins by binding to them, ensuring 
proper folding and preventing intracellular protein aggregation (Hendrick & Hartl, 1993; Ren et 
al., 2003).  This cellular protector also participates in the disposal of damaged or defective 
proteins.  Heat shock factor-1 (HSF1) is a cytoplasmic transcription factor that when activated is 
converted to a nuclear protein that regulates gene transcription of HSPs.  HSF-1 is negatively 
regulated by serial phosphorylation at Ser307 by MAPK, allowing GSK-3β to phosphorylate the 
adjacent Ser303 (Chu, Soncin, Price, Stevenson, & Calderwood, 1996).   
Lithium treatment following transient MCAO has been shown to significantly increase 
HSF-1 and HSP-70 levels as compared to saline controls (Ren et al., 2003).  The upregulation of 
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HSF-1 and HSP-70 induced by lithium occurs rapidly and is temporally allied to lithium’s 
neuroprotective effects against MCAO / reperfusion-induced brain injury (Ren et al., 2003).  
Lithium-induced neuroprotective effects resulting from increased HSP-70 are thought to be due 
to either direct inhibition of GSK-3β or activation of the phosphoinositide 3-kinase/Akt signaling 
pathway.  Both are related to disinhibition of HSF-1, thereby allowing increased transcription 
and expression of HSP-70.  Indeed, over-expression of HSP-70 was found to protect neurons 
from ischemic brain damage (Hoehn et al., 2001; Ren et al., 2003).  Additionally, activation of 
HSP-70 inhibited ischemia-induced activation of NF-κB (a pro-apoptotic factor) and subsequent 
increases in apoptotic cell death (Feinstein et al., 1996; Ren et al., 2003; Schneider et al., 1999).  
The study by Ren (2003), showed that increases in HSF-70 following MCAO were observed 
only in the ipsilateral side.  The contralateral side revealed increases in HSF-1 binding, but not in 
HSP-70.  Sham animals exhibited the same effects observed in the contralateral hemisphere.  
These data indicated that a further stimulus may be necessary to induce HSP-70 transcription 
(Pirkkala, Nykanen, & Sistonen, 2001; Ren et al., 2003).    
Chronic (2 week) treatment with lithium was evaluated for its neuroprotective effects in a 
rodent model of stroke (Xu et al., 2003).  Ischemic brain damage was produced by MCAO 
lasting 90 min followed by reperfusion.  Rats were administered 1 mmol/kg lithium (sc) each 
day, for 12 days prior to the ischemic insult, with the dose of lithium on day 12 administered 2 
hours prior to MCAO.  Treatment with lithium was continued for two additional days following 
the insult.  During these days, two hours post-injection, animals underwent neurological 
assessment.  Data from these assessments show that lithium-treated rats had significantly better 
scores on measures of neurological function, derived from two previous studies, Garcia et al. 
(1995) and Bederson et al. (1986).  The neurological functions assessed were: spontaneous 
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activity, symmetry in moving all four limbs, forepaw outstretching, climbing, body 
proprioception, response to vibrissae touch (Garcia, Wagner, Liu, & Hu, 1995), forelimb flexion, 
decreased resistance to lateral push, and circling behavior (Bederson et al., 1986).   In addition to 
improvements in the neurological functioning score, Xu and colleagues (2003) found significant 
reductions in total infarct volume (32.7%) as compared to vehicle-treated injured rats.  Edema 
formation, however, was not affected by lithium treatment.  Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL), an assay used to detect DNA fragmentation 
resulting from apoptotic cascades, revealed a significant reduction in TUNEL-positive cells of 
lithium-treated injured rats as compared to vehicle-treated injured rats.  Analysis of the apoptotic 
marker, caspase-3, revealed significantly fewer caspases-3 positive-cells in the ischemic 
penumbra of the occluded area of lithium treated rats (Xu et al., 2003).  Levels of the AP-1 
transcription factor c-Jun were increased in the ipsilateral cortex following ischemic injury 
resulting from MCAO.  Proteins modulated by AP-1 are generally increased in surviving cortical 
regions.  Lithium has been shown to indirectly reduce AP-1 levels via inhibition of NMDA 
receptor-mediated increases in pro-apoptotic p38 and JNK (Rowe & Chuang, 2004).  Indeed, Xu 
and colleagues found that c-Jun levels were significantly lower in the ischemic penumbra of 
lithium-treated rats.  The authors purport the observed neuroprotective effects of lithium are due 
to reduced apoptotic events in the cortex, as determined by inhibition of caspase-3 and decreased 
fragmentation of DNA.  Additionally, the lithium-induced alteration in c-Jun levels suggests that 
reduced AP-1 protein expression may be involved in the neuroprotective effects of lithium in 
ischemic brain injury (Xu et al., 2003). 
Extracellular signal-regulating kinase 1 and 2 (ERK1/ERK2) is a member of the mitogen-
activated protein kinase superfamily and is activated via phosphorylation on threonine and 
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tyrosine residues as a reaction to extracellular stimuli including growth factors.  
Neurotransmitters and neurotrophins can also be activated by brain injury.  ERK1/ERK2 is 
known to be involved in cell growth, proliferation, differentiation, apoptosis, synaptic plasticity, 
and learning and memory via involvement in LTP (Atkins, Selcher, Petraitis, Trzaskos, & 
Sweatt, 1998; Liou, Clark, Henshall, Yin, & Chen, 2003; Ménard et al., 2002; Schaeffer & 
Weber, 1999).  Lithium’s influence on signaling cascades, specifically, mitogen-activated protein 
kinase (MAPK) and ERK1/ERK2, was evaluated following transient global cerebral ischemia 
(Yan, Hou, Wu, Liu, & Zhou, 2007).  At 6 hours postinjury, lithium treatment was found to up-
regulate ERK1/ERK2 in the CA3 and DG of the hippocampus in both the sham and ischemic-
injured groups.  Cognitive assessment using the MWM (PID 19-21) revealed a trend towards 
shorter latencies for the lithium-treated ischemic rats as compared to ischemic rats (Yan et al., 
2007).    
Another study by Yan and colleagues (2007), evaluated preinjury lithium treatment on 
several behavioral outcome measures (beam balance, elevated plus maze, open field task, and 
MWM) following transient global ischemia (Yan et al., 2007).  Rats were pre-treated with 
lithium (1.0 mmol/kg, ip) daily for 2 weeks prior to ischemic brain injury, with treatment 
continuing for the duration of the behavioral assessments (i.e., 9 days post-insult).  Beam 
balance, elevated plus maze, and open field tasks were administered on PID 3.  The MWM task 
was performed on PID 7 – 9.  Performance in the beam balance task was significantly improved 
on PID 7 only.  The behavioral assessments revealed that untreated ischemic rats were more 
likely to engage in hyperactive behavior, as measured by the open field task, and exhibited 
greater risk taking behavior, as measured by increased open arm exploration in the elevated plus 
maze.  The MWM protocol employed two sets of four trials on the first day of testing, followed 
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by a single set of four trials for the remaining two days.  On the first day of testing the ischemic 
rats and the lithium-treated ischemic rats did not differ significantly; however, the lithium-treated 
rats did show a trend toward shorter latencies.  On the second and third days tested in the MWM, 
the lithium-treated ischemic rats performed significantly better as compared to the ischemic rats 
(Yan et al., 2007).  Histological analysis and quantification of pyramidal neurons within CA1 of 
the hippocampus was performed 9 days after reperfusion.  Significant cell death was observed 
within the CA1 region of ischemic rats.  Lithium treatment significantly reduced cell death, with 
no significant difference observed between lithium-treated and sham rats (Yan et al., 2007).  
Clinical studies.  Clinical research provides the final pieces of supporting evidence for 
lithium’s neuroprotective ability.  However, in clinical studies it is difficult to determine to what 
extent the beneficial effects of lithium are due to neuroprotection or to neurotrophic effects 
(Rowe & Chuang, 2004).  Neuroimaging techniques and post-mortem morphology studies have 
revealed decreases in brain volume and cell number in patients with mood disorders (Drevets et 
al., 1999).  These changes could be due to developmental abnormalities, disease progression, or 
alterations in neurochemistry resulting from changes in neurotransmitter levels in chronic 
affective disorders (Duman, Heninger, & Nestler, 1997). 
MRI studies have shown increased gray matter volume within several brain structures of 
individuals diagnosed with BAD and treated with lithium as compared to individuals with BAD 
not undergoing lithium treatment (Bearden et al., 2007a; Bearden et al., 2007b; Manji, Moore, & 
Chen, 2000a; Monkul et al., 2007; Moore, Bebchuk, Wilds, Chen, & Manji, 2000).  Levels of N-
acetyl-aspartate (NAA), a marker of neuronal viability, were increased following 4 weeks of 
lithium treatment.  It is difficult to determine if these effects are due to neuroprotective or 
neurotrophic effects. 
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Moore and colleagues (2000), using three-dimension magnetic resonance imaging (3D-
MRI) and quantitative brain-tissue segmentation, investigated the neuroprotective/neurotrophic 
effects of therapeutic levels of chronic lithium treatment on grey matter volume (Moore et al., 
2000).  Patients with BAD were given lithium for 4 weeks.  A baseline MRI scan was performed 
while each individual was “medication free” and had been off medication for at least 2 weeks 
prior to the initiation of the study.  These individuals were subsequently treated with lithium for 
4 weeks and upon conclusion of the treatment, a second MRI was performed.  These scans were 
then compared with scans taken following 4-weeks of lithium treatment.  Analysis of the MRI’s 
showed a significant increase (3% or approximately 24 cm3) in total grey matter volume in 8 out 
of 10 patients.  There was no significant change in either regional cerebral water content or brain 
white matter volume.  The authors postulate that the changes in grey matter volume were likely 
due to neurotrophic effects and not to cell swelling or alterations in contrast medium related to 
the lithium treatment (Moore et al., 2000). 
NAA, an accepted neuronal marker, is localized primarily within the cytosol of mature 
neurons and not found in mature glial cells, CSF, or blood (Manji, Moore, Rajkowska, & Chen, 
2000; Tsai & Coyle, 1995).  NAA is synthesized in the mitochondria and is related to 
mitochondrial oxygen and ATP consumption.  It is generally accepted as a gauge for neuronal 
viability and function (Manji et al., 2000a; Tsai & Coyle, 1995).  Individuals with BAD have 
been found to have decreased levels of NAA bilaterally in the hippocampus and DLPFC 
(Bertolino et al., 1999; Winsberg et al., 2000).  Moore and colleagues conducted another study 
using quantitative proton magnetic resonance spectroscopy in BAD patients undergoing lithium 
treatment (Moore et al., 2000).   Using an experimental design similar to the previously 
mentioned (2000) study by Moore, Bebchuk, Wilds, and co-workers, the levels of NAA were 
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examined following 4-weeks of lithium treatment (Moore et al., 2000).  Total levels of NAA 
were found to be significantly increased in all brain regions.  Based on the findings, the authors 
concluded that chronic lithium treatment may increase neuronal viability and function in the 
human brain (Moore et al., 2000).  
Neuroprotective mechanisms.  The mechanisms of action for lithium’s neuroprotective 
effects are mediated by several pathways and likely via multiple levels of the same pathway.  
This section will detail the two pathways most accepted in the literature as being involved in 
lithium-induced neuroprotection.  These are lithium’s induction of the cell survival signaling 
pathway and lithium’s inhibition of NMDA receptor-mediated calcium influx.  Within the cell 
survival signaling pathway, lithium’s effects will be discussed in relation to upstream, central, 
and downstream factors.  Upstream factors include BDNF and activated pathways (PI3K/Akt 
and MEK/ERK).  Centrally, lithium acts on GSK-3β and downstream factors include effector 
systems (β-catenin, HSF-1, AP-1, and CREB), the Bcl-2 family and caspases (Rowe & Chuang, 
2004). 
Upstream survival events.  Lithium’s role in neuroprotection begins at the cell surface-
trophic factor receptors.  BDNF, a neurotrophin involved in neuronal development, survival, and 
plasticity, is increased following lithium administration.  BDNF activates the trophic receptor, 
TrkB, inducing phosphorylation of its Tyr490.  Once activated the TrkB receptor has several 
receptor systems, including phospholipase Cγ (PLCγ) signaling, MEK/ERK signaling, and 
PI3K/Akt signaling (Huang & Reichardt, 2001).  
The importance of BDNF in lithium-induced neuroprotection is supported by two 
important pieces of evidence.  First, in vitro and in vivo studies have showed that treatment with 
lithium increases BDNF levels.  Second, lithium-induced neuroprotection is dependent on 
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activation of BNDF.  Indeed, in a study where TrkB activation was inhibited by either the TrkB 
antagonist K252a or in BDNF knockout mice, lithium-induced neuroprotection from glutamate 
toxicity was blocked (Hashimoto et al., 2002).  Once BDNF binds to the TrkB receptor, the 
PI3K/Akt and MEK/ERK pathways are activated.  Both of these pathways are vital for lithium’s 
observed neuroprotective effects.   
Via the PI3K/Akt pathway, the activation of TrkB results in the phosphorylation of the 
adaptor protein Shc that recruits Grb-2 to form a protein complex that initiates further down-
stream signaling events (Liou et al., 2003; Pearson et al., 2001).  From this point the pathway can 
go in one of two directions, both leading to the activation of PI3K.  Once PI3K is activated, it 
produces 3-phosphoinositides that in turn recruit phospholipid-dependent kinases (PDKs) that 
phosphorylate Ser473 and/or Thr308 to activate Akt-1.  Akt-1, also known as protein kinase B, is 
a serine/threonine protein kinase that regulates anti-apoptotic activity on multiple targets 
including GSK-3β, BAD (part of Bcl-2 family), CREB, some members of the forkhead family, 
and procaspase-9.  In vitro studies demonstrate that overexpression of Akt protects neurons 
subjected to serum or growth factor withdrawal (Chen, Yuan, Jiang, Huang, & Manji, 1998; 
Kermer, Klocker, Labes, & Bahr, 2000; Springer, Nottingham, McEwen, Azbill, & Jin, 2001).  
The involvement of PI3K in lithium-induced Akt-1 upregulation was demonstrated in vitro by 
inhibiting PI3K, thereby preventing lithium-induced increases in Akt-1 (Chalecka-Franaszek & 
Chuang, 1999; Kumari, Liu, Nguyen, Zhang, & D'Mello, 2001).  Glutamate excitotoxicity has 
been reported to decrease levels of Akt-1.  This is mediated by long-term lithium treatment.  
Additionally, long-term lithium treatment was found to increase recovery of Akt-1 
phosphorylation and activity (Chalecka-Franaszek & Chuang, 1999).  However, these findings 
do not universally apply to all cell types.  Using certain cell lines, some studies were unable to 
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detect changes in Akt-1, specifically, phosphor-Ser-473-Akt, following lithium treatment (De 
Sarno, Li, & Jope, 2002; Zhang, Phiel, Spece, Gurvich, & Klein, 2003).  
MAP kinases are another important pathway involved in preventing apoptosis and 
promoting neuroprotection (Rowe & Chuang, 2004).  Some of the prominent members of the 
MAP kinase family include c-Jun, N-terminal kinase (JNK), p38 kinase, and ERK.  The 
involvement of ERK in neuroprotection has been well documented in the literature (Chang et al., 
2003; Segal & Greenberg, 1996).  The ERK pathway begins with the phosphorylation of the Trk 
receptor by BDNF, leading to activation of Ras (Yan, Roy, Apolloni, Lane, & Hancock, 1998).  
Ras binds to Raf proteins (Raf-1 and B-Raf) that subsequently activate MEK, resulting in 
phosphorylation of ERK.  ERK has direct and indirect effects on effector systems, such as NF-
κB and ribosomal S6 kinase (RSK).  These effector systems subsequently regulate CREB and 
GSK-3β.  The MEK/ERK pathway also has deleterious downstream effects on the Bcl-2 family, 
caspases, and AP-1 transcription factor (Rowe & Chuang, 2004; Steelman et al., 2004).  Using 
an in vivo model, it was reported that the MEK/ERK pathway was responsible for the 
neuroprotective effects of chronic lithium treatment (Einat et al., 2003).  However, others have 
reported that lithium blocks the MEK/ERK pathway, although differences in results appear to be 
cell-type-dependent (Pardo, Andreolotti, Ramos, Picatoste, & Claro, 2003).  Together these 
findings indicate that lithium-induced neuroprotection is complex and not solely related to any 
one particular target of the drug (Rowe & Chuang, 2004).     
The stress-induced kinases p38 and JNK are typically involved in promoting apoptosis.  
Activation of these two pathways begins with a cellular stressor that activates GTPases (Rho, 
Rac, Cdc42).  The GTPases activate sets comprised of a MAP kinase kinase kinase 
(MEKK1/2/3/4), a MAP kinase kinase (MKK3/4/6/7), and a MAP kinase (JNK or p38) (Mielke 
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& Herdegen, 2000; Tibbles & Woodgett, 1999).  MAP kinase translocates to the nucleus and 
phosphorylates, thereby activating transcription factors (e.g., AP-1 and p53) (Sionov & Haupt, 
1999; Whitmarsh & Davis, 1996).  Support for lithium’s involvement in this pathway comes 
from neuroprotection studies where cell damage induced by glutamate-toxicity or deprivation of 
trophic factors was prevented by lithium (Chen et al., 2003; Hongisto et al., 2003; Rowe & 
Chuang, 2004).    
The central factor.  Glycogen synthase kinase-3 is a serine/threonine protein kinase that 
is highly abundant systemically as well as in the brain.  There are at least 2 isoforms of GSK-3.  
They are GSK-3α and GSK-3β.  GSK-3 is involved in the regulation of neuronal plasticity, gene 
expression, and cell survival, and may be involved in the pathology of neuropsychiatric and 
neurodegenerative diseases (Li, Bijur, & Jope, 2002; Martinez, Castro, Dorronsoro, & Alonso, 
2002).  There are several kinases that regulate GSK-3β activity including Akt, protein kinase A 
(PKA), protein kinase C (PKC), MAP kinases and the Wnt signaling pathway.  GSK-3 acts on 
diverse substrates, including more than 40 proteins that are involved in cellular metabolic 
processes, signaling, and structural functions (Jope & Johnson, 2004; Martinez et al., 2002).  
Among these diverse substrates are several signaling proteins (e.g., AP-1, CREB, activated T-
cells, HSF-1, β-catenin, NF-κB, c-Jun, and Myc) (Davies, Jiang, & Mason, 2001; Li et al., 2000; 
Martinez et al., 2002; Rothwarf & Karin, 1999; Rowe & Chuang, 2004; Yoganathan et al., 
2000).     
There are three potential mechanisms for lithium-induced regulation of GSK-3β: directly, 
indirectly, and autoregulation.  It is important to note that the neuroprotection afforded by 
lithium treatment is likely related to action via all three mechanisms.  Additionally, GSK-3α is 
also affected by lithium and may have relevance to lithium-induced neuroprotection (Rowe & 
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Chuang, 2004).  However, lithium’s effects on GSK-3β have been more thoroughly 
characterized and therefore will be the focus of the following discussion.     
Direct inhibition of GSK-3β.  Direct inhibition of GSK-3β by lithium is thought to be 
through competitive binding to magnesium channels.  It was theorized that the direct inhibition 
of GSK-3β may account for the observed neuroprotective effects in animal models of stroke.  
However, lithium’s inhibition of GSK-3β occurs quickly.  Only one study found that a single 
dose of lithium was effective in reducing neurobehavioral deficits, when administered 3 hours 
after the onset of MCAO (lasting 24 hours) (Ren et al., 2003).  This is in contrast to several 
studies that have shown that chronic treatment is necessary for neuroprotection (Bauer, Alda, 
Priller, & Young, 2003; Rowe & Chuang, 2004; Xu et al., 2003).  Additionally, the IC50 for 
direct inhibition of GSK-3β is between 1.5 and 2.0 mM lithium.  This range is higher than doses 
typically found in neuroprotective studies.  Thus, it was reported by Rowe and Chuang in their 
2004 review article, that neuroprotection induced by lithium treatment can occur with less than 
50% inhibition of pro-apoptotic GSK-3β.   
Indirect inhibition of GSK-3β.  Indirectly, it is speculated that lithium regulates the 
phosphorylation status of GSK-3β by increasing Ser9 phosphorylation (Klein & Melton, 1996; 
Li et al., 2002).  The activity of GSK-3β is regulated by the phosphorylation states of Ser9 and 
Tyr216.  Phosphorylation of Ser9 decreases GSK-3β activity and phosphorylation of Tyr216 
increases activity.  Another potential avenue for lithium’s action is through the survival signaling 
pathway.  On this path, lithium treatment stimulates BDNF, which in turn promotes the 
PI3K/Akt and MEK/ERK pathways, leading to inhibition of GSK-3β (Li et al., 2002).    
Autoregulation of GSK-3β.  The third potential mechanism of action for lithium-induced 
inhibition of GSK-3β is through autoregulation (Rowe & Chuang, 2004).  The activity level and 
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phosphorylation state of GSK-3β can be altered via autoregulation.  This is mediated by the 
protein phosphatase-1 / inhibitor-2 (PP-1/I-2) complex (Zhang et al., 2003).  In one direction, 
increased activation of GSK-3β phosphorylates I-2, and activates PP-1.  Activated PP-1 
dephosphorylates GSK-3β at Ser9, thereby increasing the activation of GSK-3β, which starts the 
cycle again.  Working in the opposite direction, inhibition of GSK-3β inhibits PP-1 by I-2.  This 
results in an increase in the phosphorylation of Ser9, thereby decreasing the activation of GSK-
3β.  Lithium-induced inhibition of GSK-3β inhibits PP-1, thereby inhibiting Ser9 
dephosphorylation, further reducing GSK-3β activation (Rowe & Chuang, 2004; Zhang et al., 
2003).    
 Downstream factors.  There are numerous downstream factors that may be affected by 
lithium treatment.  However, for the purposes of this dissertation, rather than detail all of these 
factors, only those that are well established in the literature as being involved in lithium’s 
neuroprotective effects will be discussed.  These factors include: β-catenin, HSF-1, AP-1, and 
CREB (Rowe & Chuang, 2004).   
 β-Catenin.  β-Catenin is a proto-oncogene produced by the canonical Wnt pathway (Yu 
& Malenka, 2003).  Briefly, Wnt proteins bind to extracellular receptors that are part of the 
family known as Frizzleds.  Frizzleds subsequently activate the intracellular protein disheveled-
1, which in turn inhibits GSK-3β (Moon, Bowerman, Boutros, & Perrimon, 2002).  Active GSK-
3β forms part of a β-catenin destruction complex.  This complex phosphorylates β-catenin, 
resulting in its breakdown.  Therefore, inhibition of GSK-3β leads to increased levels of β-
catenin.  Increases in β-catenin promote interactions with the transcription factor T-cell 
factor/lymphoid enhancer factor (Tcf-Lef) forming the Tcf/Lef-β-catenin complex.  This 
complex moves into the nucleus and promotes the transcription of several genes, many of which 
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are involved in preventing apoptosis (Huelsken & Behrens, 2002; Moon et al., 2002; Rowe & 
Chuang, 2004; Seidensticker & Behrens, 2000; Yu & Malenka, 2003).  Due to lithium-induced 
inhibition of GSK-3β and subsequent activation of the Wnt pathway, lithium is expected to 
influence β-catenin levels.  Indeed, both in vitro and in vivo studies have found that lithium 
treatment increases β-catenin levels (Gould, Chen, & Manji, 2004; Rowe & Chuang, 2004; 
Stambolic, Ruel, & Woodgett, 1996). 
 HSF-1.  As described previously in this thesis, HSF-1 is a transcription factor that when 
activated initiates the chaperone protein HSP-70.  HSF-1 can be suppressed by serial 
phosphorylation.  ERK phosphorylates HSF-1 at Ser307, which then allows GSK-3β to 
phosphorylate HSF-1 at Ser303 (Chu et al., 1996).  This dual activation hinders the binding of 
HSF-1 to DNA, as well as its ability to facilitate transcription (Bijur et al., 2000; Rowe & 
Chuang, 2004; Xavier et al., 2000).  HSP-70 is known to exert neuroprotective effects related to 
its interaction stabilizing Akt, thus impeding Apaf-1 by mediating cytochrome c release and 
caspase activation, in addition to inhibiting activation of JNK (Beere et al., 2000; Rowe & 
Chuang, 2004).  
 AP-1.  The transcription factor AP-1 can be either neuroprotective or neurodegenerative.  
It is a dimeric complex that includes members of the Jun, Fos, CREB, and ATF families.  The 
action of AP-1 is dependent on the molecules that form the AP-1 complex and the genes targeted 
by those complexes.  Stress factors and cellular signals influence what role AP-1 plays in either 
neuroprotection or apoptosis.  In general, the signals that activate AP-1 subsequently activate 
MAP kinases (e.g., JNK and p38), resulting in AP-1 binding to an assortment of genes (Rowe & 
Chuang, 2004; Shaulian & Karin, 2002; Whitmarsh & Davis, 1996).  AP-1 can be modulated by 
secondary factors such as GSK-3β.  Increases in GSK-3β cause phosphorylation of c-Jun and 
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impairs AP-1 binding activity (Boyle et al., 1991; Rowe & Chuang, 2004).  Lithium has been 
found to both inhibit and induce AP-1 activity.  Specifically, lithium inhibits the stimulus-
induced activation of AP-1 and concurrently increases the basal activity of AP-1 (Asghari, 
Wang, Reiach, & Young, 1998; Hongisto et al., 2003; Ozaki & Chuang, 1997; Rowe & Chuang, 
2004).    
 CREB.  The transcription factor, cyclic adenosine monophosphate response element 
binding protein (CREB), is functionally related to learning and memory formation (Silva, Kogan, 
Frankland, & Kida, 1998).  CREB is a nuclear protein that regulates genes that contain a CRE 
promoter region.  Increases in calcium levels or cyclic adenosine monophosphate (cAMP) can 
initiate the phosphorylation and activation of CREB.  CREB-dependent transcription is necessary 
for the cellular events involved in long-term memory formation (Silva et al., 1998).  CREB also 
plays a role in apoptosis.  The sensitivity of CREB is modulated by many pathways including 
BDNF, MEK/ERK, and GSK-3β (Bonni et al., 1999; Hansen, Rehfeld, & Nielsen, 2004; 
Kopnisky et al., 2003; Rowe & Chuang, 2004).  CREB-induced neuroprotective effects are 
dependent on the induction and increased expression of anti-apoptotic factors such as Bcl-2 and 
BDNF.  As stated above, CREB can be induced by BDNF.  The induction of CREB by BDNF 
initiates a feedback loop whereby increases in CREB upregulate BDNF expression which then 
increases CREB (Kopnisky et al., 2003; Rowe & Chuang, 2004).   
 Glutamate and NMDA receptors.  Dixon and Hokin (1998), in an effort to determine the 
mechanism of action for lithium, speculated that lithium was exerting therapeutic effects via 
glutamate.  They discovered that acute treatment with high levels of lithium (20 – 25 mM) 
increased glutamate levels by blocking the reuptake of glutamate by the presynaptic neuron.  
Due to the toxic effects of lithium associated with dosages higher than 1.2 mM, it is likely that 
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the elevation in glutamate is related to lithium toxicity.  Alternately, chronic lithium 
administration in mice at therapeutic levels resulted in a significant increase in glutamate 
reuptake.  The reduction of glutamate in the synaptic cleft is hypothesized to be involved in the 
anti-manic effects of the drug (Shaldubina et al., 2001).  Increased reuptake of glutamate may 
also be involved in lithium’s neuroprotective effects.   
The NMDA receptor is an ionotropic glutamate receptor involved in numerous essential 
processes including development, neuroplasticity, and excitotoxicity.  When activated under 
normal conditions, the NMDA-receptor allows calcium and sodium into the cell.  When over-
stimulated, the calcium influx is detrimental, as it is the primary element in glutamate 
excitotoxicity (Rowe & Chuang, 2004; Sattler & Tymianski, 2001).  Excessive calcium 
accumulates in the mitochondria and disrupts the mitochondrial membrane potential, initiating 
apoptotic pathways (Rowe & Chuang, 2004; Stout, Raphael, Kanterewicz, Klann, & Reynolds, 
1998).  It is generally supported that inhibiting the overflow of calcium into the cell would 
mediate the excitotoxic effects and protect the cell (Hashimoto et al., 2002; Rowe & Chuang, 
2004).  NMDA receptor-mediated neurotoxicity is also dependent on the MAP kinases.  
Glutamate-induced excitotoxicity activates apoptotic-inducing factors such as JNK, p38, p53, 
and AP-1.  Pre-treatment with lithium provides neuroprotection from these potentially harmful 
factors (Chen et al., 2003).  
 The NMDA receptor is comprised of heteromeric subunits, NMDA receptor 1 (NR1) and 
NMDA receptor 2 (NR2).  NMDA receptors must contain at least one NR1 and two or more 
NR2 subunits A – D (NR2A – D) (Rowe & Chuang, 2004).  The NR1 is required for receptor 
function and the NR2 regulates the receptor function.  Activation of the NMDA receptor allows 
the influx of calcium into the cell.  The activation state of the receptor is controlled by the 
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phosphorylation state of the NR2A and NR2B subunits.  Growing evidence supports the 
regulation of NMDA receptors by the sarcoma family of protein tyrosine kinases (Src) (Salter, 
1998).  Src is found throughout the CNS, particularly in neurons, and increases in Src activation 
are correlated with increased LTP in the CA1 of the hippocampus (Lu et al., 1998).  Based on 
these findings, overstimulation of Src-mediated receptor tyrosine phosphorylation may be 
responsible for the over-activation of NMDA receptors, as in the case of glutamate-induced 
toxicity (Rowe & Chuang, 2004; Salter, 1998).   
 Calcium-induced damage is one of the primary instigators of cytochrome c release and 
apoptosis.  An analysis of calcium levels, via uptake studies and Fura-2 calcium imaging, 
revealed that glutamate-induced toxicity increased NMDA receptor-mediated calcium influx.  
Lithium pre-treatment was able to prevent this insult-dependent increase in calcium and this was 
correlated with a significant decrease in NR2B phosphorylation by tyrosine (Hashimoto et al., 
2002).  In a rat model, ischemic injury was produced using permanent occlusion of both 
vertebral arteries (Ma & Zhang, 2003).  This injury type resulted in increased NMDA receptor 
activation due to increased phosphorylation of the NR2A subunit.  Injury-induced elevations in 
the level of postsynaptic density protein 95 kDa (PSD-95) (NMDA receptor scaffolding protein) 
was found to modulate the interaction of Src and Fyn with the NR2A subunit, resulting in 
increased phosphorylation of NR2A.  Pre-treatment with lithium for 7 days resulted in complete 
inhibition of the interactions of Src and Fyn, members of the Src family and regulated by PSD-
95, with NR2A.  Interestingly, no difference was observed in overall protein expression of Src, 
Fyn, NR2A, or PSD-95.  This indicates that some of lithium’s neuroprotective effects are related 
to preventing the modulation of Sch, Fyn, and NR2A by PSD-95 (Ma & Zhang, 2003).         
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Lithium-induced neurogenesis and plasticity.  Lithium’s neuroprotective properties 
have been well established in the literature and there is compelling evidence that chronic lithium 
treatment also enhances hippocampal neurogenesis (Chen, Rajkowska, Du, Seraji-Bozorgzad, & 
Manji, 2000; Yan et al., 2007).  Support for lithium-induced neurogenesis comes from in vitro 
and in vivo studies, which show lithium promotes differentiation of hippocampal neural 
progenitor cells into neurons (Chen et al., 2000; Kim et al., 2004; Yan et al., 2007).  Some of the 
mechanisms that are reported to be involved in lithium-induced neuroprotection are thought to 
also be involved in promoting neurogenesis, such as Bcl-2 and BDNF (Chen et al., 1999; 
Fukumoto, Morinobu, Okamoto, Kagaya, & Yamawaki, 2001; Hashimoto et al., 2002; Wei et al., 
2001). 
Following lithium treatment, bcl-2 levels are markedly increased in the CNS, particularly 
within the hippocampus (Chen et al., 1999).  Bcl-2 has been found to exert neurotrophic effects, 
thereby enhancing axonal regeneration, promoting neurite outgrowth, and increasing axonal 
growth rate (Chen, Schneider, Martinou, & Tonegawa, 1997).  Based on findings from human 
MRI studies showing increased brain volume following lithium treatment, Chen et al., 2000, 
examined the effects of lithium treatment on the levels of bromodeoxyuridine (5-bromo-2-
deoxyuridine, BrdU) expression, a measure of proliferating cells, in the hippocampus of 
C56BL/6 mice.  The mice were given lithium chow for 3 – 4 weeks, resulting in an average 
serum level of 0.97 ± 0.20 mM lithium.  BrdU was administered for the last 12 days of lithium 
treatment.  Neurons were also stained with Neuronal Nuclei (NeuN), an antibody that recognizes 
the vertebrate nervous system and binds to neuron-specific nuclear protein (Mullen, Buck, & 
Smith, 1992).  Chen, (2000) found a significant increase in BrdU positive neurons in the 
hippocampus, specifically in the dentate gyrus (DG) of lithium-treated animals as compared to 
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controls.  However, there was no difference in NeuN expression between the lithium (66%) and 
control (68%) animals (Chen et al., 2000).         
Vazey and Connor (2009) investigated the effect of lithium on the priming and 
differentiating of neural progenitor cells (NPC) derived from the subventricular zone (SVZ).  
Cells were primed using 3 mM lithium for 14 days.  After the last day of priming, the 
neurospheres were plated.  Four weeks later, the lithium-treated cells showed a significant 
increase in neuronal differentiation as compared to non-primed cultures.  Using calbindin and 
glutamic acid decarboxylase 67 (GAD-67) as indicators, it was determined that lithium chloride 
significantly increased the generation of mature, region-specific neurons.  The authors suggest 
that lithium has a role in increasing the ratio of cells expressing neuronal markers while 
concurrently decreasing glial progeny (Vazey & Connor, 2009).  
Su, Chu, and Wu (2007) examined the effect of lithium on survival, proliferation and 
differentiation of spinal cord-derived neural progenitor cells (NPC) in vitro and after 
transplantation into the spinal cord of uninjured animals.  NPCs from transgenic Sprague-
Dawley rats, expressing green fluorescent expressing protein (GFP), were injected into the dorsal 
funiculi of female Sprague Dawley rats.  Half of the animals that received the transplanted cells 
also received daily treatment with lithium chloride (85 mg/kg, ip), the others received saline.  At 
2 and 4 weeks post-transplantation, lithium-treated animals had significantly more GFP 
expressing cells and increased neuronal differentiated cells compared to saline controls.  The 
authors cite several possible mechanisms for the observed increase in cell survival including 
inhibition of GSK-3β and activation of TrkB receptors via upregulation of BDNF (Su et al., 
2007).    
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Lithium and learning.  There are conflicting reports regarding lithium’s effects on 
learning and memory in both clinical and animal studies.  Many older clinical studies have 
reported that lithium impairs long-term and short-term verbal memory recall (Kropf & Muller-
Oerlinghausen, 1979; Kusumo & Vaughan, 1977; Shaw, Stokes, Mann, & Manevitz, 1987).  
However, some studies have found lithium treatment either had no effect on learning and 
memory (Squire, Judd, Janowsky, & Huey, 1980), or that it increased recall on tests that assess 
immediate and delayed memory function (Person-Data Test and 30 Face Test) (Smigan & Perris, 
1983).  Pachet and Wisniewski (2003) reviewed these studies and determined that the correlation 
between lithium treatment and verbal memory impairment was comparatively weak and they 
indicated that additional research was needed to verify the findings of the previous studies.  
Some of the concerns brought up in the article were discrepancies in testing procedures, a lack of 
standardized testing, and insufficient control for comorbid illnesses.   
In a recent study, Senturk et al. (2007) found that euthymic BAD patients on 
monotherapy with lithium had significantly impaired immediate verbal memory recall assessed 
by the Logical Memory Subscale of the Wechsler Memory Scale I (WMS).  Similar to previous 
studies, other areas of cognitive functioning were not affected by lithium treatment.  Cognitive 
functioning such as psychomotor speed, working memory, and visuospatial abilities, were 
assessed using subsets of the Wechsler Adult Intelligence Scale Revised (WAIS-R) and revealed 
no significant impairments relative to control subjects (Senturk et al., 2007).   
Preclinical studies have also reported inconsistent effects of lithium treatment on memory 
tasks.  The study by Al Banchaabouchi, de Ortíz, Menéndez, Ren, and Maldonado-Vlaar (2004) 
investigated the effect of chronic lithium treatment, within the therapeutic range, on performance 
in memory-dependent behavioral tasks.  Male Long Evans rats were administered lithium 
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carbonate chow for 4 weeks and were subsequently assessed for object recognition memory and 
spatial discrimination learning ability, using the novel object recognition task and hole-board 
spatial discrimination task respectively.  No significant difference between groups was observed 
in the novel object recognition task.  However, lithium-treated animals showed delayed 
acquisition in the hole-board task, but only on the first 2 days (out of 3) of testing.  Two sessions 
were performed on each of the three testing days.  Similar to the acquisition data, lithium-treated 
rats made more reference errors and had significantly longer search times as compared to non 
lithium-treated rats in only the first two out of six test sessions.  These data indicate that 
treatment with lithium may selectively impair initial performance in spatial discrimination 
learning tasks (Al Banchaabouchi, de Ortíz, Menéndez, Ren, & Maldonado-Vlaar, 2004).   
Lithium’s effects on spatial memory and working memory under chronic stress 
conditions were evaluated using the MWM and a passive avoidance task respectively 
(Vasconcellos, Tabajara, Ferrari, Rocha, & Dalmaz, 2003).  The animals were randomly 
assigned to one of four treatment groups (control, lithium, stress, stress + lithium), and were 
trained to locate a hidden platform in the MWM over a five-day period (4 trials per day).  In the 
training sessions, no significant difference was detected between the treatment groups.  In the 
recall test (probe trial), the hidden platform was removed and the swim behavior of the animals 
was recorded.  The authors found that lithium-treated rats showed a trend towards shorter 
latencies to reach the location of the hidden platform.  Additionally, lithium-treated rats had 
significantly more crossings in the area of the hidden platform (Vasconcellos et al., 2003).  These 
data suggest that lithium may diminish stress-induced impairments in spatial memory tasks.  
Eight-days later, these same animals were used in a working memory version of the MWM.  In 
this task, the daily location of the platform was changed; however, during the daily sessions the 
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location of the platform was fixed.  Lithium-treated animals did not exhibit significant 
differences in performance in the reference memory task, indicating that under chronic stress, 
working memory is unaffected by the selected doses of lithium (Vasconcellos et al., 2003).  The 
improvement observed in the reference memory portion of the MWM, a task dependent on the 
hippocampus, and the lack of effect found in the working memory portion of the MWM, a task 
reported to rely more heavily on the medial PFC region (O'Dell et al., 2000), suggest that the 
beneficial cognitive enhancing effects of chronic lithium treatment are associated with 
hippocampal functioning.  
Data from Tsaltas et al., 2007, provide additional support for lithium-induced 
improvements in spatial memory.  Chronic lithium treatment was found to significantly enhance 
spatial working memory in the T-maze, using a delayed non-matching to place rule.  The authors 
reported that lithium treatment did not affect spatial reference memory because there were no 
differences in the acquisition of this task as compared to control animals.  Lithium treatment 
enhanced performance in the T-maze, as compared to saline-treated rats, when moderate 
demands were placed on memory (i.e., test intervals > 30 s and < 60 s).  However, when a 
greater demand was placed on working memory, a test interval of 60 s, the lithium-treated 
animals performed similar to saline-treated controls.  The effect of lithium treatment on long-
term retention was assessed using a single trial step-through passive avoidance task.  Lithium-
treated rats demonstrated longer retention of the passive avoidance task as compared to saline-
treated rats.  Based on these data, it was suggested that lithium treatment potentiated the long-
term retention of a weak conditioning trace (Tsaltas et al., 2007).  
These studies combined suggest that the previously held belief that lithium impairs 
memory functioning may be incorrect (Tsaltas et al., 2007; Vasconcellos et al., 2003).  Due to 
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the lack of consensus between studies investigating the effects of lithium treatment and cognitive 
function, and the new data emerging on the neuroprotective effects of lithium, it is necessary to 
further evaluate the effects of lithium as they relate to cognitive performance.  
Study Rationale 
 Data from both in vitro and in vivo studies in animal models of various neurodegenerative 
diseases and human patients with BAD indicate that chronic administration of lithium inhibits 
NMDA-receptor-mediated calcium influx and induces both up-regulation of numerous survival 
signaling pathways (such as Bcl-2, CREB, BDNF, PI3K/Akt and MEK/ERK pathways, Hsp70, 
and β-catenin), and down-regulation of pro-apoptotic activities (e.g., p53, Bax, caspase, 
cytochrome c  release, beta-amyloid peptide production, and tau hyperphosphorylation), thereby 
limiting neuronal cell death cascades (Rowe & Chuang, 2004; Wada, Yokoo, Yanagita, & 
Kobayashi, 2005).  To our knowledge, however, no data are available describing the mechanism 
of action of this drug in animal models of TBI.  The purpose of the present thesis is, therefore, to 
provide additional rigorous evidence in support of the beneficial effects of lithium in the 
treatment of TBI, to define the best dosing paradigm, and to shed more light on the potential 
mechanisms of action for the observed effects in the TBI setting. 
Hypotheses 
The general hypothesis is that postinjury lithium treatment will significantly improve 
outcome following TBI.  Specifically, lithium will reduce TBI-induced deficits in 
vestibulomotor, cognitive, and behavioral functioning.  It is also hypothesized that lithium 
treatment will reduce TBI-induced cell death in the hippocampus.  Lastly, that lithium treatment 
will result in reduced activation of caspase-3 and increased expression of BDNF and growth 
associated protein-43 (GAP-43) within the hippocampus.   
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Specific Aims 
 The first aim was to determine the optimal dose of lithium that, when administered 
following TBI, would significantly reduce injury-associated cognitive deficits.  The second aim 
was evaluate the effects of lithium treatment as a therapy to ameliorate depressive-like behavior 
in rats following TBI.  The third aim was to use the most effective dose of lithium and determine 
the therapeutic time window for administering that dose while still maintaining the observed 
beneficial effects on cognition.  The fourth aim was to evaluate the neuroprotective properties of 
lithium as they relate to cell survival in the CA3 and hilar subregions of the hippocampus.  The 
fifth aim was to evaluate the effect of lithium on selected markers known to be affected by TBI 
that are involved in neurogenesis, neuroprotection, and apoptosis.        
General Methods 
The methodologies contained within this section are common to all the experiments 
described in this thesis.  Methodologies specific to the individual experiments (Experiments 1 – 
4) are detailed in the corresponding chapters.   
Subjects 
Adult male Sprague Dawley rats (Hilltop Lab Animals, Inc., Scottsdale, PA), weighing 
between 300 – 370 grams were used in the present thesis.  Animals were individually housed in a 
vivarium, maintained at 22 °C, on a 12 hour light/dark cycle.  All animals were given ad libitum 
access to food and water.  The procedures used in the present thesis followed the guidelines 
established in the Guide for the Care and Use of Laboratory Animals (U.S. Department of 
Health and Human Services) and were approved by the Institutional Animal Care and Use 
Committee (IACUC).   
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Experimental TBI  
Surgical preparation.  Each rat was initially anesthetized, in a Plexiglas bell jar, by 
inhalation of 4% isoflurane gas, in a carrier gas of 70% nitrous oxide: 30% oxygen, for 4 min.  
The surgical site was shaved and the animal was placed in a stereotaxic device, fitted with a 
nosecone to deliver the gas anesthesia during the procedure.  The optimal depth of anesthesia 
was achieved with 2% isoflurane, in the same carrier gas mixture used previously.  The surgical 
site was prepped using gauze sponges soaked in betadine and ethanol.  The scalp was sagittally 
incised and a 4.8 mm diameter burr hole was performed over the right cerebral hemisphere 
between the lambda and bregma craniometrical points.  Two small nickel-plated screws were 
placed 1 mm rostral to bregma on the ipsilateral side of the burr hole, and another 1 mm lateral to 
the central suture, midway between bregma and lambda, on the contralateral side to the burr 
hole.  A Luer-Lok syringe hub was secured on the skull at the site of the burr hole first with α-
cyanoacrylate, then with dental acrylic applied around the syringe hub and two screws were 
added for additional stability.  The scalp was sutured and bacitracin applied to the surgical site.  
Each subject was monitored for full recovery from anesthesia before being returned to their 
home cage. 
Fluid-percussion injury device.   The fluid-percussion injury (FPI) device used to 
produce experimental TBI was identical to that described in detail by Dixon et al., 1987.  Figure 
1 shows an image of the injury device.  The device consists of a 60-cm-long and 4.5 cm diameter 
Plexiglas cylinder with a rubber-covered O ring-fitted Plexiglas piston at one end and, on the 
opposite end of the cylinder, a 2-cm-long metal housing mounted with an extracranial pressure 
transducer (Entran Devices, Inc., Model EPN-0300*-100A).  This metal housing was attached to 
a 5-mm transfer tube with a 2.6 mm inner diameter that ends with a male Luer taper fitting.  At 
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the time of injury, an injection port with a Luer taper was used to connect the male end of the 
transfer tube and the surgically implanted female Luer-Lok fitting.  The entire system was then 
filled with distilled water.  The injury was produced by releasing a metal pendulum positioned to 
strike the piston of the injury device.  A small volume of distilled water was injected into the 
closed cranial cavity to produce a brief displacement and deformation of brain tissue.  The 
magnitude of injury was controlled by varying the height from which the pendulum was 
released.  
 
 
 
Figure 1.  Image of fluid percussion injury (FPI) device. 
 
Lateral fluid-percussion injury.  Twenty-four hours after surgical preparation, at the 
time of injury, the rats were anesthetized by breathing 4.0% isoflurane gas, in a carrier gas of 
70% nitrous oxide to 30% oxygen, for 4 min.  The surgical site was exposed and the animal was 
connected to the FPI device.  The force of the injury administered was between 2.0 to 2.2 
atmospheres of pressure (atm), which is equivalent to a moderate-level severity brain injury.  The 
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atm were recorded by the in-line transducer connected to a storage oscilloscope (Tektronix 5111; 
Beaverton, OR).  Sham-injured controls received the same surgical preparation, anesthesia, and 
connection to the injury device, however, no injury was delivered.  All animals were 
immediately ventilated with room air until spontaneous breathing was resumed.      
Postinjury neurological assessment.  The injury resulted in loss of consciousness and 
temporary suppression of the animal’s reflexes.  Immediately following the injury, the animal 
was placed supine and suppression of the righting reflex was assessed.  The amount of time 
required for the animal to regain this reflex after TBI is a good predictor of injury severity 
(Gennarelli, 1993; Hallam et al., 2004; Hamm, 2001; Schmidt & Grady, 1995; Thompson et al., 
2005).  
Drug Preparation and Administration   
Lithium chloride (Sigma, St. Louis, MO) was dissolved in 0.9% sterile saline to make 
1.00, 0.50, 0.25, and 0.125 mmol/kg solutions.  Lithium was administered via intraperitoneal 
injection, in a volume of 1 ml/kg.  Vehicle treated animals were administered 1 mg/kg, 0.9% 
sterile saline. 
Statistical Analysis 
 Injury severity was evaluated by analysis of the suppression of the righting reflex.  A 
one-way ANOVA was used to determine if the level of injury was comparable among the groups 
that received a TBI.  Where appropriate, a Fisher least significant difference (LSD) post hoc 
analysis was used to compare individual group differences. 
Experiment 1 
Study Rationale 
Cognitive impairments in memory and attention can occur following even mild TBI and 
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can persist for years after the traumatic event (Draper & Ponsford, 2008; Kashluba, Hanks, 
Casey, & Millis, 2008; McDonald, Flashman, & Saykin, 2002).  It is widely believed that these 
sequelae are largely attributable to the damage caused by secondary injury events, including 
ischemia, excitotoxicity, excess calcium release, and mitochondrial dysfunction that ultimately 
may lead to neuronal injury or death.  Findings from preclinical studies show that these 
disruptions to cognitive and cellular functioning can be attenuated by the administration of 
neuroprotective agents and drugs used in clinical settings for the treatment of memory and 
attention deficits (Marklund, Bakshi, Castelbuono, Conte, & McIntosh, 2006).  Thus, 
pharmacotherapies that positively modulate neuroprotective mechanisms and/or have cognitive 
enhancing effects are sought after as potential therapies for brain-injured patients.   
One such drug is lithium, a therapeutic agent extensively used for over 50 years in the 
treatment of BAD.  The renewed interest in lithium is due to findings from preclinical studies 
that have demonstrated both neuroprotective and cognitive enhancing effects following lithium 
treatment.  Indeed, several studies using animal models of ischemic injury and stroke have 
demonstrated that lithium treatment improved cognitive outcome and prevented neuronal cell 
loss (Kopnisky et al., 2003; Ren et al., 2003; Yan et al., 2007; Yan et al., 2007).  Furthermore, 
some recent studies have reported that lithium treatment, in non-brain-injured rodents, was found 
to enhance cognitive function (Nocjar, Hammonds, & Shim, 2007; Tsaltas et al., 2007; 
Vasconcellos et al., 2003).   
Similar to what has been reported in clinical studies, the data from animal studies lack a 
consensus regarding the benefit to vs. impairment of cognitive functioning following lithium 
treatment.  Despite the discord among preclinical studies, there are sufficient data to warrant 
further examination of lithium-induced cognitive enhancement.  Studies that support this 
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assertion are briefly described here.  Lithium treatment was found to block drug-induced 
impairment of spatial memory retention by the protein kinase AII (PKAII) inhibitor H-89, thus 
reducing the swim latencies in the MWM (Sharifzadeh et al., 2007).  Rats exposed to chronic 
stress demonstrate impaired performance in tasks that require reference memory abilities.  
Lithium treatment negated the effect of stress on spatial learning and significantly improved 
MWM performance (Vasconcellos et al., 2003).  Furthermore, lithium administration to naïve 
rats was found to improve performance in neurobehavioral tasks, such as delayed non-matching 
to place in the T-maze, spatial memory retention in the MWM, and passive avoidance 
assessments (Tsaltas et al., 2007; Vasconcellos et al., 2003).      
Irrelevant of the severity level of TBI (mild, moderate, severe), individuals who have 
sustained a brain injury are more likely to present with psychiatric and mood disorders, including 
depression, anxiety, psychosis, and behavioral problems (e.g., poor motivation, agitation, 
aggression, disinhibition) (Fleminger, 2008; Jones et al., 2008; Jorge & Starkstein, 2005; Rogers 
& Read, 2007).  The most commonly reported psychiatric illness following TBI is depression.  
Based on the cumulative effects of depression combined with the other sequelae associated with 
human TBI, it is important to evaluate potential therapies that target the psychological, in 
addition to the biological, components of brain injury. 
Lithium is effective as a prophylaxis and a treatment for the manic and depressive 
episodes associated with BAD, and is highly effective as an adjunct antidepressant in treatment-
refractory patients (Bauer et al., 2003; Gould et al., 2008; O'Donnell & Gould, 2007; Schou, 
2001).  Eroğlu and Hizal (1987), using Wistar rats, showed that chronic lithium treatment, via 
intraperitoneal injection, was associated with antidepressant-like effects in the forced swim test 
(FST).  Chronic treatment with lithium chow was found to significantly reduce the time 
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immobile in a mouse model of the FST (Gould et al., 2008; O'Brien et al., 2004; Shaldubina et 
al., 2006).  
There are several lines of evidence from preclinical studies that indicate lithium treatment 
has neuroprotective effects against insult-induced neuronal injury and that it may have memory-
enhancing effects.  Lithium has also been found to reduce depressive-like behavior in rodents.  
The physiological and behavioral response to lithium treatment, as observed in preclinical 
studies, appears to affect key aspects of the sequelae associated with TBI (i.e., neuronal cell loss, 
cognitive impairment, and neuropsychiatric illness).  Based on these reported findings, it seems a 
logical progression to investigate the potential benefit of post-TBI lithium treatment.  
Surprisingly, there is a paucity of research combining lithium treatment and TBI.   
Treatment paradigm.  A predominant feature of lithium-induced neuroprotection 
studies is the usage of a preinjury treatment paradigm (Chuang, 2004; Chuang, 2005; Rowe & 
Chuang, 2004; Wada et al., 2005; Xu et al., 2003; Yan et al., 2007).  To our knowledge, there has 
been only one in vivo study (Ren et al., 2003) that has evaluated the effect of post-insult lithium 
treatment.  Animals were subjected to MCAO for 1 hr followed by reperfusion for 23 hours.  
This injury produced an extensive infarction in the cerebral cortex.  Single doses of lithium 
chloride (between 0.50 – 3.00 mEq/kg, sc) administered immediately after initiation of MCAO 
significantly reduced the infarct volume when assessed at 24 hours post-insult (Ren et al., 2003).  
A single dose of lithium, 1.00 mEq/kg, delayed up to three hours after the onset of MCAO, was 
associated with a significant reduction in ischemia-induced neurological deficits at 24 hours 
post-insult.  Neurological deficits were assessed using tests for motor (flexion of hind limb and 
forelimb, head movement, ability to walk in a straight line, circling to paralytic side, and falling 
down on paralytic side), sensation (visual and proprioceptive tests), and reflex response (pinna, 
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and startle reflex) (Ren et al., 2003).  Lithium treatment, administered immediately after the 
onset of MCAO and continued daily for 7 days, was correlated with a significant reduction in 
ischemia-induced neurological deficits on post-insult days 1 – 7.  Additionally, the benefits 
associated with 7-day-lithium treatment were still observed up to 14 days post-insult.  These 
data, taken together, support the use of an early postinjury time point for initiating lithium 
treatment, that lithium must be administered over the course of several days and that the 
beneficial effects of lithium treatment can continue beyond the duration of treatment.  
It is well known that time is a critical factor when treating an individual with a TBI.  
Secondary injury cascades are initiated immediately after sustaining a TBI and the resulting 
neuronal death or dysfunction and can last from hours to weeks postinjury.  To mitigate these 
harmful effects, it is generally accepted that pharmacological interventions that target 
neuroprotective mechanisms must be administered early after injury since treatment delays may 
render the drug ineffective due to irreparable damage.  Additionally, the innate mechanisms that 
support neuronal plasticity and recovery are initiated within the first week after a TBI.  Drugs, 
such as lithium, that have been shown to affect neuronal plasticity, may require early initiation of 
treatment to facilitate and maximize recovery.         
Experimental TBI studies that have focused on the mechanisms associated with the acute 
phase of secondary brain injury typically administer a pharmacological treatment immediately 
prior to (30 – 15 min) or immediately following (10 – 30 min) injury.  The time point selected 
for administering the initial dose of lithium in Experiment 1, 30 min post-TBI or sham-injury, is 
an approximate midpoint between the furthest time point successfully used in an animal model of 
ischemia (2 hr post-MCAO) (Ren et al., 2003) and preinjury drug administration time points.  
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Dose selection.  The doses selected for use in the present experiment (1.00, 0.50, 0.25, 
and 0.125 mmol/kg, lithium chloride) were chosen based on previous in vitro and in vivo studies.  
These studies reported lithium-induced therapeutic and neuroprotective effects were observed 
following treatment with doses of lithium ranging between 0.5 – 1.0 mEq/kg (mEq/kg equivalent 
to mmol/kg) (Nonaka & Chuang, 1998; Ren et al., 2003; Xu et al., 2003; Yan et al., 2007).  To 
put these doses of lithium into perspective, the intraperitoneal dose of lithium chloride used in 
rodent taste aversion studies is approximately 3.0 mmol/kg (127.20 mg/kg) (Masaki & 
Nakajima, 2006; Nachman & Ashe, 1973; Nolan et al., 1997).   
Neurobehavioral outcome assessment.  In the present study, the neuroprotective effects 
of lithium were evaluated based on the performance of the animals on neurobehavioral outcome 
measures: i.e., beam walk (BW), MWM, and FST.  In order to best determine the dose/doses of 
lithium that would provide neuroprotective effects in the injured brain, a dose response was 
carried out using the animal stroke literature as a guide in selecting the dose range.   
Vestibulomotor functioning was evaluated based on performance in the BW task.  This 
task was selected because it is a reliable, sensitive, and valid measure of motor deficits following 
TBI (Hamm, 2001).  The postinjury time points that we selected for assessment on the BW (PID 
1, 3, 7) were based on previous data from our laboratory showing that motor deficits produced by 
lateral FPI are most pronounced between PID 1 – 3 and typically resolve by PID 7.   
The MWM was selected as the primary cognitive outcome measure because it has been 
extensively used with the lateral FPI model and it is known to be sensitive to hippocampal 
damage, a brain region known to be vulnerable in human TBI.  The MWM was selected to test 
the ability of the rat to utilize reference memory for spatial learning and memory (Morris, 
Garrud, Rawlins, & O'Keefe, 1982).  Performance in the MWM is directly correlated with the 
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functionality of the hippocampus (Morris et al., 1982).  Similar to the BW, the MWM is 
relatively quick and easy to learn for rats and food does not have to be withheld for the 
acquisition of this task.  The timeframe for assessment in the MWM (PID 10 – 14) was selected 
because any motor deficits produced by the injury have subsided and TBI-induced cognitive 
deficits are more pronounced, thus making any drug effects more apparent (Hamm et al., 1993).   
The FST is a well-established behavioral model used to assess the efficacy of 
antidepressant medications and as a measure of depressive-like behavior (Castagne, Porsolt, & 
Moser, 2009; Jones et al., 2008; Lahmame, Grigoriadis, De Souza, & Armario, 1997; Porsolt, 
Anton, Blavet, & Jalfre, 1978; Porsolt, Le, & Jalfre, 1977).  Based on clinical data pertaining to 
the incidence of depression among TBI patients and the potentially debilitating effects of this 
illness, the FST was included in the present thesis to evaluate the impact of lithium on 
depressive-like behavior following TBI.  Lithium, on its own, has been shown to significantly 
reduce the time spent immobile in the FST in both rats (Eroglu & Hizal, 1987; Tomasiewicz, 
Mague, Cohen, & Carlezon, Jr., 2006) and mice (Gould et al., 2007; O'Brien et al., 2004; 
Shaldubina et al., 2006).  In the study by Eroğul and Hizal (1987), male Wistar rats were 
administered daily injections of lithium chloride (0.5, 2.0, & 5.0 mEq/kg, ip) over a 19 day 
period.  On day 18 (day 1 of the FST), the animals were placed in a cylinder, filled with water 
from which they could not escape, for the 15 minute (exposure) session.  During the 5 minute 
(recall) test session, on day 19 of lithium treatment (day 2 of the FST), the lithium-treated groups 
spent significantly less time immobile as compared to saline-treated controls.  These data 
indicate that lithium reduced the depressive-like behavioral response to the FST (Eroglu & Hizal, 
1987).  In studies using rodent TBI models, only a handful have used the FST as an outcome 
measure and there is a lack of consistency in these findings.  Some studies report that there is no 
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difference between brain-injured and sham-injured rats while others have found significant 
behavioral differences after TBI, as well as dysregulation of the neuroendocrine stress response 
system (Jones et al., 2008; Milman, Rosenberg, Weizman, & Pick, 2005; Tweedie et al., 2007; 
Yucel et al., 2008).   
Hypotheses 
 It is our hypothesis that treatment with lithium will reduce the cognitive and motor 
deficits associated with lateral FPI.  Research supporting the neuroprotective effects of lithium 
treatment in animal models of brain injury and neurodegenerative diseases found that serum 
concentrations of lithium at or below the levels used clinically in human patients provided the 
greatest neuroprotection.  All the doses of lithium selected for use in the present study fall within 
this desired range.  Therefore, we theorize that all the selected doses of lithium will ameliorate 
postinjury deficits.  We extrapolated, from a thorough review of the literature, that lower doses 
of lithium, within the desired therapeutic range, provided the most benefit.  Therefore, we 
hypothesized that the middle and low doses of lithium (0.50, 0.25, 0.125 mmol/kg) would be 
more effective (i.e., neuroprotective) as compared to the high dose (1.00 mmol/kg).  
The findings from other TBI-focused laboratories, where the FST was employed as a 
measure of depressive-like behavior following TBI, support the use of this assessment in rodent 
models of brain injury.  It is hypothesized that TBI will increase the amount of time spent 
immobile in the vehicle-treated rats as compared to the other treatment groups.  Based on 
lithium’s mood stabilizing effects, it our hypothesis that animals receiving lithium treatment 
(both injured and sham) will exhibit less time spent immobile in the FST as compared to the  
TBI-Vehicle group and Sham-Vehicle group.        
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Specific Aims  
The first aim of this study was to identify the dose of lithium associated with the greatest 
reduction in TBI-induced deficits, as measured by BW and MWM performance.  The second aim 
of this study was to evaluate the efficacy of lithium treatment in preventing or reducing 
depressive-like behavior after brain injury, as assessed by the FST.    
Methods 
Information pertaining to the subjects, surgical preparation, experimental brain injury, 
neurological evaluation, and drug preparation used in this experiment are identical to what was 
described in Chapter 2, General Methods.   
Experimental design.  Animals underwent surgical preparation and lateral FPI or sham-
injury.  Injured animals were randomly assigned to one of five treatment groups, 1.00, 0.50, 0.25, 
and 0.125 mmol/kg lithium, or vehicle (0.9% sterile saline).  Sham-injury animals were 
randomly assigned to one of two treatment groups, 1.0 mmol/kg lithium or vehicle.  Table 1 
illustrates the treatment group design for Experiment 1.  Once-daily lithium- or vehicle- 
treatment was initiated 30 min postinjury and continued through the last day of behavioral 
assessment in the FST (PID 19).  All drug vials were coded to prevent experimenter bias.  
Animals were injected at approximately the same time each day.  On the days when the animals 
were behaviorally assessed, the start time for the testing was approximately 30 – 60 minutes after 
lithium or vehicle was administered.   
Animals were assessed on the BW on PID 1, 3, and 7.  MWM assessment took place on 
PID 11 – 15.  Hidden platform testing in the MWM occurred on PID 11-14.  The probe trial and 
visible platform assessments were performed on PID 15.  The FST was performed on PID 18 and 
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19.  The first session was a 15 min training session followed 24 hours later by the 5 min test 
session.  Figure 2 illustrates the treatment plan for animals in Experiment 1.  
 
 
Table 1   
 
Experimental group design for beam walk and MWM portion of Experiment 1 
 
 Treatment Group
a    
 TBI-Vehicle
b     
 TBI + 1.00
c     
 TBI + 0.50
c     
 TBI + 0.25
c     
 TBI + 0.125
c     
 Sham + 1.00
c    
 Sham-Vehicle
b    
 
 
Note. an = 10 for each group.  bvehicle (0.9% sterile saline) injection volume 
1 ml/kg.  cdosage of lithium as mmol/kg, dose volume 1 ml/kg 
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Figure 2.  Timeline for Experiment 1.  This figure provides a detailed timeline for the 
neurobehavioral assessments and dosing paradigm for all treatment groups in 
Experiment 1.  
 
 
Drug preparation.  Lithium chloride (Sigma, St. Louis, MO) was dissolved in 0.9% 
sterile saline to make 1.00, 0.50, 0.25, and 0.125 mmol/kg solutions.  Lithium was administered 
via intraperitoneal injection, in a volume of 1 ml/kg.  Vehicle treated animals were administered 
1 mg/kg, 0.9% sterile saline, also called normal saline.    
Lithium dose response.  The doses of lithium selected for the present study correspond 
to the following doses in mg/kg: 1.00 mmol/kg (42.350 mg/kg), 0.50 mmol/kg (21.175 mg/kg), 
0.25 mmol/kg (10.587 mg/kg), and 0.125 mmol/kg (5.293 mg/kg).  These doses were selected 
based on previous in vivo studies that reported therapeutic and neuroprotective effects following 
lithium treatment that produced serum levels within the therapeutic range used clinically to treat 
BAD (0.60 – 1.20 mmol/kg) or below (Allagui et al., 2008; Nonaka & Chuang, 1998; Omata et 
al., 2003; Ozaki & Chuang, 1997; Xu et al., 2003; Yan et al., 2007).  Significant amelioration of 
insult-induced deficits on behavioral and histological measures were reported following daily (23 
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day) treatment with lithium chloride, 1.00 mmol/kg via intraperitoneal injection (the highest dose 
selected for the present study), that produced serum levels within the therapeutic range, 0.97 ± 
0.31 mM (Yan et al., 2007).  
Neurobehavioral assessment.  Three neurobehavioral outcome assessment measures 
were selected for use in the present study: BW, MWM, and the FST.  Vestibulomotor 
functioning was evaluated using the BW.  Cognitive ability was assessed using the MWM.  
Finally, depressive-like behavior was determined by performance in the FST. 
 Beam walk task.  The vestibulomotor functioning of each rat was assessed using the 
BW, similar to that detailed by Feeney and colleagues (1982) (Feeney, Gonzalez, & Law, 1982; 
Dixon, Lyeth, Povlishock, Findling, Hamm, et al., 1987).  The rat must escape a bright light and 
loud noise via walking along an elevated 100 cm long, 2.5 cm wide wooden beam to enter a 
darkened goal box at the opposite end of the beam.  The latency for the rat to reach the goal box 
(not to exceed 60 s) was recorded and averaged over three trials for each assessment day.  If the 
rat fell off the beam, 60 s was recorded as the time for that trial.  On the training day there was 
no limit on the number of trials allowed for each rat.  Each rat was trained on the BW until they 
met criterion, traversing from one end of the beam to the goal box on three consecutive trials in 
less than 10 s per trial.  Rats were trained on the BW one day prior to injury or sham-injury.  All 
subsequent assessments following the training day consisted of three trials per day. 
Morris water maze.  The MWM is a large circular tank (180 cm diameter by 45 cm high) 
filled to a depth of 30 cm with thermostatically controlled warm water maintained between 25 – 
28 oC.  Figure 3 is an image of the MWM and tracking system.  For assessment, rats were given 
four trials per day for 4 consecutive days on PID 11-14.  For each daily block of four trials, the 
rats were placed in the tank facing the wall at one of the four designated entry points.  The order 
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of the entry points was randomized to minimize practice effects.  Each rat started the trials once 
from each of the four cardinal directions (north, east, south, and west) in random order.  The 
hidden goal platform was positioned 45 cm from the outside wall and was not moved during the 
experiment.  Rats were given a maximum of 120 s to find the hidden platform.  If the rat failed to 
find the platform within the allotted time, it was placed on the platform by the experimenter.  
Upon completion of each trial, all rats remained on the platform for 30 s before being placed in a 
heated incubator between trials.  The inter-trial interval for all the trials was approximately 10 
min. 
The Videomex Water Maze Program (Columbus Instruments, Columbus, OH) was used to track 
the movement of an animal during each trial in the MWM and calculated several pieces of data 
useful in interpreting the maze performance of the test subjects, such as goal latency, cumulative 
distance, and proximity.  Goal latency is the amount of time, in s, required for each animal to 
locate the goal platform and total distance traveled is recorded in meters per second (m/s).  The 
swim speed is calculated by dividing the average distance traveled by the animal by the average 
latency to reach the goal platform.  This outcome measure can indicate whether or not the 
latency to reach the platform is affected by injury-induced motor disturbances and/or drug-
induced alterations in motor performance.    For this experiment, the swim speed of different 
groups was compared to ensure that differences in performance were not due to motor function. 
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Figure 3.  Schematic of Morris water maze (MWM) and tracking system.    
 
 Gallagher, Burwell, and Burchinal (1993) first described a method of calculating the 
proximity based on the relative position of the animal to the center point of the goal platform.  
The distance of the subject from the platform center is calculated each second, and at the end of 
the trail, is summed.  An “ideal” straight line, determined by the program, based on the entry 
position of the animal relative to the platform, is subtracted from the actual path swum by the 
animal.  The resulting value is the cumulative index, a scalar value that represents how much the 
subject deviated from the “ideal” path to the goal and how close the animal was to the goal 
platform.  The benefit of the cumulative index is that it is relatively insensitive to the starting 
position of the animal and distance to the goal platform.  By dividing the cumulative value by the 
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latency to reach the goal platform, a proximity average value is produced.  The proximity 
average was originally developed as a means of direct comparison between the performance of 
young, faster swimmers, and older, slower swimmers.  Although the cumulative and proximity 
values are nominally presented in centimeters, they are calculated based on a scalar index and as 
such do not represent actual distance values.  The lower the proximity score, the better the 
animal matched the “ideal” path to the goal.  Fast swimmers that swam directly to the target area 
and then spent time exploring in the target area will commonly have negative values (Gallagher, 
Burwell, & Burchinal, 1993). 
 Probe trial.  Assessment using the probe trial was carried out on PID 15 (i.e., after the 
last day of hidden platform testing).  The probe trial consisted of a single 60-s trial in the MWM, 
with the hidden platform removed.  Animals were randomly assigned a start position (one of the 
four cardinal points) and were allowed to swim freely for 60 s prior to removal from the pool by 
the investigator.  The data collected by the Videomex tracking system was used to determine the 
proximity score.  Lower proximity scores indicated that the animal took a more direct path to the 
platform.  This test was always performed prior to the visible platform test.       
Visible  platform.  The visible platform test (PID 15) was used to assess the visual acuity 
of each rat.  The water level in the MWM was drained to 1 cm below the top of the previously 
hidden platform, and a 10 cm painted black pole was attached to the platform to make the 
platform more visible.  For each of the 8 trials, the platform was moved to a new, randomly 
selected, location, which was different from the hidden platform location.  The point of entry 
(one of the four cardinal directions) for each rat was randomly selected for each trial.  To 
adequately perform this task, each rat had to locate the platform within 15 s after placement in 
the pool.   
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  Forced swim test.  The FST procedure detailed in the 1977 article by Porsolt and 
colleagues, modified by Lahmame et al., (1997), was used in the present study.  The FST is a 
two-day procedure that took place on PID 18 and 19 with one trial per day.  Animals were 
assessed between 11:00 and 16:00 hours.  Each rat was placed in a clear Plexiglas cylinder 
(height, 45 cm, internal diameter, 25 cm) containing water maintained at a temperature of 25˚C 
and filled to a level of 30 cm.  At this water level the rats cannot touch the bottom or escape.   
The water was changed following each trial and the Plexiglas cylinder was wiped down using a 
70% ethanol and 30% water solution.  For the first exposure (PID 18), the rats were placed in the 
water for 15 min.  Twenty-four hours later, during the second exposure (PID 19), the animals 
were placed in the water for a 5 minute test session.  After completing the test period the animals 
were placed in an incubator and allowed to dry before being returned to their home cage.  Both 
sessions were videotaped using a camera mounted on a metal pole lateral to the Plexiglas 
cylinder, such that the full length of the rat’s body could be seen on the tape.  The 15 minute 
(exposure session) was used to train the rats that there was no escape (i.e., a model of learned 
helplessness and depressive-like behavior).  Both test sessions were recorded on videotape, 
however, only the 5 min (recall session) tape was later evaluated by two reviewers blinded to the 
treatment conditions.  The recall testing session revealed how the animals responded to a 
situation where there is no escape.  Based on previous studies, the time to become immobile 
(TTBI) and the total time immobile (TTI) were selected as outcome measures for the present 
study.  Immobility was operationally defined as when the rat remained motionless, or performed 
minimal movements, without breaking the surface of the water and not moving all four limbs to 
maintain their head/nose above the water (Lahmame et al., 1997).   
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Statistical analysis.  Injury severity, as assessed by the suppression of the righting reflex, 
was analyzed as described in the general methods section.  Statistical analyses specific to this 
experiment are described in the following paragraphs.  
The mean daily latency for each group to traverse the beam and reach the goal box were 
calculated for PID 0, 1, 3, and 7.  These data were then compared using a split-plot analysis of 
variance and a Fisher LSD post hoc analysis was performed to compare specific groups of 
interest.  Data from the training session on the BW was not used for any statistical analysis. 
The mean latency to locate the goal platform and proximity score for each treatment 
group was computed daily during the hidden platform portion of the MWM testing (PID 11–14).  
The average goal latencies and proximity scores were then analyzed using a separate split-plot 
analysis of variance.  The swim speed was averaged for each day in the MWM, and a one-way 
ANOVA was performed to determine any relationship between the groups.  The probe trial data 
and visible platform data (PID 15) were also analyzed using a one-way ANOVA.  Where 
appropriate, a Fisher LSD post hoc test was performed to compare specific groups of interest.   
The TTBI and the TTI from the 5 min test session on PID 19 were evaluated using a one-way 
ANOVA and an independent samples t-test respectively.  Where appropriate a Fisher LSD post 
hoc was performed to compare groups of interest.   
Results 
Neurological outcome.  There was no significant difference in the suppression of the 
righting reflex among injured groups.  A one-way ANOVA was used to compare the mean 
duration of the suppression of the righting reflex, TBI-Vehicle, M = 428.00 s, TBI-1.00, M = 
422.00 s, TBI-0.50, M = 560.00 s, TBI-0.25, M = 457.70 s, TBI-0.125, M = 424.80, F(4, 45) = 
1.965, p = .116.  The sham groups regained their righting reflex in less than 2 min from the time 
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they were removed from the bell jar used to anesthetize the animals.  Based on our experience in 
the laboratory, this is the same amount of time an animal requires to regain the righting reflex 
after anesthesia alone.  
Beam walk.  A split plot [7 group x 4 day] ANOVA revealed a significant group effect, 
F(6, 63) = 3.585, p = .004.  A Fisher LSD post hoc analysis revealed a significant reduction in 
motor deficits in the TBI-1.00 (p = .021), TBI-0.25 (p = .035), Sham-Vehicle (p = .001), and 
Sham-1.00 (p = .003) as compared to TBI-Vehicle.  Although the TBI-0.125 group did not 
significantly differ from the TBI-Vehicle group, there was a trend toward significantly shorter 
latencies (p = .057).  No significant difference was detected in the BW performance of the TBI-
1.00, TBI-0.25, TBI-0.125, Sham-Vehicle, and Sham-1.00 groups.  No significant difference was 
observed between the TBI-Vehicle and TBI-0.50 groups (p = .719), the two groups with the 
longest latencies to reach the goal box.  Figure 4 illustrates the primary groups of interest based 
on performance, TBI-Vehicle, TBI-1.00, TBI-0.25, TBI-0.125, and Sham-Vehicle.  A graph 
comparing the average latencies to reach the goal box across all treatment groups in the BW task 
is provided in Figure A1 in Appendix A.  
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Figure 4.  Comparison of pre- and post-TBI motor performance among treatment groups 
of interest in Experiment 1. These data are expressed as the mean latency across days 
± SEM, n = 10/group.  A split-plot ANOVA showed that there was a significant effect of 
group.  Post hoc analysis of the data using the Fisher LSD test showed that the TBI-
1.00 and TBI-0.25 groups had significantly shorter latencies to reach the goal box as 
compared to the TBI-Vehicle group.  The difference between the TBI-Vehicle and TBI-
0.125 groups was not statistically significant; however, there was a trend indicating 
shorter latencies for the TBI-0.125 group.  The three injured lithium-treated groups had 
statistically similar latencies to reach the goal box.  All the doses of lithium are mmol/kg.  
Vehicle treated animals received 0.9% sterile saline.  All treatments were administered 
in a volume of 1 mg/kg.  Specific statistical information is provided in the text.  
Comparisons are made to the Sham-Vehicle group.  *** p ≤ .001. 
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Morris water Maze.   
Hidden platform.   The hidden platform portion of the MWM revealed a significant 
group effect, F(6, 63) = 9.483, p < .001.  A Fisher LSD post hoc test determined that both the 
0.25 and 0.125 mmol/kg doses of lithium were equally effective in reducing TBI-induced deficits 
in the MWM as compared to the TBI-Vehicle group.  These data are presented in Figure 5.  The 
0.50 and 1.00 mmol/kg doses of lithium did not significantly improve maze performance as 
compared to the TBI-Vehicle treated group; however, the 1.00 mmol/kg dose did approach the 
level of significance (p = .053).  None of the treatment groups, including the Sham-1.00 group, 
performed as well as the Sham-Vehicle group.  See Figure A2 in Appendix A, for a comparison 
of MWM performance across all the treatment groups.  
Swim speed.  A one-way ANOVA revealed that there was a significant difference in the 
average swim speed of the treatment groups, F(6, 63) = 4.896, p < .001.  A Fisher LSD post hoc 
analysis revealed that all the TBI-Lithium groups (1.00, 0.50, 0.25, 0.125 mmol/kg lithium) 
swam significantly faster as compared to the Sham-Vehicle, Sham-1.00, and TBI-Vehicle 
groups.  These data are illustrated in Figure 6.  There was no significant difference in the swim 
speeds across the TBI-Lithium groups.  Additionally, there was no significant difference in the 
swim speeds of the two sham- and injured-vehicle-treated groups. 
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Figure 5.  Comparison of MWM latency data among selected groups in Experiment 1.  
This graph shows the daily average latency to reach the goal platform for each 
treatment group (n = 10/group), ± SEM.  A split-plot ANOVA and Fisher LSD post hoc 
revealed that the TBI-Vehicle group had significantly longer latencies to reach the goal 
platform as compared to the TBI-0.125, TBI-0.25, Sham-Vehicle, and Sham-1.00 
groups.  None of the groups performed as well as the Sham-Vehicle group.  All doses of 
lithium are mmol/kg.  (*) indicate comparisons made to the Sham-Vehicle group.  (†) 
represent comparisons made to the Sham-1.00 group.  (#) represents comparisons 
made to the TBI-Vehicle group.  * p < .05.  **, ## p < .01.  ***, ††† p < .001.     
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Figure 6.  Comparison of the overall average swim speed for each treatment group in 
Experiment 1.  Data are expressed as the mean ± SEM.  n = 10/group (N = 70).  A one-
way ANOVA showed a significant difference in the overall swim speeds, F(6, 63) = 
4.896, p < .001.  A Fisher LSD post hoc analysis showed that all of the TBI-Lithium-
treated groups swam significantly faster as compared to both sham groups and the TBI-
Vehicle-treated group.  There was no significant difference in the swim speeds of the 
Sham-Vehicle, Sham-1.00, and TBI-Vehicle groups (p > .05).  No differences were 
observed in the swim speeds of the TBI-Lithium-treated groups (p > .05).  (*) indicates 
comparisons made to the Sham-Vehicle group.  (†) indicates significant differences in 
treatment groups as compared to Sham-1.00.  (#) indicates comparisons made to TBI-
Vehicle.  *, †, # p < .05.  **, ††, ## p < .01.   
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Proximity score hidden platform.  The average daily proximity score was calculated for 
each treatment group (n = 10/group).  Lower scores indicated a more direct path to the goal 
platform.  A split-plot ANOVA revealed a significant main effect of treatment group, F(6, 63) = 
4.459, p = .001.  A Fisher LSD post hoc analysis showed that only the Sham-Vehicle (p < .001) 
and Sham-1.00 (p = .003) had significantly lower proximity scores as compared to the TBI-
Vehicle group.  There was no significant difference among the proximity scores of the injured-
vehicle and -lithium groups.  Figure 7 illustrates data from the two most effective doses of 
lithium, as determined by the analysis of the MWM latency data (i.e., TBI-0.25 and TBI-0.125), 
in addition to the TBI-Vehicle and both sham groups.  The scores for the Sham-Vehicle and 
Sham-1.00 groups were statistically similar (p = .235).  Although the Sham-Vehicle group had 
significantly lower proximity scores as compared to the injured lithium-treated groups, the scores 
from the two most effective doses of lithium, TBI-0.25 and TBI-0.125, did not statistically differ 
from the proximity score of the Sham-1.00, p = .061 and .185 respectively.  A comparison of 
proximity scores during MWM across all treatment groups is provided in Figures A3 and A4 of 
Appendix A. 
Probe trial.  The average proximity score for each treatment group during the probe trial 
(PID 15) was analyzed using a one-way ANOVA.  These data are illustrated in Figure 8.  There 
was a significant main effect of group, F(6, 59) = 3.407, p = .006.  A Fisher LSD post hoc 
analysis determined that the Sham-Vehicle group had a significantly lower proximity score as 
compared to all the other treatment groups, p < .01.  No other differences were found. 
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Figure 7.  Comparison of the proximity scores for the groups of interest across days 
during hidden platform testing in MWM.  This graph shows the daily average proximity 
score for the treatment groups of interest (n = 10/group) during MWM testing, ± SEM.  
All doses of lithium are in mmol/kg.  A repeated measure ANOVA revealed a significant 
difference among the average daily proximity scores of the treatment groups.  A Fisher 
LSD post hoc found that the two sham groups had significantly lower proximity scores 
(indicating better performance) as compared to the TBI-Vehicle group.  The two injured 
groups that had significantly shorter latencies to reach the goal platform as compared to 
the TBI-Vehicle group during the hidden platform testing, TBI-0.25 and TBI-0.125, had 
significantly higher proximity scores as compared to the Sham-Vehicle group (i.e., 
poorer performance).  However, these two injured groups did not significantly differ from 
the Sham-1.00 group, suggesting that these groups took a more direct path to the goal 
platform.  There was no appreciable difference in the proximity scores of the TBI-
Vehicle group and the TBI lithium-treated groups.  (*) indicate comparisons to the 
Sham-Vehicle group.  (†) indicate comparisons made to the Sham-1.00 group.  **, †† p < 
.01.  *** p < .001.      
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Figure 8.  Analysis of the proximity scores for the groups of interest during the probe 
trial in Experiment 1.  The data are expressed as the mean ± SEM, (n = 10/group).  An 
ANOVA found significant differences between the treatment groups.  A Fisher LSD post 
hoc revealed that the Sham-Vehicle group had a significantly lower proximity score as 
compared to all other treatment groups.  * p < .05.  ** p < .01.  *** p < .001.   
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Visible platform.  The mean latency, in seconds, for each group (n = 10/group) to locate 
the visible platform revealed the following data, expressed as the group mean (± SEM): TBI-
Vehicle, M = 10.87 s (± 1.07); TBI-1.00, M = 12.58 s (± 1.18), TBI-0.50, M = 13.79 s (± 2.49); 
TBI-0.25, M = 10.85 s (± 1.51); TBI-0.125, M = 14.08 s (± 2.14); Sham-Vehicle, M = 10.04 s (± 
2.93); Sham-1.00, M = 9.88 s (± 1.13).  A one-way ANOVA revealed that there were no 
significant differences between any of the treatment groups in the average latency to locate the 
visible platform, F(6, 63) = 0.836, p = .547.   
Forced swim test.  The mean latency, in seconds, for animals in the TBI-Vehicle (n = 
10), TBI-0.25 (n = 9), and Sham-Vehicle (n = 10) groups to become immobile (i.e., TTBI) are 
illustrated in Figure 9.  These data were analyzed using a one-way ANOVA, and no significant 
difference was detected in the TTBI, F(2, 26) = 0.610, p = .551.  Because the TTBI data was not 
significant, we analyzed only the TBI-Vehicle and Sham-Vehicle groups for the TTI data.  An 
independent samples t-test was used to evaluate any difference in the TTI between the TBI-
Vehicle (n = 10), M = 165.41 s, SD = 43.78 and Sham-Vehicle (n = 9), M = 176.30 s, SD = 36.81 
groups; t(17) = -.576, p = .567.  Similar to what was found with the TTBI data, the FST was not 
able to detect differences between injured and sham animals.  
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Figure 9.  Mean latency for animals to become immobile in the forced swim test.  The 
time to become immobile (TTBI) was assessed on the second day in the FST (PID 19).  
Data are expressed as the mean TTBI ± SEM.  A one-way ANOVA showed that there 
was no significant difference in the TTBI between the TBI-Vehicle (n = 10), TBI-0.25 (n 
= 9), and Sham-Vehicle (n = 10) groups.  Within the parameters of the present study, 
the FST lacks the sensitivity to detect differences between sham and injured animals.   
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Discussion 
The aim of the present study was to determine the best dose or doses of lithium for 
reducing TBI-induced motor and cognitive (spatial navigation and depressive-like behavior) 
deficits.  A dose response was used to determine the most effective doses of lithium as a therapy 
to ameliorate motor and cognitive deficits associated with moderate-severity TBI.  Previous 
studies have shown lithium to be an effective therapy when administered prior to a traumatic 
insult in vitro and when administered pre- and post-MCAO in vivo.  The results from the present 
study support the use of low doses of lithium as a postinjury therapy to ameliorate TBI-induced 
cognitive and vestibulomotor deficits.   
Beam walk task.  The effects of the different doses of lithium on vestibulomotor 
functioning indicate that the doses of lithium corresponding to the upper and lower end of the 
clinically relevant therapeutic range were the most beneficial.  Injured animals treated with 1.00, 
0.25, and 0.125 mmol/kg, doses of lithium showed marked improvement in their latency to reach 
the goal box on PID 1 and 3, as compared to animals that received the 0.50 mmol/kg dose.  
These findings partially fit with the working hypothesis of this study that the middle and lower 
doses of lithium would be more effective as compared to the high dose.  Although the benefit 
associated with the higher dose was unexpected, it is not uncommon for high and low doses of 
drugs, particularly those used in brain injury studies, to have positive effects on performance 
whereas doses falling within the middle range of this scale are associated with a lack of 
improvement.  Indeed, the review article by Calabrese (2008) examined multiple ischemic brain-
injury and TBI studies, which varied greatly in their methodologies, and found over 30 drugs that 
were reported to have this same pattern of effective recovery of motor function with high and 
low doses of a drug, that was not observed following administration of mid-range doses.  As 
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expected, by PID 7 all the injured groups had a return to near preinjury levels of performance in 
the BW task.   
Morris water maze. 
 Hidden platform.  The results from the hidden platform portion of the MWM task 
showed that lowest doses of lithium tested (0.25 and 0.125 mmol/kg) were the most effective in 
reducing TBI-induced cognitive deficits.  It was speculated that the 0.50 mmol/kg dose would 
have also provided neuroprotection, however, this was not the case.    
 To ensure that the differences we found in the MWM performance between the treatment 
groups was not affected by motor deficits, the average swim speed per group was calculated.  
Although there were small differences in the overall swim speeds of the treatment groups, there 
was no significant difference in the swim speeds of the sham and injured vehicle-treated animals.  
Neither injury nor lithium treatment alone were sufficient to alter the average swimming speed of 
the groups.  However, when TBI and lithium treatment were combined, the average swim speed 
of these groups (i.e., TBI-1.00, TBI-0.50, TBI-0.25, TBI-0.125) significantly increased.  
Additionally, there was no appreciable difference in the swim speeds of the injured lithium-
treated groups.  Based on these data, we hypothesize that there may be a combined effect of 
injury and lithium treatment on motor function and that an aspect of this effect is manifest as 
increase in swim speed.  The differences in the group swim speeds could be a confounding 
variable, however, it is unlikely that the group differences in swim speed significantly affected 
the latencies to locate the hidden platform.  All the injured lithium-treated groups swam faster 
than the TBI-Vehicle group.  The groups treated with the lower doses (0.25 & 0.125 mmol/kg) 
had significantly shorter latencies to locate the hidden platform than the TBI-Vehicle, whereas 
the higher doses (1.00 & 0.50 mmol/kg) had similar latencies to reach the goal platform as 
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compared to the TBI-Vehicle group.  A factor that could have contributed to the differences in 
swim speed is the mass of the animals.  However, an analysis of the average daily mass for each 
treatment group did not reveal any significant between-group differences.  The finding that the 
mass of the animals was comparable over the course of the study supports the theory that the 
differences in swim speed were due to drug effects rather than weight loss or gain. 
The proximity score has been reported to be a better indication of spatial learning than 
goal latency when there are differences in overall swim speeds (Gallagher et al., 1993).  Analysis 
of the proximity score data from the hidden platform testing in the MWM showed that none of 
the injured lithium-treated groups significantly differed from TBI-Vehicle.  However, relative to 
the other TBI groups, the TBI-0.25 and TBI-0.125 were the only ones that performed as well as 
the Sham-1.00 group (i.e., had lower proximity scores).  These data parallel the latency data in 
the MWM, which showed chronic postinjury treatment with the two lowest doses of lithium 
(0.25 and 0.125 mmol/kg) was associated with shorter latencies to the goal platform that were 
statistically similar to those observed in the Sham-1.00 group.  The higher doses of lithium (1.00 
and 0.50 mmol/kg) were not able to significantly reduce MWM latency relative to the low doses 
of lithium and both sham groups.   
Despite the differences in swim speeds, because all of the injured lithium-treated animals 
swam significantly faster than sham groups, it is not likely that the swim speed is a confounding 
variable.  The similarity in the proximity scores of the TBI-0.25, and TBI-0.125, and Sham-1.00 
groups, despite having significantly different swim speeds, provides further support for the use 
of the selected dose of lithium (0.25 mmol/kg) in the subsequent experiments in this dissertation.   
 Probe trial.  The probe trial was administered on PID 15 (day 5 in the MWM).  This test 
was incorporated to measure the cumulative learning of each rat for the location of the hidden 
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platform.  The proximity score from this assessment was compared across groups and was 
expected to support the data from the hidden platform testing portion of the MWM.  However, 
the only difference that was detected was a significantly lower proximity score in the Sham-
Vehicle group, indicating improved performance, as compared to all other treatment groups.  
These data could indicate that the injured lithium-treated groups did not effectively learn the 
location of the hidden platform.  Additionally, the Sham-1.00 group had significantly higher 
proximity scores, indicating poorer performance, as compared to the Sham-Vehicle group, 
suggesting that lithium itself may have deleterious effects on MWM learning.  Based on the 
similarities in performance between the Sham-Vehicle and Sham-1.00 groups on the BW and 
hidden platform portion of the MWM (i.e., latency, proximity, and swim speed), it is unusual 
that the probe trial data indicated that these groups were significantly different and that the 
Sham-1.00 group performance was statistically similar to all the injured groups.  An alternate 
explanation for the observed results in this task is that the probe trial lacks the sensitivity to 
detect the injury- and drug-induced effects on MWM learning as compared to the latency and 
proximity outcome measures from the hidden platform test.   
Visible platform.  The visible platform test was used to ensure adequate visual acuity as 
well as motivation to locate the platform.  Analysis of these data showed that all the animals met 
the criterion established for the visible platform task (i.e., they were able to locate the hidden 
platform within an average of 15 s over 8 trials).  There was no significant difference between 
any of the treatment groups in the average latency to locate the visible platform, thereby 
excluding the possibility that the differences in overall performance between the treatment 
groups was attributable to visual or motivational differences.     
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Forced swim test.  The FST was used to assess depressive-like behavior following TBI.  
However, in the present study we did not detect any differences in either the TTBI or the TTI 
between the TBI-Vehicle and Sham-Vehicle groups.  Because there was no discernable effect of 
injury, further use of this test with the different doses of lithium was not carried out.  The lack of 
an injury effect could be attributed to the animal’s prior experience in the MWM.  Based on this 
assumption, the prior exposure to a swimming task may have desensitized the animals to the 
stress and subsequent “learned helplessness” associated with longer periods of immobility and 
shorter latencies to become immobile.  Behavioral assessment of depressive-like behavior using 
the FST may be best suited for animals not previously subjected to assessment in the MWM.     
Experiment 2 
Rationale 
 It is well established that the therapeutic time window is critical when evaluating the 
effectiveness of a treatment.  According to the biphasic model of TBI, there is a sharp increase in 
neuronal and metabolic activity followed by a steep decline in overall brain functioning that can 
persist for some time postinjury.  Drug treatments typically target either the acute or chronic 
phases.  Indeed, agents that are beneficial when administered during the acute postinjury phase 
(e.g., mu-opioid receptor agonists and glutamate antagonists) may be ineffective or even impair 
recovery when administered during the chronic postinjury phase (Hamm, O'Dell, Pike, & Lyeth, 
1993; Lyeth, Jiang, Gong, Hamm, & Young, 1995).  During the chronic postinjury phase, 
marked by a hypofunctional state, drugs that have excitatory effects are associated with 
improved outcome.   
The findings from Experiment 1 showed that the lowest doses of lithium, administered 30 
min postinjury, were effective in reducing cognitive and motor deficits associated with TBI.  
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This finding is encouraging and it may provide further insight into mechanisms of action for 
lithium as well as secondary injury processes occurring after lateral FPI.  However, a 30 minute 
therapeutic time window does not translate well to clinical populations.  The primary difficulty 
in translating successful therapies from the bench to the bedside is ensuring that the initiation of 
treatment is equivalent (Marklund et al., 2006).  Therapies that are effective in the acute 
postinjury phase, in preclinical models, must be administered within a brief time period in 
clinical trials.  This can present a challenge for investigators due to the time lag between the 
traumatic event, the arrival of the individual to a medical center, and obtaining informed consent 
from the patient or a family member.  In the present study, we determined which of two 
postinjury time points (8 and 24 hr) is most effective in ameliorating the sequelae associated with 
the lateral FPI model of TBI, and provide insight into the therapeutic time window for initiating 
lithium treatment.  The 8 and 24 hr postinjury time points were selected based on the clinical 
relevance, because a longer therapeutic time window will offer the best chance for translating 
these findings to clinical practice.  Furthermore, delaying treatment may provide insights into the 
mechanisms of action through which lithium may exert its neuroprotective effects. 
The data collected from the 8 and 24 hr treatment delays was analyzed with the data 
obtained from the 30 min treatment delay group that was treated with the optimal dose of lithium 
(0.25 mmol/kg) from Experiment 1 (i.e., the TBI-0.25 group).  The data from the TBI-0.25 
group, along with the two treatment delays from the present study, were used to establish the 
furthest time point from injury that chronic lithium treatment can be administered while still 
offering significant protection of vestibulomotor and cognitive function.   
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Hypotheses  
It was hypothesized that the optimal dose (0.25 mmol/kg, ip), selected from Experiment 
1, would be effective in reducing TBI-induced vestibulomotor and cognitive deficits at both 
treatment delay time points (8 and 24 hr).   
Specific Aims 
The aim of the present study was to evaluate the effect of delayed postinjury lithium 
treatment on cognitive and vestibulomotor function.  Using the optimal dose from Experiment 1, 
we aimed to define a therapeutic time window for lithium administration.   
Methods 
The subjects, surgical preparation for lateral FPI, lateral FPI, postinjury neurological 
assessment, drug preparation, and neurobehavioral outcome assessment for BW and MWM, are 
identical to those described in Experiment 1.  Due to the lack of a detectable difference between 
sham and injured animals in the FST, this test was not administered.  The treatment timeline used 
for this study is detailed in Figure 10.  
Experimental design.   
Drug treatment.  Animals received daily (PID 0-19) intraperitoneal injections of either 
lithium chloride or vehicle (0.9% sterile saline).  Daily treatment was initiated at either 8 or 24 
hours postinjury.  Sham animals were randomly assigned to one of two treatment groups, 
lithium-treated (0.25 mmol/kg, ip) with treatment initiated 24 hours post-sham-injury (to test for 
any effects of the optimal dose of lithium in uninjured rats), or vehicle-treated (1 ml/kg, ip).  See 
Table 2 for treatment group design.   
Statistical analysis.  In Experiment 1, the selected dose of lithium (0.25 mmol/kg, ip) was 
found to be effective in reducing TBI-induced cognitive and motor deficits when administered 
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30 min after injury.  To determine the relative efficacy of the two time delays in the present 
study, the BW and MWM data from the optimal dose in Experiment 1 were included in the data 
analysis of the present study.  
Data from the MWM was analyzed for goal latency using a split-plot ANOVA [6 
(Group) x 4 (Day)] comparing injured animals and sham-injured animals.  A mean daily latency 
to find the goal platform during MWM testing on day’s 11 – 14 postinjury was computed for 
each group.  Proximity scores and swim speed were averaged individually for each day in the 
MWM, and a one-way ANOVA was performed for each outcome measure to determine the 
relationship between the groups.  For each of the other tasks involving the MWM (i.e., probe 
trial and visible platform), a one-way ANOVA was used to determine any relationship between 
the groups.  Where appropriate, a post hoc analysis was performed to compare specific groups of 
interest. 
Figure 10.  Timeline of events in Experiment 2.  This figure shows the schedule for 
administration of both the drug-treatment and neurobehavioral assessments used in 
Experiment 2.  Abbreviations: beam walk test (BW), Morris water maze (MWM), 
postinjury day (PID) 
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Table 2.   
 
Experiment 2: Treatment Groups 
 
Treatment group n 
 
 
TBI-Vehiclea 10  
Sham-Vehiclea 10 
 
 
TBI-30 minc 10   
TBI-8 hrb 10   
TBI-24 hrb 9   
Sham-24 hrb 9   
 
Note.  avehicle (0.9% sterile saline, dose volume: 1 ml/kg), 30 min 
postinjury or sham.  b24 or 8 hr treatment delay (dosage: 0.25 mmol/kg 
lithium, dose volume: 1 ml/kg). cData from the TBI-30 min group are from 
the TBI-0.25 Lithium group in Experiment 1.   
   
 
Results 
Neurological assessment.  The suppression of the righting reflex was assessed 
immediately after the delivery of the TBI.  The mean latency (in seconds) necessary for each 
animal to recover the righting reflex was calculated for each treatment group that received a TBI.  
These data are as follows (± SEM): TBI-Vehicle, M = 403.30 s (± 24.95) (n = 10); TBI-30 min, 
M = 430.20 s (± 12.73) (n = 10); TBI-8 hr, M = 430.20 s (± 12.73) (n = 10); TBI-24 hr, M = 
413.67 s (± 21.49) (n = 9).  A one-way ANOVA failed to detect any significant differences in the 
suppression of the righting reflex among the injured groups, F(3, 35) = 0.859, p = .471.  This 
finding indicates that all the injured animals had equivalent injury severities.   
Animal mass.  The mass of the animals was compared over the 21 days from the surgical 
preparation for the injury (PID -1) to the final day of lithium treatment (PID 19).  The ANOVA 
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did not find any significant difference in the average mass of the treatment groups, F(5, 47) = 
1.814, p = .128.  The Sham-Vehicle and TBI-30 min data are the same that was used in the 
animal mass data analysis in Experiment 1. 
Beam walk.  Data from the BW assessment are presented in Figures 11-12.  A split-plot 
ANOVA [6 (Group) x 4 (Day)] revealed significant group differences in the mean latencies to 
reach the goal box, F(5, 52) = 5.012, p = .001.  A Fisher LSD post hoc analysis showed that the 
Sham-Vehicle (p < .001), Sham-24 hr (p < .001), TBI-8 hr (p = .019), and TBI-30 min (p = .004) 
groups had significantly shorter latencies to reach the goal box as compared to the TBI-Vehicle 
group.  Additionally, the average BW latencies for these four groups were not significantly 
different from each other (p = .125).  No significant difference was observed between the TBI-
Vehicle and TBI-24 hr group (p = .403).  While the TBI-8 hr group was significantly different 
from the TBI-Vehicle, it did not significantly differ from the TBI-24 hr group (p = .139).      
Morris Water Maze. 
 Hidden platform.  The mean latency for each group to locate the hidden platform was 
compared across days.  A split-plot ANOVA [6 (group) x 4 (day)] showed that there was a 
significant difference in the latency to reach the goal platform between treatment groups, F(5, 
52) = 8.042, p < .001.  A Fisher LSD post hoc analysis found that the TBI-Vehicle group had 
significantly longer latencies to reach the goal platform as compared to the Sham-Vehicle (p < 
.001), Sham-24 hr (p < .001), TBI-30 min (p = .002), and TBI-8 hr groups (p = .002).  No 
difference was detected between TBI-24 hr and TBI-Vehicle groups, (p = .319).  The TBI-30 
min (p = .040) and TBI-8 hr (p = .037) groups had significantly shorter latencies to reach the 
hidden platform as compared to the TBI-24 hr group.  No significant difference was observed 
between the TBI-30 min and TBI-8 hr groups (p = .967).  Animals in the Sham-Vehicle group 
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performed significantly better as compared to animals that received a TBI.  No significant 
difference in performance was detected between the Sham-Vehicle and Sham-24 hr groups (p = 
.352).  MWM data for the 24 hr and 8 hr treatment-delay groups are presented in Figure 13 and 
14 respectively.         
 Swim speed.  The mean swim speed across days in the MWM was calculated for each 
treatment group.  These data are presented in Figure 15.  A one-way ANOVA found a significant 
difference between the swim speeds, F(5, 52) = 2.981, p = .019.  A Fisher LSD post hoc analysis 
revealed that there was no appreciable difference in the average swim speeds between the Sham-
Vehicle, TBI-Vehicle, Sham-24 hr, and TBI-24 hr groups.  Additionally, both of the 24 hr 
treatment delay groups (TBI-24 hr and Sham-24 hr) had statistically similar swim speeds as 
compared to the TBI-8 hr or TBI-30 min groups.  However, the TBI-8 hr and the TBI-30 min 
groups swam significantly faster (p = .008 and .002 respectively) in the MWM as compared to 
the Sham-Vehicle group (p = .571), but only the TBI-30 min group swam significantly faster 
than the TBI-Vehicle group, p = .015.  The average speed of the TBI-8 hr group was faster than 
the TBI-Vehicle group and there was a trend toward a significant difference (p = .057) in speeds 
between the two groups.   
Proximity to hidden platform.  The proximity score data from the hidden platform testing 
was compared using a split-plot [6 (group) x 4 (day)] ANOVA and revealed a significant effect 
of group, F(5, 52) = 5.379, p < .001.  A Fisher LSD post hoc analysis found that the TBI-30 min 
(p = .031) and TBI-8 hr (p = .03) had significantly lower proximity scores, indicating a more 
direct route to the goal platform, as compared to the TBI-Vehicle group.  However, the proximity 
scores of the TBI-30 min and TBI-8 hr were significantly higher than the Sham-Vehicle (p = 
.034 and .036 respectively) but did not differ from the Sham-24 hr group (p = .122 and .128 
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respectively).  Both sham groups had significantly lower proximity scores (p < .001) as 
compared to the TBI-Vehicle group.  The TBI-24 hr group significantly differed (p < .01) only 
from the sham groups.  The proximity data for the 24 hr and 8 hr treatment-delay groups are 
presented in Figure 16 and 17 respectively.         
 Probe trial.  The probe trial (60 s) was conducted in the MWM on PID 15, 24 h after the 
last trial of the hidden platform testing.  This test was performed with the platform removed from 
the MWM.  The mean proximity score was calculated for each treatment group using the data 
collected by the VideoMex tracking software.  The proximity score was determined by 
comparing the swim path of the animal and the most efficient path to the goal, as determined by 
the VideoMex program.  In this analysis, a lower score is indicative of better learning for the 
location of the hidden platform.  Data from the 24 hr and 8 hr treatment-delay groups are 
presented in Figure 18 and 19 respectively.  A one-way ANOVA showed that there was a 
significant effect of treatment group on the proximity score, F(5, 45) = 2.959, p =.022.  A Fisher 
LSD post hoc analysis revealed that the Sham-24 hr (p = .009) and Sham-Vehicle (p = .039) 
were the only groups with significantly lower scores as compared to the TBI-Vehicle group.  The 
Sham-24 hr group also had significantly lower proximity scores as compared to the TBI-30 min 
(p = .023), TBI-24 hr (p = .006); however, no difference was observed between Sham-24 hr and 
TBI-8 hr (p = .257).  Sham-Vehicle differed only from TBI-24 hr (p = .030).  No difference was 
found in the proximity score between the Sham-Vehicle and TBI-30 min (p = .07) or TBI-8 hr (p 
= .314) groups. 
Visible platform.  The mean latency, in seconds, for each treatment group to locate the 
visible platform was calculated based on the performance of each animal over 8 trials (PID 15).  
The group means (± SEM) are as follows: TBI-Vehicle, M = 10.54 s (± 1.56); TBI-30 min, M = 
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10.85 s (± 1.51); TBI-8 hr, M = 11.35 s (± 1.54); TBI-24 hr, M = 12.99 s (± 1.06); Sham-Vehicle, 
M = 13.03 s (± 2.71); Sham-24 hr, M = 8.88 s (± 0.56).  A one-way ANOVA failed to detect any 
statistically significant differences among the group means, F(5, 52) = 0.862, p = .513.   
 
      
 
Figure 11.  Comparison of 24 hr treatment delay on beam walk performance.  These 
data represent the mean latency to reach the goal box, ± SEM.  TBI-Vehicle (n = 10), 
TBI-24 hr (n = 9), Sham-24 hr (n = 9), Sham-Vehicle (n = 10).  An ANOVA followed by a 
Fisher LSD post hoc test determined that the TBI-24 hr and TBI-Vehicle group 
performed significantly worse on the beam walk task as compared to both sham groups.  
There was no difference in performance detected between the two injured groups and 
no significant difference between the two sham groups.  (*) indicates comparisons made 
to the Sham-Vehicle group.  (†) indicate significant differences in treatment groups as 
compared to Sham-1.00.  †††, ***p < .001. 
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Figure 12.  Comparison of 8 hr treatment delay on beam walk performance.  These data 
represent the mean latency to reach the goal box, ± SEM.  TBI-Vehicle (n = 10), TBI-30 
min (n = 10), TBI-8 hr (n = 10), and Sham-Vehicle (n = 10).  The TBI-30 min group data 
is identical to the TBI-0.25 from Experiment 1 and is included in the data analysis as a 
basis for comparing the effectiveness of the selected dose of lithium when the initiation 
of treatment is delayed.  The TBI-8 hr and TBI-30 min had significantly shorter latencies 
to reach the goal box as compared to the TBI-Vehicle and TBI-24 hr groups.  (*) indicate 
comparisons made to the Sham-Vehicle group.  (#) indicate comparisons made to TBI-
Vehicle.  * p < .05.  ## p < .01.  *** p < .001. 
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Figure 13.  Effect of 24 hr treatment delay on MWM performance.  Data are the mean 
latency for the selected treatment groups, TBI-Vehicle (n = 10), TBI-24 hr (n = 9), 
Sham-Vehicle (n = 10), and Sham-24 hr (n = 9), ± SEM.  There was a significant main 
effect for group.  A Fisher LSD showed that the TBI-24 hr and TBI-Vehicle groups had 
significantly longer latencies to reach the goal as compared to both sham groups.  
There was no significant difference between the latencies of the two sham groups or the 
two injured groups.  (*) indicate comparisons made to the Sham-Vehicle group.  (†) 
indicate significant differences in treatment groups as compared to Sham-1.00.  †† p < 
.01.  †††, *** p < .001. 
  
*** †††
*** ††
0
20
40
60
80
100
120
1 (PID 11) 2 (PID 12) 3 (PID 13) 4 (PID 14)
La
te
nc
y 
to
 g
oa
l p
la
tfo
rm
 (s
)
Days tested in the MWM (postinjury day)
TBI-Vehicle
TBI-24 hr
Sham-Vehicle
Sham-24 hr
 
 
107 
 
 
      
 
 
Figure 14.  Effect of 8 hr treatment delay on MWM performance.  Data represent the 
mean latency for the selected groups (n = 10/group) to reach the hidden platform, ± 
SEM.  The dose of lithium used is 0.25 mmol/kg (ip).  The TBI-30 min group data is the 
TBI-0.25 from Experiment 1 and is included in the data analysis as a basis for 
comparing the effectiveness of the selected dose of lithium when the initiation of 
treatment is delayed.  An ANOVA showed significant differences between the treatment 
groups.  A Fisher LSD post hoc analysis found that the TBI-30 min and TBI-8 hr groups 
had significantly shorter latencies to reach the hidden platform as compared to the TBI-
Vehicle group (p = .002).  The Sham-Vehicle group performed significantly better in this 
task as compared to the TBI-Vehicle (p < .001), TBI-30 min (p = .032), and TBI-8 hr (p = 
.035) groups.  (*) indicate comparisons made to the Sham-Vehicle group.  (#) indicate 
comparisons made to the TBI-Vehicle group.  * p < .05.  ## p < .01.  *** p < .001. 
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Figure 15.  Average swim speed for each treatment group in Experiment 2.  Data 
represent the mean swim speed for each treatment group across days in the MWM 
during hidden platform testing, ± SEM.  TBI-Vehicle (n = 10), TBI-24 hr (n = 9), TBI-8 hr 
(n = 10), TBI-30 min (n = 10), Sham-Vehicle (n = 10), Sham-24 hr (n = 9).  The TBI-30 
min group data is the TBI-0.25 from Experiment 1 and is included in the data analysis 
as a basis for comparing the effectiveness of the selected dose of lithium when the 
initiation of treatment is delayed.  The swim speed is calculated by dividing the distance 
traveled by the latency to reach the goal platform (cm/s).  A significant difference in 
swim speed was found for the TBI-30 min and TBI-8 hr groups as compared to all other 
treatment groups.  Initial comparisons were made to the Sham-Vehicle group (*).  
Additional significant between-group comparisons are indicated by braces.  *p < .05.  
**p < .01.   
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Figure 16.  Comparison of 24 hr treatment delay on proximity to the goal platform during 
MWM testing.  Data represent the proximity score obtained during hidden platform 
testing in the MWM for the TBI-Vehicle (n = 10), TBI-24 hr (n = 9), Sham-Vehicle (n = 
10), and Sham-24 hr (n = 9) groups, ± SEM.  Lower scores indicate the animal took a 
more direct path the hidden platform (i.e., improved performance).  Both sham groups 
had significantly lower proximity scores relative to the two injured groups.  No 
statistically significant difference was observed between the proximity scores of the two 
sham groups or the two injured groups.  (*) indicate comparisons made to the Sham-
Vehicle group.  (†) indicate significant differences as compared to Sham-1.00.  ††p < .01.  
†††, ***p < .001. 
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Figure 17.  Comparison of 8 hr treatment delay on proximity to the goal platform during 
MWM testing.  Data represent the mean proximity score for each treatment group (n = 
10/group), ± SEM.  The TBI-30 min group data is the TBI-0.25 from Experiment 1 and is 
included in the data analysis as a basis for comparing the effectiveness of the selected 
dose of lithium when the initiation of treatment is delayed.  An ANOVA, followed by a 
Fisher LSD post hoc analysis found that the Sham-Vehicle group performed significantly 
better (i.e., lower scores) as compared to the selected injured groups.  (*) indicate 
comparisons made to the Sham-Vehicle group.  (#) indicate significant differences as 
compared to TBI-Vehicle.  *, #p < .05.  ††p < .01.  †††, ***p < .001. 
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Figure 18.  Comparison of 24 hr treatment delay on the proximity score from the probe 
trial on PID 15.  The bars represent the mean proximity score for each treatment group, 
TBI-Vehicle (n = 10), TBI-24 hr (n = 9), Sham-Vehicle (n = 10), Sham-24 hr (n = 9), ± 
SEM.  Proximity score is based on a 60 s probe trial (no platform in MWM) on postinjury 
day (PID) 15.  A Fisher LSD post hoc analysis revealed that the Sham-Vehicle (p = 
.039) and Sham-24 hr (p = .009) groups had significantly lower scores (i.e., took the 
most direct route and remained closest to the location of the hidden goal platform) as 
compared to the TBI-Vehicle group.  (*) indicate direct comparisons made to the Sham-
Vehicle group.  Other statistically significant group differences are indicated by braces.  
**p < .01.  
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Figure 19.  Comparison of 8 hr treatment delay on proximity score from the probe trial 
on PID 15.  The TBI-30 min group data is from the TBI-0.25 group in Experiment 1.  The 
mean proximity score for each treatment group, obtained from the 60 s probe trial (no 
platform in MWM) on postinjury day (PID) 15.  The bars represent the mean proximity 
score for each treatment group (n = 10/group), ± SEM.  The TBI-30 min group data is 
the TBI-0.25 from Experiment 1 and is included in the data analysis as a basis for 
comparing the effectiveness of the selected dose of lithium when the initiation of 
treatment is delayed.  An ANOVA followed by a Fisher LSD post hoc analysis revealed 
that the Sham-Vehicle and TBI-8 hr groups had significantly lower proximity scores (i.e., 
took the most direct route and remained closest to the location of the hidden goal 
platform) as compared to the TBI-Vehicle group.  The proximity score for the TBI-30 min 
group was significantly higher as compared to Sham-Vehicle and did not statistically 
differ from TBI-Vehicle.  (*) indicate direct comparisons made to the Sham-Vehicle 
group.  Other significant group differences are indicated with braces.  *p < .05.  **p < 
.01. 
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Discussion 
In the present study we examined the therapeutic time window for administering the 
selected dose of lithium from Experiment 1.  Lithium treatment was delayed for either 8 or 24 
hours postinjury.  We selected the 8 and 24 hr time delays for initiating treatment because they 
are clinically relevant, i.e., they would allow sufficient time for the treatment to be administered, 
taking into account time for transportation and obtaining informed consent.  The current 
investigations into the therapeutic window for the optimal dose of lithium, selected from 
Experiment 1, revealed that lithium treatment can be delayed up to 8 hours postinjury and still 
provide significant neuroprotection as evidenced by improved motor and cognitive performance 
postinjury.  
Beam walk.  The TBI-8 hr group showed a significant reduction in the latency to traverse 
the beam in the days following the TBI and performed similarly to the TBI-30 min group from 
Experiment 1.  The beneficial effects observed following the 8 hr delay did not carry over for the 
TBI-24 hr group.  In fact, the latter group performed comparably to the TBI-Vehicle treated 
group.  These data indicate that lithium may mediate posttraumatic vestibulomotor impairment.     
Morris Water Maze. 
Hidden platform.  Analysis of the hidden platform data revealed similar findings to those 
observed in the BW.  The TBI-8 hr group exhibited significantly shorter latencies to reach the 
goal platform as compared to the TBI-Vehicle group.  Delaying treatment with lithium for up to 
8 hr postinjury appears to maintain the cognitive protective effects observed after the 30 min 
treatment delay in Experiment 1.  All benefit associated with this dose of lithium (0.25 mmol/kg, 
ip) was lost when treatment was delayed for 24 hr.  In fact, a comparison of latency between 
TBI-Vehicle and TBI-24 hr groups was statistically indistinguishable.  Although the 24 hr 
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treatment delay, using the selected dose of lithium, was not protective, the findings from the 8 hr 
treatment delay are very encouraging. 
Similar to the findings from the previous study, there was no difference in swim speed 
between the Sham-Lithium, Sham-Vehicle and TBI-Vehicle groups.  However, the hypothesized 
interaction between TBI and lithium on swimming speed did not carry over into this experiment.  
There was no appreciable difference in the swim speed of the TBI-24 hr relative to any treatment 
group.  The TBI-8 hr group swam significantly faster than the Sham-Vehicle group but did not 
statistically differ from the swim speed of the TBI-Vehicle group.  At this time, it is unclear what 
is producing these group differences in swim speed.     
Dissimilarities in group swim speeds can represent a confounding variable, leading 
Gallagher et al. (1993) to develop the proximity score, which is a measure of spatial memory that 
is not affected by swim speed or entry position in the maze.  This score provided additional 
information about the spatial distribution of the rat’s search, and was designed to supplement 
existing measures frequently used in assessing MWM performance (e.g., latency, path length, 
swim speed) (Gallagher et al., 1993).  The results from our analysis of the daily proximity score 
data from the hidden platform assessment are congruent with the corresponding latency data.  
The proximity score data indicates that both the TBI-30 min and TBI-8 hr groups had learned, 
more efficiently, the location of the hidden platform as compared to the TBI-Vehicle group.  
Although the TBI-30 min and TBI-8 hr groups did not perform as well as Sham-Vehicle, there 
was no difference in performance as compared to the Sham-24 hr group.    
Probe trial.  The single probe trial was performed on PID 15, after the last day of hidden 
platform testing.  This assessment shows the spatial bias of the animals search pattern (Gallagher 
et al., 1993) and was included to assess the cumulative learning of each rat for the location of the 
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hidden platform.  The only difference that we observed was between the Sham-Vehicle group 
and the other treatment groups.  The homogeneity of the scores from the other treatment groups 
suggests that this measure is not sensitive enough to detect small between-group differences.   
Visible platform.  The visible platform was used to assess the visual acuity of the animals 
and ensured that any differences detected in the latency to reach the goal platform were not due 
to the inability of the rat to see the external maze cues.  There were no differences observed in 
the latency to locate the visual platform across treatment groups.     
Experiment 3 
Study Rationale 
The hippocampus, a brain structure critical for learning and memory, is known to be 
vulnerable to TBI (Dixon et al., 1987; Hicks et al., 1996; Lowenstein, Thomas, Smith, & 
McIntosh, 1992).  Lateral fluid percussion injury has been shown to produce cell loss within the 
CA3, hilus, and DG of the hippocampus (Dietrich, Alonso, & Halley, 1994; Hicks et al., 1996; 
McIntosh et al., 1989).  The time course and regional variability for neuronal loss in the 
hippocampus was evaluated following lateral FPI in rats (Sato, Chang, Igarashi, & Noble, 2001).  
Injured animals were evaluated at the following time points postinjury: 3 hr, 1, 3, 7 and 28 days.  
Affected cells were identified using Fluoro-Jade, a marker of irreversible cell damage that stains 
the axon, cell body, and processes of apoptotic and necrotic cells (Hornfelt, Edstrom, & Ekstrom, 
1999; Schmued, Albertson, & Slikker, Jr., 1997); silver staining, used to detect degenerating 
neurons; and terminal deoxynucleotidyl transferase nick-end labeling (TUNEL), used to identify 
irreversibly damaged neurons by labeling fragmented DNA.  Quantification of cell loss was 
evaluated from three adjacent slices directly beneath the site of injury.  Pyramidal neurons in the 
hippocampus, CA1, CA2, and CA3, exhibited Fluoro-Jade staining at 3 hours, and on PID 1 
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through 7, with the most intense staining observed on PID 1 in the CA1 region.  The relative 
number of Fluoro-Jade postitive structures on PID 7 was significantly reduced as compared to 
PID 1 and was nonexistent on PID 14.  Brain slices adjacent to those used for Fluoro-Jade were 
processed using silver stain and TUNEL in the brains of animals from the 3 hour and 1 day time 
points.  These adjacent slices exhibited silver staining and TUNEL-positive cells that 
corresponded to the same regions that were marked by the Fluoro-Jade (Sato et al., 2001).  The 
study by Sato did not perform histological examination of the dentate hilar region of the 
hippocampus; however, in a different study that also used the lateral FPI model, a marked 
increase in Fluoro-Jade B positive cells was detected in the ipsilateral hilus at 6 and 12 hours 
postinjury.  Analysis of this region at 24 hours postinjury found a significant decline in Fluoro-
Jade B positive cells, suggesting that by 24 hours significant cell death has occurred (Lee & 
Agoston, 2009).       
 The Giemsa stain is a hematoxylin and eosin stain that is useful for histology because of 
the high-quality staining of chromatin and the nuclear membrane, the metachromasia of some 
cellular components, and the different qualities of cytoplasmic staining depending on the cell 
type (Barcia, 2007).  This stain is composed of methylene blue, azure B, and eosin.  Methylene 
blue and azure B, basic dyes, bind to acidic cellular components (e.g., DNA, RNA, neutrophil-
specific granule matrices, platelets, and ribosome-rich cytoplasm).  Eosin, the acidic part of the 
stain, binds to basic cellular components (e.g., hemoglobin, eosinophilic granual contents, and 
basic cellular proteins) (Woronzoff-Dashkoff, 2002).  Differentiation of neuronal types within 
the hippocampus is determined by color.  Neurons within the CA3 and hilus stain violet in color 
and neurons within the DG stain a blue or dark blue color.     
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Previous studies that have examined post-TBI cell survival in the hippocampus found that 
7 days postinjury was sufficient for significant cell loss to have occurred.  Following this time 
point there is little evidence for further significant cell death (Sato et al., 2001).  The analysis of 
neuronal survival within the CA3 and hilus may correlate with alterations in MWM performance 
following lateral FPI.  To evaluate this potential interaction, animals were treated daily for 7 
days postinjury.  To address this question, hippocampal neurons within the CA3 and hilar 
regions were counted using unbiased stereological methods, optical dissector and fractionators 
sampling (West, Slomianka, & Gundersen, 1991). 
Hypotheses 
 Injured vehicle-treated rats will have significantly fewer healthy neurons in both the 
CA3 and hilus, as compared to sham animals.  It is also hypothesized that injured lithium-treated 
rats will have more surviving neurons in these subregions of the hippocampus as compared to 
injured vehicle-treated rats. 
Specific Aims 
The aim of the present study is to evaluate the effect of lithium treatment on cell survival 
in the ipsilateral CA3 and hilar regions of the hippocampus.   
Methods 
Animals underwent surgical preparation identical to that described in Chapter 2, General 
Methods.  Twenty-four hours after surgical preparation, on the day of injury, animals were 
randomly assigned to one of three treatment groups: TBI-Vehicle (n = 4), TBI-Lithium (n = 4), 
and Sham-Vehicle (n = 4).  Postinjury neurological assessment and preparation/administration of 
the 0.25 mmol/kg dose of lithium was identical to that described in Experiment 1.  Treatment 
with either lithium chloride (0.25 mmol/kg) or 0.9% saline was initiated 30 min post- TBI or 
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sham injury.  Both the lithium and saline were administered via intraperitoneal injection, in a 
volume of 1 ml/kg.  Injections with lithium or saline were continued daily for 7 days.  The same 
animals were used to obtain the cell counts from the CA3 and hilus. 
 Tissue preparation.  On PID 7, animals were sacrificed by an overdose of sodium 
pentobarbital (200 mg/kg, ip) to effect and subsequently underwent transcardial perfusion with 
500 ml of 0.9% saline, followed by 500 ml of 4% paraformaldehyde in 0.1M phosphate-buffered 
saline (PBS).  After completing the perfusion process the brain was excised and placed in 4% 
paraformaldehyde for 24 – 48 hr and then stored in PBS solution.  Coronal slices of brain tissue, 
60 μm thick, were cut using a vibratome (Leica VT1000s).  Sections of cortex were collected 
from bregma -2.30 mm through -4.16 mm, based on stereotaxic coordinates obtained from a rat 
atlas (Paxinos & Watson, 1982), including the area beneath the injury site.  The tissue was 
mounted on microscope slides (Superfrost/Plus) and allowed to air-dry overnight prior to Giemsa 
staining.  
Giemsa cell staining.  10% Giemsa solution was prepared fresh and heated in an oven to 
60 °C.  Slides were placed in a staining dish placed indirectly under tepid running tap water and 
allowed to soak for 3 min.  The slides were then placed into the pre-heated Giemsa staining 
solution, in a 60 °C oven, for 30 min.  The slides were then removed from the oven and soaked 
in tepid indirect running tap water for 2 min.  The slides were then differentiated in 0.5% Acetic 
acid for 1 - 2 min, at which point the intensity of the stain was assessed by visual inspection 
under a microscope.  Once the desired stain intensity was reached, the slides were quickly rinsed 
in dH2O and placed in 95% alcohol for 1 min.  This was followed by two, 1 min immersions in 
100% alcohol and then two 5 min immersions in Xylene.  Separate glass staining dishes were 
used for each solution.  Slides were then coverslipped using permount and allowed to dry.   
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  Hippocampal cell counts.  The number of neurons in the hippocampal subregions, CA3 
and hilus, was determined by using unbiased stereological methods, optical dissector and 
fractionators sampling, with the Olympus image system CAST program.  Every third coronal 
hippocampal section for a total of 10 sections per brain was examined.  This ensured that 120 μm 
would separate the slices used for counting and thereby prevented counting the same cell twice.  
The dissector was set to count cells within the range of -3 μm to -15 μm and the step size across 
each section was fixed at 175 μm.  The sampling areas were outlined under a 10X objective 
while cell counting was done under a 64X oil immersion lens.  Giemsa stained neurons (dark 
blue/violet) in the CA3 and hilus region were counted.  Neurons were identified by their distinct 
morphological features; only those cells with a clearly defined nucleolus within a defined nuclear 
membrane were included in the counts.  Additionally, a cell was counted only when the 
nucleolus of that cell first came into focus within the specified depth (12 μm) of the dissector 
frame, and part or all of the soma was within the frame of the counting box but not touching the 
bottom or left sides of the frame and/or the extensions of these lines.  Due to the scarcity of 
neurons within the hilar region, all cells with a neuronal phenotype were counted to ensure 
accurate cell counts.  Alternately, within the CA3 region, due to the high density of cells, 
counting frames, randomly selected by the CAST software, representing 12% of the sampling 
area samples was used in establishing the cell counts for this region.  The 12% parameter used 
for the CA3 region yielded cell counts above 150 cells per brain in injured vehicle-treated rats, 
the group that is expected to have the greatest hippocampal cell loss.  Based on the article by 
West and colleagues, counting 100 – 200 cells per brain ensures the accuracy of the results (West 
et al., 1991).   
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  CA3.  The CA3 region of the hippocampus, or regio inferior, consists of roughly half of 
the pyramidal cell layer, the other half is the CA1, or regio superior.  The CA3 region contains 
pyramidal cells that are larger in size as compared to those found in the CA1.  The border 
between CA2 and CA3 served as one of the anatomical markers that were used when delineating 
the CA3 region of interest.  CA2 is the narrow zone of pyramidal neurons that forms the 
transition between CA3 and CA1, distinguishable by the mixing of neurons with large and small 
cell bodies.  The other boundary was represented by an imaginary plane, perpendicular to the 
suprapyramidal and infrapyramidal blades of the DG.  This imaginary plane marks the transition 
of CA3 neurons from a tightly packed grouping of cell bodies, roughly 4 – 5 cells deep, to a 
distinctly less organized, loosely packed formation (West et al., 1991).    
Hilus.  The hilus was defined as the crescent-shaped area between the C-shaped blades of 
the DG, excluding the loosely packed cells of the CA3 that extend into this area.  This region 
contains large, lightly packed polymorphic cells with a uniform distribution (West et al., 1991).  
There are several neuronal types found within the hilus, including mossy cells, granule cells, 
basket cells, multipolar cells and fusiform cells.  Only those cells with a pyramidal shape were 
included in the cell counts in this study (i.e., no granular cells).           
Statistical analysis.  A one-way ANOVA was performed to determine the relationship 
between treatment groups and neuronal survival within the CA3 and hilus.  Where appropriate, a 
Fisher LSD test was performed to compare specific groups of interest.    
Results 
 CA3 cell counts.  The number of healthy cells in the CA3 was calculated using unbiased 
stereological methods.  These data are presented in Figure 20.  A one-way ANOVA revealed a 
significant difference between treatment groups F(2,9) = 11.727, p .003.  A Fisher LSD post hoc 
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analysis revealed a significant effect of injury.  Animals in the TBI-Vehicle group had 
significantly greater (p = .001) cell loss in the CA3 region as compared to animals in the Sham-
Vehicle group.  Daily treatment with lithium following TBI significantly ameliorated injury-
induced cell loss in the CA3 region of the hippocampus (p = .022).  Additionally, there was no 
significant difference detected between the Sham-Vehicle and TBI-Lithium groups (p = .07).   
 Hilus cell counts.  The graph in Figure 21 shows the group differences in cell survival in 
the ipsilateral hilus.  The comparison of the mean cell counts (± SEM) for each group revealed a 
large difference between the Sham-Vehicle, M = 5782 (± 917) and injury groups, TBI-Vehicle, 
M = 2275 (± 191) and TBI-Lithium, M = 3462 (± 386).  A one-way ANOVA revealed a 
significant difference in the hilar cell counts of the treatment groups, F(2, 9) = 9.302, p =.006.  A 
Fisher LSD post hoc analysis showed that the Sham-Vehicle group had significantly more cells 
in the ipsilateral hilus as compared to both the TBI-Vehicle (p = .002) and TBI-Lithium (p = 
.021) groups.  No significant difference in hilar cell counts was detected between the TBI-
Vehicle and TBI-Lithium groups (p = .185).                        
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Figure 20.  Effect of post-TBI daily lithium treatment on cell survival in the ipsilateral 
CA3 subregion of the hippocampus.  The number of surviving cells was quantified using 
stereological technique 7 days after injury or sham in the ipsilateral hippocampus.  
Groups were treated with either vehicle (0.9% sterile saline) or lithium (0.25 
mmol·kg·day), initiated 30 min postinjury (n = 4/group).  Data are expressed as mean, ± 
SEM.  A one-way ANOVA indicated a significant group difference (p < .05) when 
comparing the average cell counts for each group.  Further comparisons using a Fisher 
LSD post hoc analysis revealed significantly more healthy neurons in the CA3 region of 
TBI-Lithium and Sham-Lithium groups as compared to the number of healthy CA3 
neurons in the TBI-Vehicle group.  No significant difference in cell survival was 
observed between the TBI-Lithium and Sham-Vehicle groups.  (*) indicate significant 
group differences relative to Sham-Vehicle, additional between group comparisons are 
indicated by braces.  *p < .05.  **p < .01.   
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Figure 21.  Effect of post-TBI daily lithium treatment on cell survival in the ipsilateral 
hilar subregion of the hippocampus.  The number of surviving cells in the hilus was 
assessed 7 days after injury or sham, using stereological technique.  Treatment groups 
(n = 4/group) received daily injections with either vehicle (0.9% sterile saline, ip) or 
lithium (0.25 mmol·kg·day, ip), initiated 30 min postinjury.  Data are expressed as mean, 
± SEM, of the total cell counts (x1000) for the ipsilateral hilar region.  A one-way 
ANOVA showed an effect of group.  A Fisher LSD post hoc analysis determined that 
there was a significant effect of injury on neuronal survival in the ipsilateral hilus.  The 
Sham-Vehicle group had a significantly larger number of neurons within the hilus as 
compared to the TBI-Vehicle and TBI-Lithium groups.  There was no appreciable 
difference in number of cells within the ipsilateral hilar regions of the two injury groups.  
(*) indicate comparisons made to the Sham-Vehicle group.  *p < .05.  **p < .01. 
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Discussion 
The CA3 and hilus are known to be selectively vulnerable to lateral FPI and are also 
brain regions that are commonly affected following TBI in humans.  Neuroprotective therapies 
that can prevent secondary injury-induced cell loss or facilitate the repair of injured neurons are 
hypothesized to mitigate vestibulomotor and cognitive sequelae associated with TBI.  The 
reported protective effect of lithium treatment against the induction of apoptosis in vitro as well 
as in models of acute brain injury (e.g., MCAO, transient global ischemia) (Nonaka et al., 1998; 
Ren et al., 2003; Rowe & Chuang, 2004) was the basis for our interest in the potential benefits to 
cell survival following lithium administration in our injury model.   
Cell loss in the CA3 and hilus regions of the hippocampus following lateral FPI has been 
correlated with poorer performance in cognitive tasks such as the MWM.   In accordance with 
the findings of previous studies, the CA3 and hilus of animals in the TBI-Vehicle group showed 
significant cell loss as compared to animals in the Sham-Vehicle group (Cortez et al., 1989; 
Hicks et al., 1993; Sato et al., 2001; Smith et al., 1991).  It was hypothesized that lithium 
treatment would enhance cell survival in the CA3 and hilus regions of the hippocampus.  The 
data obtained from the ipsilateral CA3 region cell counts support the working hypothesis.  Not 
only did lithium treatment significantly increase cell survival as compared to the TBI-Vehicle 
group, there was no significant difference found between the Sham-Vehicle and TBI-Lithium 
groups.  Based on these findings, we expected the same neuroprotective effects observed in the 
CA3 would also be seen in the hilus.  We were surprised to find that lithium treatment did not 
show any benefit to cell survival in the hilus.  Both the TBI-Vehicle and, to a lesser extent, TBI-
Lithium groups had significant cell loss as compared to the Sham-Vehicle group.  Taken 
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together, these data indicate that 7-day lithium treatment, initiated 30 min post-TBI, offers 
significant protection to cells in the CA3 region but not the hilus.   
A possible explanation for this observation is that the cells within the hilus are more 
vulnerable to TBI-induced pathology as compared to those in the CA3 region, thus requiring 
greater neuroprotection than that provided by the selected dose of lithium.  This assumption is 
supported by data from Lowenstein and colleagues, who found that, following lateral FPI, a 
significant reduction in the number of healthy cells occurs bilaterally within the hilus, while no 
significant changes are detectable in the number of surviving neurons within the CA3 region of 
the hippocampus (Lowenstein et al., 1992), although this region has been shown in previous 
research (Cortez et al., 1989; Hicks et al., 1993; Sato et al., 2001; Smith et al., 1991) as well as in 
the present study, to be also selectively vulnerable to FPI.  Additional insight into the regional 
pattern of neuroprotection that we have observed is discussed in the article by Toth and 
colleagues (1997), which identifies the existence of a temporal pattern of cell death in the hilus 
following lateral FPI.  In particular, these authors have reported that the primary damage to 
neurons within the hilus occur at the moment of the fluid pulse and not as a result of delayed, 
secondary injury processes.  The authors showed this by means of the Gallyas silver stain, used 
to detect injury to neuronal processes in a rapid fashion after an insult (Toth, Hollrigel, Gorcs, & 
Soltesz, 1997).  This silver stain accumulates in injured neurons presumably as a result of the 
interaction of silver with charged monomers derived from the breakdown of polymeric 
cytoskeletal elements, in a fashion similar to the intensification process occurring during 
photography (Gallyas, Zoltay, & Dames, 1992; Toth et al., 1997).  Thus, it is possible that the 
damage to cells within the hilus occurs prior to the initiation of treatment with lithium.      
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In a recent clinical study, brain tissue samples from 21 individuals, obtained surgically 
during temporal lobectomies to alleviate temporal lobe epilepsy that developed after these 
individuals sustained head trauma, were used for histopathological analysis of neuronal 
organization and number in addition to other neurological inflammatory changes, and chronic 
gliosis (Swartz et al., 2006).  The individuals included in this study had no other risk factors for 
epilepsy, defined by the authors as “family history, perinatal distress, prolonged febrile 
convulsion, history of significant substance abuse, history of CNS infection, and history of other 
CNS pathology”.  Of the 21 neocortical specimens, 15 included hippocampal tissue and, of these, 
11 were processed with cresyl violet (a stain used to identify nissl substance) and NeuN (used to 
identify neurons).   All 11 brains showed some degree of cell loss in the hilus, however, only 
those samples with moderate to severe cell loss in the hilus, based on visual pathologic 
examination, also had damage to other hippocampal regions (Swartz et al., 2006).  Although the 
samples from this clinical study were obtained from individuals with epilepsy, a neurological 
disease that is associated with cell loss in the hippocampus even when it is not preceded by brain 
injury, it does demonstrate an ordered progression of cell death in the hippocampus that starts 
with the hilus. 
Experiment 4 
Study Rationale 
At this time, the exact mechanisms of action through which lithium treatment protects the 
brain are not clear.  One reason for this is the widespread effect of lithium on multiple 
neuroprotective targets and pathways, sometimes acting at several points within the same 
pathway (Rowe & Chuang, 2004).  Based on the known actions of lithium in the brain, it is 
possible that lithium may protect against both the acute and chronic phases of secondary brain 
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injury.  The neuroprotective effects of this drug against excitotoxic insults and cell death, 
detailed in the previous sections of this dissertation, suggest to us that lithium treatment may 
reduce neuronal damage by acting on targets associated with the acute (excitotoxic) phase of 
secondary injury.  Additionally, lithium treatment is reported to promote neuronal reorganization 
and plasticity, suggesting that this drug could facilitate functional recovery during the chronic 
(hypofunctional) postinjury phase.   
Long-term treatment with lithium has been shown to protect neurons against apoptosis, 
prolong cell survival, and promote regeneration of axons in the mammalian brain (Chen et al., 
2000; Shaldubina et al., 2001).  To elucidate further the potential mechanisms involved in 
lithium-induced neuroprotection, we selected three markers: GAP-43, a measure of postinjury 
structural reorganization; BDNF, an indicator of neuronal plasticity and neuroprotection; and 
caspase-3, to evaluate apoptotic cell death.  These markers are described in detail in the 
following sections.  
GAP-43.  GAP-43 levels are widely accepted as a good marker for synaptic plasticity in 
the adult CNS (Benowitz & Routtenberg, 1997; Christman, Salvant, Jr., Walker, & Povlishock, 
1997; Emery et al., 2000; Hulsebosch, DeWitt, Jenkins, & Prough, 1998).  This phosphoprotein, 
specific to the central nervous system, is a primary constituent of growth cones that head the 
extension of growing axons.  GAP-43 is also known as protein F1, neuromodulin, neural 
phosphoprotein B-50, axonal membrane protein GAP-43, calmodulin-binding protein P-57, 
nerve growth-related peptide GAP43, neuron growth-associated protein 43, and PP46 (Kosik et 
al., 1988).  For the purposes of this thesis, and from this point onward, it will be referred to as 
GAP-43.  GAP-43 expression and axonal transport are only found in young animals and in 
neurons undergoing reorganization (e.g., following brain injury) (Karns, Ng, Freeman, & 
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Fishman, 1987; Skene, 1989).  The function of GAP-43 is to regulate the interactions between 
the membrane skeleton/cytoskeleton components and plasma membrane (Meiri & Gordon-
Weeks, 1990; Meiri, Pfenninger, & Willard, 1986).  The activity of this protein is shaped by 
extracellular signals such as phosphorylation (e.g., PKC), calmodulin (CaM) binding, and 
calcium-dependent proteolysis (Apel, Byford, Au, Walsh, & Storm, 1990; Apel & Storm, 1992).  
When GAP-43 is phosphorylated it is associated with growing axons whereas unphosphorylated 
GAP-43 is associated with retracting axons.  Previous literature showed increases in GAP-43 
levels as early as 48 hours following TBI (Emery et al., 2000; Hulsebosch et al., 1998) and 
continuing for up to 28 days postinjury (Christman et al., 1997; Hulsebosch et al., 1998).   
Several studies, using a variety of injury models, have reported increased GAP-43 
messenger and protein expression.  The involvement of GAP-43 in structural remodeling, 
neurogenesis, and induction of LTP have lead to a general consensus that increased expression 
postinjury is indicative of a period of enhanced plasticity (Christman et al., 1997; Emery, Royo, 
Fischer, Saatman, & McIntosh, 2003; Hulsebosch et al., 1998).  Following axotomy in the CNS, 
GAP-43 is upregulated and rapidly transports to distal parts of the axon (Tetzlaff, Alexander, 
Miller, & Bisby, 1991).  In a previous study, using the central FPI model, GAP-43 protein 
expression was significantly increased in the hippocampus and cortex of injured animals 
(Hulsebosch et al., 1998).  Another study, using the same injury model in cats, found that injured 
axons expressed increased levels of GAP-43 protein for up to 28 days postinjury (Christman et 
al., 1997).  Following lateral FPI, in a rat model, GAP-43 levels were increased in the 
hippocampus of injured animals as compared to sham animals.  This increased expression was 
observed at 48 and 72 hr postinjury in several hippocampal subregions, but decreased over time 
(Emery et al., 2000).  These aforementioned effects of FPI-induced injury on GAP-43 expression 
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were observed following moderate-severity brain injuries.  However, following severe brain 
injury, produced by CCI, there was no change in GAP-43 protein expression in either the 
hippocampus or cortex (Thompson, Gibson, Thompson, Deng, & Hall, 2006).  These data taken 
together suggest that there is a negative correlation between injury severity and postinjury GAP-
43 expression.  This indicates that the degree to which the injured brain is able to modulate 
mechanisms involved in neuroplasticity is linked to the severity of the injury.  
BDNF.  Brain derived neurotrophic factor (BDNF) is a neurotrophic factor that is 
important in the survival, growth, and plasticity of several neuronal types, including dorsal root 
ganglion, hippocampal, and cortical neurons (Binder & Scharfman, 2004; Fukumoto et al., 2001; 
Huang & Reichardt, 2001; Mai, Jope, & Li, 2002).  Strong support exists for the role of BDNF in 
LTP in multiple brain regions, including the hippocampus (Binder & Scharfman, 2004; Mai et 
al., 2002).  The effects of BDNF are mediated by the TrkB receptor, part of a family of tyrosine 
kinases that act as receptors for several other neurotrophins.  Activation of the TrkB receptor is 
important for initiating multiple signaling cascades such as the PI3K/Akt and MEK/ERK 
pathways, regulating transcription factors, and controlling gene expression.  This receptor is also 
necessary for the induction of LTP in the hippocampus. (Barnabe-Heider & Miller, 2003; Binder 
& Scharfman, 2004).     
To determine a potential mechanism of action for lithium’s reported neuroprotective 
effects, Fukumoto et al. (2001) investigated the effect of lithium treatment on several 
neurotrophic factors, including BDNF.  Male Wistar rats were fed a 2% lithium-carbonate diet 
for 1, 7, 14, and 28 days.  BDNF levels in the hippocampus, temporal cortex, and frontal cortex 
were measured by ELISA.  There were no differences in BDNF levels on treatment day 1 
between the lithium-chow and regular-chow fed rats.  However, 14 and 28 days of treatment 
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significantly increased BDNF expression in both the hippocampus and temporal cortex.  In the 
PFC of lithium-treated rats, expression was significantly increased at 14 days, with a trend 
towards significance on day 28 (Fukumoto et al., 2001).  In contrast, a study by Angelucci and 
colleagues (2003) determined that chronic (6 week) lithium treatment did not significantly 
increase BDNF levels in the hippocampus as determined by ELISA (Angelucci, Aloe, Jiménez-
Vasquez, & Mathé, 2003).  However, there were several differences in the methodologies 
employed in the Angelucci study as compared to the Fukumoto study.  These differences include 
the estimated serum concentration of lithium (0.5 mEq/L vs. 1.02 ± 0.04 and 0.80 ± 0.02 
mEq/L), duration of treatment (6 weeks vs. 2 and 4 weeks), and strain of rat used (Flinders 
Sensitive Line and Flinders Resistant Line vs. Wistar) (Angelucci et al., 2003; Fukumoto et al., 
2001).   
Lithium alone has been shown to increase the expression of BDNF in the hippocampus 
and cortex of rats (Fukumoto et al., 2001) as well as the overall brain expression of BDNF 
mRNA (Nibuya, Morinobu, & Duman, 1995).  Increases in BDNF expression have been 
observed in specific regions of the hippocampus as early as 30 min following mild- and 
moderate-severity FPI (Hicks et al., 1999; Hicks, Zhang, Dhillon, Prasad, & Seroogy, 1998; 
Truettner et al., 1999).  A significant increase in BDNF mRNA expression in the DG of the 
hippocampus was reported at 1 hr and remained elevated for up to 72 hr following lateral FPI.  
Within the CA3 region, significant increases in BDNF mRNA expression was observed between 
1 – 6 hours postinjury.  However, at 24 hr postinjury, expression levels had returned to sham 
values.  These alterations in BDNF expression indicate that these increases are related to 
neuroprotection and plasticity (Hicks, Numan, Dhillon, Prasad, & Seroogy, 1997; Hicks et al., 
1998).   
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A recent clinical study using serum acquired by immunoaffinity capillary electrophoresis, 
reported a negative correlation between neurotrophin levels (BDNF, CNTF, NT-3, NT-4, beta-
NGF) and severity of head injury.  Specifically, the serum concentration of BDNF among 
patients with severe brain injuries was 93% lower as compared to the BDNF concentration found 
in mild brain-injured patients (Kalish & Phillips, 2009).  BDNF expression has been also 
associated with improved outcome following spinal cord injury when infused continuously after 
treatment with the drug methylprednisolone (Kim & Jahng, 2004).    
Caspase-3.  Cysteinyl aspartate-specific proteinase-3 (caspase-3) was selected as a 
marker for apoptosis.  Several studies have investigated the neuroprotective effects of lithium 
against a variety of insults and have correlated activated caspase-3 inhibition with improved 
outcome (Xu et al., 2003).  Additionally, the inhibition of pro-apoptotic caspases following TBI 
is speculated to improve outcome by preventing secondary injury-induced cell loss.   
Caspases are part of a family of cysteine proteases that are involved in the initiation of 
apoptosis.  So far, there are 14 identified mammalian caspases (Nicholson & Thornberry, 1997).  
They are synthesized as pro-enzymes that subsequently undergo proteolysis and activation by 
other caspases in a sequential fashion.  Based on function, caspases can be categorized into three 
classes.  The first two are initiator and effector caspases and are involved in apoptosis.  The third 
class is related to cytokine maturation.  Only the initiator and effector caspases (i.e., those 
involved in apoptosis) will be discussed further.   
Initiator caspases include caspase-2, -9, -8, -10, and CED-3.  These caspases have a long 
prodomain (e.g., DED or caspase recruitment domain) that allows the interaction between the 
caspases and the complexes that activate them.  This interaction results in the cleavage and 
thereby activation of the initiator caspase, allowing it to activate an effector caspase.  Effector 
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caspases include caspase-3, -6 and -7.  These caspases have a short prodomain that is removed 
by cleavage following activation, leaving a large and small subunit (Lawen, 2003).  All cleavage 
occurs after aspartate (Asp) residues.  Effector caspases are also known as executioner caspases 
because once they are activated, cell death is imminent.    
  The proform, or inactive form of caspase-3, is a 32-kDa protein synthesized in the 
cytoplasm until it is cleaved, thereby activating the 17-kDa active form of caspase-3.  Based on 
previous findings from Tseng and Lin-Shiau (2002), 24 hr pre-incubation with lithium did not 
afford any neuroprotection to cultured neurons.  Additionally, following a 3 day pre-incubation 
period, lithium was able to only partially protect neurons; significant neuroprotection was not 
observed until 6 or more days of pre-incubation (Tseng & Lin-Shiau, 2002).  However, Ren et al. 
(2003), using an in vivo model of ischemia (MCAO), found that a single dose of lithium 
effectively reduced neurobehavioral deficits and infarct size 24 hr post-insult.  Neurobehavioral 
deficits were assessed using ten different tests for motor, sensation, and reflex abnormalities.  
This study also reported that daily treatment with lithium for 7 days, initiated 3 hours post-insult, 
was able to minimize caspase-3 activation and DNA damage, as determined by a significant 
reduction in TUNEL staining (Ren et al., 2003). 
Hypotheses  
GAP-43.  The TBI-Lithium group will have elevated GAP-43 levels as compared to TBI-
Vehicle and Sham-Vehicle groups.  Both injured groups will have increased GAP-43 protein as 
compared to the Sham-Vehicle group on PID 7.  The relative abundance of GAP-43 protein in 
the TBI-Lithium group will be higher as compared to the TBI-Vehicle group on PID 1 and 7.  By 
PID 21 we expect that all treatment groups will have similar levels of GAP-43 protein.   
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BDNF.  It is hypothesized that relative abundance of BDNF protein within the ipsilateral 
hippocampus of animals in the TBI-Lithium group will be significantly increased as compared to 
the other treatment groups on PID 1.  The TBI-Lithium group will have higher levels of BDNF 
protein as compared to both the TBI-Vehicle and Sham-Vehicle groups on PID 21. 
 Caspase-3.  In Experiment 3, we found significant cell loss in the CA3 region of the 
hippocampus among animals in the TBI-Vehicle group as compared to both the TBI-Lithium and 
Sham-Vehicle groups.  Based on these data, in addition to the reported antiapoptotic effects of 
pre-insult lithium treatment in other models of brain injury, we hypothesize that lithium 
treatment after lateral FPI will significantly ameliorate TBI-induced increases in apoptosis via 
the inhibition of activated caspase-3, on PID 1 and 7.  We also theorize that animals in the TBI-
Lithium group will have significantly higher levels of proform caspase-3 expression as compared 
to TBI-Vehicle.  Additionally, animals in the TBI-Vehicle group, as compared to Sham-Vehicle, 
are expected to have significantly greater levels of activated caspase-3 protein with a 
concomitant reduction in the expression of proform caspase-3 at both postinjury time points.  We 
do not expect to find significant differences between the TBI-Lithium and Sham-Vehicle groups.  
Specific Aims 
 The aim of this experiment was to evaluate, in the ipsilateral hippocampus, potential 
mechanisms of action for the observed neuroprotective effects of lithium treatment.  Expression 
levels of GAP-43 protein were used to assess structural remodeling on PID 1, 7, and 21.  
Neuronal plasticity was assessed by analysis of BDNF protein expression on PID 1, 7, and 21.  
Lastly, caspase-3 levels were evaluated to determine the impact of postinjury lithium treatment 
on apoptosis.  
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Methods 
Four animals per treatment group (i.e., TBI-Vehicle, TBI-Lithium, Sham-Vehicle) per 
time point (i.e., PID 1, 7, 21) were used for the protein analysis using a western blot technique (N 
= 36).  Each rat was anesthetized using 4% isoflurane gas, in a carrier gas of 70% (nitrous 
oxide):30% (oxygen), for 4 min.  The anesthetized animal was immediately decapitated and the 
brain quickly removed from the skull.  The hippocampus was bilaterally dissected on an ice-cold 
glass plate and was quickly transferred to a centrifuge tube containing 125µl RIPA lysis buffer 
(1x RIPA, Upstate; 1 tablet Complete Protease Inhibitor, Roche).  Samples were homogenized 
and centrifuged at 14,000g for 20 min at 4 ºC.  Aliquots of the supernatant were transferred into 
tubes and stored at -80 °C.   
Western blot.  Total protein concentrations in each sample were assessed using a 
FLUOStar microplate reader and BCA Protein Assay Kit (Pierce, 23227).  Samples were diluted 
1:20 and the final amount of protein loaded into each lane was 20μg.  Sample buffer (7.5 µl) and 
reducing agent (1.5 µl) were added to each tube prior to heating the samples for 5 min at 95 ºC.  
After heating, the samples were loaded onto SDS-PAGE precast gels (12% Bis-Tris Criterion 
XT, Bio-Rad), and were run using 1x MES Running Buffer (Bio-Rad) at 150 V for 1 hour.  Once 
competed the separated gels were then transferred to PVDF membranes (Bio-Rad, 100V, 1 hour) 
using Transfer Buffer (1x Tris/Glycine Buffer [Bio-Rad] + methanol).  After the transfer was 
complete, the gels were removed and stained with Coumassie Brilliant Blue to ensure complete 
transfer to the membranes.  The PVDF membranes were washed two times in nanopure water 
and once in phosphate-buffered saline before blocking in 0.5% non-fat dry milk + 0.05% Tween 
20 (milk TBS-T), for one hour on a shaker.  After blocking, the PVDF membranes were 
incubated at 4 ºC, overnight in milk TBS-T and the appropriate dilution of primary antibody.  
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The following antibodies and dilutions were used: mouse monoclonal anti-GAP-43 (1:1000) 
(Invitrogen, 7B10), rabbit polyclonal BDNF (1:300) (Santa Cruz Biotechnology, Inc., sc-546), 
and rabbit monoclonal caspase-3 (1:1000) (Cell Signaling, MA, 9665).  Mouse monoclonal anti-
β-actin (1:1000) (Sigma Aldrich, A1978) was used as a control to ensure equal loading of the 
protein.  Membranes were washed six times in milk TBS-T, and incubated for 1 hour in milk 
TBS-T with the appropriate dilution of the secondary antibody.  Goat anti-mouse secondary 
antibody conjugated to horseradish peroxidase (1:20,000, Rockland) was used for GAP-43 and 
β-actin; goat anti-rabbit secondary antibody conjugated to horseradish peroxidase (1:20,000, 
Rockland) was used for BDNF and caspase-3.  Each membrane was thoroughly washed in TBS-
T and developed for 5 min with Dura SuperSignal (Pierce).  The blots were then imaged using 
GeneSnap and GeneTools software (Syngene).  Negative controls were used to verify the 
absence of nonspecific binding of the secondary antibody.  These blots received identical 
treatment with the exception of omitting the primary antibody, see Figure 18.   
Western strip and re-probe.  The GAP-43 blots corresponding to PID 1 and 7 were 
stripped and re-probed using the caspase-3 antibody.  These blots were selected for re-probing 
because the bands of interest for the two antibodies, GAP-43 (45-kDa) and caspase-3 (17-kDa & 
32-kDa), do not overlap.  Additionally, the specificity of the GAP-43 antibody (a solitary band at 
45-kDa) removed any question regarding the authenticity of the bands observed after using the 
caspase-3 specific antibody.  All of the blots were stripped and re-probed for β-actin, used as a 
load control.  Each PVDF blot was stripped and re-probed no more than three times, including β-
actin.  
Positive control.  A positive control for activated caspase-3 was used to confirm the 
ability of the selected antibody to detect both the 32-kDa, proform and 17-kDa, activated form of 
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the pro-apoptotic marker caspase-3.  Samples containing staurosporine in cell lysate were 
obtained from Cell Signaling Technologies, MA.  Three levels (low, medium, high) of 
staurosporine + cell lysate and cell lysate alone were loaded onto a SDS-PAGE precast gel (12 % 
Bis-Tris Criterion XT, Bio-Rad) along with 3 samples each from TBI-Vehicle, TBI-Lithium, and 
Sham-Vehicle groups from PID 1, selected for comparison.  All samples were prepared using the 
same protocol detailed in the western blot section of the methods.  The PID 1 time point was 
selected based on the findings from previous studies that showed the highest levels of activated 
caspase-3 expression in the hippocampus occurred between 24 – 48 hr post-TBI (Conti, 
Raghupathi, Trojanowski, & McIntosh, 1998; Knoblach et al., 2002; Newcomb, Zhao, Pike, & 
Hayes, 1999).   
 Statistical analysis.  The relative abundance of the proteins of interest for TBI-Vehicle, 
TBI-Lithium, and Sham-Vehicle treatment groups were standardized to, and reported as, the 
percent of Sham-Vehicle.  The raw value from the relative optical density from each subject was 
divided by the average optical density of the corresponding Sham-Vehicle group and converted 
into a percent.  Each antibody, at each postinjury time point, was evaluated separately using a 
one-way ANOVA.  Additional comparisons were made to assess the change in protein 
expression over time for each treatment group.  A Fisher LSD post hoc analysis was performed 
where appropriate. 
Results 
The following sections detail the results obtained from the quantification and statistical 
analysis of the abundance of GAP-43, BDNF, caspase-3, and β-actin (used as a loading control) 
protein in the ipsilateral hippocampus at the specified postinjury time points.  Figures 22 and 23 
show images of the blots used for the negative control.  Figure 24 shows representative samples 
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from each blot.  The primary aim of this experiment is to evaluate if postinjury lithium-treatment 
alters the relative abundance of the specified proteins of interest as compared to the TBI-Vehicle 
and Sham-Vehicle groups.  Although we did run and analyze samples taken from animals in the 
Sham-Lithium group, to evaluate the actions of lithium alone on these proteins, these data do not 
directly pertain to the specific aims of this experiment and as such the analysis of the Sham-
Lithium group data will not be discussed in this chapter.  A separate analysis of the relative 
abundance of GAP-43, BDNF, and caspase-3 between the two sham-injured groups are 
presented in Tables C1 – C3.  The comparison of the two sham groups revealed that lithium-
treatment alone may have an effect on β-actin, a commonly used loading control.  These data are 
provided in Figure C1 in Appendix C.  Additional analyses using an ANOVA and Fisher LSD 
post hoc test where appropriate were performed on all four treatment groups (TBI-Vehicle, TBI-
Lithium, Sham-Vehicle, Sham-Lithium).  These analyses compare the raw data (relative optical 
density) and the raw data normalized to the load control β-actin, see Tables C4 – C6 in Appendix 
C.  
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Figure 22.  Negative control for secondary antibody used with GAP-43 and caspase-3.  
Protein from one animal per treatment group was run twice on a gel.  The resulting 
PVDF membrane was cut into strips, lanes 2 – 5 were incubated with the primary 
antibody (1°) followed by the secondary antibody.  This strip, labeled as +1°, shows that 
the primary antibody is able to detect the 45 kilodalton (45 kDa) band corresponding to 
the molecular weight of GAP-43 protein.  The strip that contains lanes 7 – 9 was 
incubated with the secondary antibody only.  No bands were detected in lanes 7 or  8, 
showing that there was no nonspecific binding associated with the secondary antibody.  
Lanes 5 and 9 contain the standard MagicMark (MM), the molecular weights 
corresponding to these bands are presented on the right of the minus primary (-1°) blot.  
These blots clearly show that there was no nonspecific binding associated with the 
secondary antibody.   
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Figure 23.  Negative control for secondary antibody used with BDNF.  Protein from one 
animal/treatment group was run twice on a gel.  The resulting PVDF membrane was cut 
into strips, lanes 2 – 5 were incubated with the primary antibody (1°) followed by the 
secondary antibody.  This strip, labeled as +1°, shows that the primary antibody is able 
to detect the 14 kDa band corresponding to the molecular weight of BDNF protein.  The 
strip that contains lanes 7 – 10 was incubated with the secondary antibody only.  No 
bands were detected in lanes 7 – 9, showing that there was no nonspecific binding 
associated with the secondary antibody.  Lanes 5 and 10 contain the standard 
MagicMark (MM), the molecular weights corresponding to these bands are presented 
on the right of the minus primary (-1°) blot.  These blots clearly show that there was no 
nonspecific binding associated with the secondary antibody.   
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Figure 24.  Representative images from western blot analysis of GAP-43, BDNF, 
caspase-3.  This figure illustrates the relative abundance of protein for GAP-43, BDNF, 
and caspase-3 for each treatment group, at each analyzed time point.  The molecular 
weight of each protein is indicated to the right of the images.  There was no significant 
difference in the relative abundance of β-Actin (43 kDa), used as a loading control, 
across any of the blots.         
 
 
GAP-43.  This section contains the results from the statistical analysis of the between-
group differences in the relative abundance of GAP-43 protein in the ipsilateral hippocampus for 
each postinjury time point (PID 1, 7, 21).  Additionally, the temporal changes in GAP-43 protein 
expression were assessed for each treatment group.   
PID 1 (GAP-43).  Figure 25 illustrates the relative abundance of GAP-43 protein levels 
in the ipsilateral hippocampus on PID 1 and analyzed as the percent of Sham-Vehicle.  An one-
way ANOVA revealed no significant difference in the relative abundance of GAP-43 protein on 
PID 1, F(2, 9) = 2.047, p = .185.    
 
  35 kDa 
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PID 7 (GAP-43).  The relative abundance of GAP-43 protein on PID 7 among the three 
treatment groups of interest are presented in Figure 26.  A one-way ANOVA showed a 
significant difference in GAP-43 protein levels on PID 7, F(2, 8) = 6.440, p = .022.  A Fisher 
LSD post hoc analysis revealed significantly greater abundance of GAP-43 protein in the TBI-
Lithium (p = .019) and Sham-Vehicle (p = .013) groups as compared to the TBI-Vehicle group.  
There was no statistically significant difference between the TBI-Lithium and Sham-Vehicle 
groups.  
PID 21 (GAP-43).  A one-way ANOVA was used to compare GAP-43 expression on 
PID 21 and revealed significant between-group differences, F(2, 9) = 7.731, p = .011.  Further 
analysis using the Fisher LSD post hoc test showed that the TBI-Lithium group had appreciably 
lower GAP-43 protein levels as compared to the Sham-Vehicle (p = .004) and TBI-Vehicle (p = 
.037) groups.  There was no significant difference between the TBI-Vehicle and Sham-Vehicle 
groups.  These data are presented in Figure 27.   
Temporal changes in the relative expression of GAP-43.   
TBI-Vehicle.  The change in GAP-43 expression for each treatment group over time 
revealed that there was no significant difference between groups in GAP-43 expression across 
the postinjury time points, F(2, 9) = 0.743, p = .503.  
TBI-Lithium.  The analysis of the relative abundance of GAP-43 protein across days, 
within the TBI-Lithium group, revealed that lithium treatment significantly altered the temporal 
expression of this protein, F(2, 8) = 12.875, p = .003.  A Fisher LSD post hoc analysis found that 
GAP-43 protein expression on PID 1 was significantly elevated as compared to PID 7 (p = .05) 
and PID 21 (p = .001).  Additionally, GAP-43 protein levels on PID 7 were significantly 
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increased as compared to PID 21 (p = .044).  The temporal changes in the relative expression of 
GAP-43 across groups are illustrated in Figure 28. 
 
 
    
  
Figure 25.  Western blot quantification of relative abundance of GAP-43 protein in 
ipsilateral hippocampus on PID 1.  The raw data are expressed as the mean percent of 
Sham-Vehicle, ± SEM, (n = 4/group).  An one-way ANOVA failed to detect any 
significant between-group difference, F(2, 9) = 2.047, p = .185.  We did notice a trend 
towards elevated GAP-43 levels in the TBI-Lithium group as compared to the TBI-
Vehicle group.   
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Figure 26.  Relative abundance of GAP-43 protein in the ipsilateral hippocampus on 
postinjury day (PID) 7.  TBI-Vehicle (n = 4), TBI-Lithium (n = 3), Sham-Vehicle (n = 4).  
The raw data are expressed as the mean percent of Sham-Vehicle, ± SEM.  An ANOVA 
was used to compare the raw data and revealed a significant difference between 
treatment groups.  GAP-43 protein levels in the TBI-Vehicle group were significantly 
lower as compared to the TBI-Lithium (p = .019) and Sham-Lithium groups (p = .013).  
No difference was found between the Sham-Vehicle and TBI-Lithium groups.   
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Figure 27.  Relative abundance of GAP-43 protein in the ipsilateral hippocampus on PID 
21.  The raw data are expressed as the mean percent of Sham-Vehicle, ± SEM, (n = 
4/group).  An ANOVA revealed a significant effect of group.  A Fisher LSD post hoc 
analysis showed that the TBI-Lithium group had significantly lower GAP-43 expression 
as compared to both the Sham-Vehicle and TBI-Vehicle groups.  No difference was 
detected between the TBI-Vehicle and Sham-Vehicle groups.  Initial comparisons were 
made to Sham-Vehicle, indicated by an asterisk(s); subsequent between-group 
comparisons are indicated by a brace.  *p < .05.  **p < .01. 
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Figure 28.  Changes in the relative abundance of GAP-43 protein across days.  The 
graphs show the average optical density for each group compared relative to Sham-
Vehicle, ± SEM.  Separate ANOVAs were performed to compare changes in GAP-43 
expression within the individual treatment groups across time, PID 1, 7, 21.  There was 
no significant change in GAP-43 protein levels in the TBI-Vehicle animals across the 
three time points, p > .05.  The TBI-Lithium group was the only group to show significant 
changes in GAP-43 expression over time, p = .003.  A Fisher LSD post hoc showed that 
GAP-43 levels on PID 1 were significantly higher as compared to levels on PID 21 (p = 
.001) and showed a trend suggesting higher levels of GAP-43 as compared to PID 21 (p 
= .068).  GAP-43 expression on PID 7 was significantly higher as compared to PID 21 
(p = .033).  Initial comparisons were made to PID 1; subsequent between-group 
differences are indicated by a brace. Trends in the data are indicated by a brace with a 
dashed line.  *p < .05.  ***p < .001. 
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BDNF.  This section contains the results from the statistical analysis of the between-
group differences in the relative abundance of BDNF protein in the ipsilateral hippocampus for 
each postinjury time point (PID 1, 7, 21).  Additionally, the temporal changes in BDNF protein 
expression were assessed for each treatment group. 
PID 1 (BDNF).  Figure 29 shows the raw data from the analysis of BDNF protein levels 
on PID 1.  The relative abundance of BDNF protein was assessed in the ipsilateral hippocampus 
on PID 1 and analyzed as the percent of Sham-Vehicle.  A one-way ANOVA showed there was 
no significant difference in BDNF expression across groups on PID 1, F(2, 9) = 3.012, p = .10.   
PID 7 (BDNF).  The average percent change in BDNF protein levels on PID 7 was 
analyzed using a one-way ANOVA.  There was no significant difference in the relative 
abundance of BDNF protein detected among the groups, F(2, 9) = 1.766, p = .225.  However, 
there was a trend toward elevated BDNF levels in the TBI-Lithium group as compared to the 
TBI-Vehicle and Sham-Vehicle.  These data are shown in Figure 30.   
PID 21 (BDNF).  The relative abundance of BDNF protein in the ipsilateral 
hippocampus on PID 21 was evaluated across treatment groups.  These data are presented in 
Figure 31.  A one-way ANOVA revealed a significant difference in BDNF levels between the 
treatment groups, F(2, 9) = 17.579, p = .001.  A Fisher LSD post hoc analysis of the data 
revealed a significant decrease in the amount of BDNF protein detected in the TBI-Vehicle (p < 
.001) and the TBI-Lithium (p = .004) groups relative to Sham-Vehicle.   Additionally, we 
observed a trend suggesting an increase in BDNF protein in the TBI-Lithium group as compared 
to the TBI-Vehicle group (p = .081).    
Temporal changes in the relative expression of BDNF.  The temporal changes in BDNF 
protein expression were evaluated for each of the treatment groups across the postinjury time 
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points (PID 1, 7, 21).  Figure 32 illustrates the raw data for each treatment group at each time 
point, expressed as the percent change relative to the Sham-Vehicle.  In the following 
paragraphs, only the data from the TBI-Vehicle and TBI-Lithium groups will be discussed.  The 
reason for this is that the Sham-Vehicle group is the basis of comparison for all the treatment 
groups, including itself.  The statistical value of the F test is always equal to zero, and the p value 
is always 1.00.   
TBI-Vehicle.  BDNF protein levels from each postinjury time point were analyzed using a 
one-way ANOVA.  A significant effect of time was observed, F(2, 9) = 24.402, p < .001.  A 
Fisher LSD post hoc analysis revealed that BDNF expression on PID 1 and PID 7 was 
significantly higher as compared to expression levels on PID 21, p = .001 and p < .001 
respectively.  There was no significant difference in the relative abundance of BDNF protein 
between PID 1 and PID 7, p = .170.  
TBI-Lithium.  The TBI-Lithium group showed significant changes in protein levels over 
the three postinjury time points, F(2, 9) = 5.874, p = .023.  A Fisher LSD post hoc test revealed 
that BDNF expression was significantly higher on PID 1 (p = .01) and PID 7 (p = .033) as 
compared to PID 21.  No statistically significant difference was found between the PID 1 and 
PID 7 time points (p = .474).   
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Figure 29.  Comparison of the relative abundance of BDNF protein levels in the 
ipsilateral hippocampus on PID 1.  These data are expressed as the percent of Sham-
Vehicle ± SEM, (n = 4/group).  No significant difference in BDNF protein amount was 
detected among the treatment groups.  However, there appears to be an increase in 
BDNF protein levels in the TBI-Lithium group relative to the other groups.     
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Figure 30.  Comparison of the relative abundance of BDNF protein on PID 7. 
These data are expressed as the percent of Sham-Vehicle ± SEM.  No significant 
difference in BDNF protein amount was detected among the treatment groups.   
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Figure 31.  Comparison of the relative abundance of BDNF protein on PID 21.  Values 
are expressed as percent of Sham-Vehicle ± SEM, (n = 4/group).  A significant 
difference was found between the Sham-Vehicle group and both injured groups.  A 
trend was observed suggesting that the relative abundance of BDNF in the TBI-Lithium 
group was higher as compared to TBI-Vehicle.  Initial comparisons were made to Sham-
Vehicle.  Trends in the data are indicated by a brace with a dashed line.  **p < .01.  ***p 
< .001. 
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Figure 32.  Comparison of BDNF levels among individual treatment groups across time. 
Values are expressed as percent of Sham-Vehicle ± SEM.  Individual ANOVAs were 
performed for each treatment group.  A Fisher LSD post hoc analysis found significant 
decreases in BDNF protein levels on PID 21 in both the TBI-Vehicle and TBI-Lithium 
groups relative to the levels on PID 1 and 7.  Significant between-group comparisons 
are indicated using braces.  *p < .05.  **p ≤ .01.  ***p ≤ .001.  
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Caspase-3.  Data from the statistical analysis of the relative abundance of the proform of 
caspase-3 protein levels, at the two specified postinjury time points (PID 1, 7), are presented in 
the following paragraphs.  TBI-induced increases in activated caspase-3 protein levels have been 
reported during the early postinjury phase (within 1 week of injury); therefore, we did not 
examine the levels of this protein (activated or proform) on PID 21.  The temporal changes in the 
detected levels of proform caspase-3 within the TBI-Vehicle and TBI-Lithium groups are also 
illustrated.  We were not able to detect any activated caspase-3 in any of our samples.     
Caspase-3 (PID 1).  The proform of caspase-3 protein was evaluated across the treatment 
groups as the percent of Sham-Vehicle.  A one-way ANOVA revealed that there was no 
significant difference in proform caspase-3 protein expression between the treatment groups, 
F(2, 9) = 1.929, p = .201.  These data are presented in Figure 33.   
Caspase-3 (PID 7).  We further investigated the potential neuroprotective effects of post-
TBI lithium treatment on apoptotic activity by analysis of the relative abundance of proform 
caspase-3 protein in the ipsilateral hippocampus on PID 7.  There was no significant difference 
in proform caspase-3 expression across groups on PID 7, F(2, 8) = 1.594, p = .261.  These data 
are illustrated in Figure 34.   
Temporal change in relative amount of proform caspase-3.  The raw data showing the 
relative change of proform caspase-3 levels for each treatment group are displayed in Figure 35.  
These data show an apparent injury-induced increase in the detected levels of proform caspase-3 
protein within the ipsilateral hippocampus from PID 1 to 7.  There was no evidence of activated 
caspase-3 in our samples.  However, the trend towards elevated proform caspase-3 over time in 
the TBI-Vehicle group suggests that activated caspase-3 plays a role during early postinjury time 
points. 
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TBI-Vehicle.  The difference in proform caspase-3 levels for the TBI-Vehicle groups on 
PID 1 and 7 were compared using an independent samples t-test, t(6) = -2.234, p = .067.  
Although there was no significant difference detected between the two time points, there appears 
to be a trend indicating increased proform caspase-3 levels on PID 7.   
TBI-Lithium.  The TBI-Lithium group did not exhibit significant alterations in the relative 
abundance of proform caspase-3 protein between PID 1 and PID 7, t(5) = -1.428, p = .213.   
 
 
 
Figure 33.  Comparison of proform caspase-3 levels on PID 1 across treatment groups.  
Data from each treatment group (n = 4/group) are expressed as the percent of Sham-
Vehicle ± SEM.  An ANOVA failed to detect any significant differences between the 
treatment groups.  However, the TBI-Lithium group appears to have an increase in the 
detected levels of proform caspase-3 protein as compared to the TBI-Vehicle group.   
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Figure 34.  Comparison of proform caspase-3 levels on PID 7 across treatment groups.  
Data are expressed as the percent of Sham-Vehicle ± SEM.  TBI-Vehicle (n = 4), TBI-
Lithium (n = 3), Sham-Vehicle (n = 4).  No significant difference was detected in the 
levels of proform caspase-3 across all treatment groups.     
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Figure 35.  Changes in proform caspase-3 protein levels over time.  Data are presented 
as the mean, ± SEM.  Analysis of the raw data showed a trend for increased proform 
caspase-3 on PID 7 as compared to PID 1 in the TBI-Vehicle group.  No significant 
difference was found between PID 1 and 7 in the TBI-Lithium group.  Trends in the data 
are indicated by a brace with a dashed line.   
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Caspase-3 positive control.  It was hypothesized that lithium was exerting 
neuroprotective effects by preventing the activation of caspase-3.  However, on the blots from 
PID 1 and 7 there was an absence of the 17-kDa band corresponding to the activated caspase-3 
protein.  The positive control, using pre-prepared samples (Cell Signaling Technology, Inc., 
Boston, MA) clearly showed a band corresponding to the 17-kDa, activated caspase-3 protein, in 
the lanes containing the normal cell lysate (NCL) + staurosporine only, see Figure 36.  These 
data confirm that the absence of a protein band for activated caspase-3 on the PID 1 and 7 blots 
is legitimately due to the absence of detectable levels of this protein in our experimental samples, 
thus confirming the accuracy of our findings from the both the PID 1 and 7 blots.   
 
Figure 36.  Image of positive control immunoblot used to detect activated caspase-3.  
Image taken of the western blot that was used to evaluate the specificity of the caspase-
3 antibody for activated caspase-3 (17 kDa).  The numbers on the right side correspond 
to the molecular weights of the MagicMark (MM) protein standard.  Normal cell lysate 
(NCL) was used as a control (lane 7) and no activated caspase-3 was detected in this 
lane.  Low (L), medium (M) and high (H) indicate the relative level of apoptosis-inducing 
staurosporine + NCL.  Higher levels of staurosporine resulted in increased levels of 
activated caspase-3, as evidenced by the dark band corresponding to the 17 kDa 
activated caspase-3, in lanes 1, 3, and to a lesser extent lane 5.  The analysis of the 
positive control confirms the lack of activated caspase-3 in our samples.  
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Discussion 
We evaluated potential mechanisms of action for the observed lithium-induced 
neuroprotective effects found in Experiments 1 – 3.  Previously, we showed that chronic, 
postinjury treatment with the selected dose of lithium chloride (0.25 mmol/kg, ip) was effective 
in reducing TBI-induced cognitive and motor deficits.  In addition, this dose was found to 
significantly enhance neuronal survival in the ipsilateral CA3 region of the hippocampus 
following lateral FPI.  In the present study, the western blot technique was used to measure the 
levels of GAP-43, indicative of axonal sprouting, to characterize the effect of lateral FPI and 
postinjury lithium-treatment on this marker of plasticity.  Additionally, the abundance of BDNF 
protein, a neurotrophin that is reported to be involved in neuronal plasticity and neuroprotection, 
was evaluated.  The pro-apoptotic marker, caspase-3 was used to evaluate the effect of our injury 
model and postinjury lithium treatment on TBI-induced apoptosis.  
GAP-43.  The relative optical density, used to quantify the abundance of GAP-43 protein 
in the ipsilateral hippocampus, showed that there was no significant difference in the GAP-43 
protein levels across the treatment groups on PID 1.  This finding is in accordance with the 
studies by Emery et al. (2000) and Hulsebosch et al. (1998), which reported that, 24 hr following 
FPI, GAP-43 levels in the hippocampus were not significantly different from sham controls.   
However, in another study, GAP-43 protein levels were significantly elevated in the ipsilateral 
hippocampus at both 24 and 48 hr post-TBI (Thompson et al., 2006).  The apparent disparity 
between the findings from these studies are likely due to experimental differences; Hulsebosch 
(1998) and Emery (2000) used the central and lateral FPI model respectively, whereas Thompson 
(2006) used CCI.  Additionally, there were differences in the postinjury time points selected for 
evaluating GAP-43.  With these factors taken together, their data collectively show increased 
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levels of GAP-43 between 24 – 36 hr postinjury that decrease to baseline values or lower by 7 
days postinjury (Emery et al., 2000; Hulsebosch et al., 1998; Thompson et al., 2006).  This is 
similar to what we observed in our study.       
The analysis of the relative optical density of GAP-43 protein on PID 7 indicate that the 
Sham-Vehicle and TBI-Lithium groups had statistically similar levels of GAP-43 protein and 
that both groups had significantly higher levels of GAP-43 as compared to the TBI-Vehicle 
group.  Our finding that the TBI-Vehicle group had significantly lower levels of GAP-43 is 
contrary to Emory et al. (2000), who reported no significant difference in GAP-43 protein levels 
between injured- and sham-vehicle treated animals.  Additionally, the in vitro study by Chen et 
al. (2003) investigated the effects of 1 mmol/L lithium treatment on that healthy (i.e., uninjured) 
hippocampal cells, treated for 7-days with lithium.  They found that lithium-treatment resulted in 
a slight increase in GAP-43 expression; however, it did not reach the level of significance (Chen, 
Wang, Sun, & Young, 2003).   
We hypothesized that on PID 7, GAP-43 protein levels would be increased in both TBI 
groups relative to Sham-Vehicle and that the TBI-Lithium group would have increased GAP-43 
protein levels relative to the TBI-Vehicle group.  Our data, however, support a very different 
outcome.  Animals in the TBI-Vehicle group showed a significant decline in the relative 
abundance of GAP-43 relative to TBI-Lithium and Sham-Vehicle groups.  Furthermore, post-
TBI lithium treatment was able to completely reverse the injury-induced decrease in GAP-43 
protein, returning it to sham levels.  These data provide support for the role of GAP-43 as a 
potential mechanism of action for lithium-induced neuroprotection in our injury model.  The 
significant increase in the relative abundance of GAP-43 protein levels on PID 7 in the TBI-
Lithium group relative to TBI-Vehicle could suggest that postinjury lithium-treatment supports 
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neurite outgrowth, remodeling, and reorganization.  Additional studies will be needed to evaluate 
this hypothesis.   
The final postinjury time point (PID 21) that we assessed for evidence of lithium-induced 
axonal sprouting and remodeling by analysis of GAP-43 protein expression revealed a significant 
decrease in GAP-43 levels in the TBI-Lithium group relative to the other treatment groups.  This 
finding was unexpected, but might indicate decline in structural remodeling several weeks after 
injury in animals treated with lithium. 
No changes were detected in the total amount of GAP-43 protein in the TBI-Vehicle 
group across the three postinjury time points.  However, the effect of postinjury lithium-
treatment did reveal a significant change in protein expression across the three time points.  The 
highest levels were observed on PID 1 and declined in a stepwise fashion over the remaining two 
time points.  These findings are contrary to previous studies that indicated that lithium treatment 
had no significant effect on GAP-43 expression at 7-days in hippocampal neurons (Chen et al., 
2003).  Taken together, these data suggest that post-TBI treatment with lithium may facilitate 
structural remodeling in the ipsilateral hippocampus via modulation of growth cone activity. 
BDNF.  This neurotrophic factor was selected as a measure of neuroprotection and 
neuroplasticity.  During development of the nervous system, BDNF plays an important role in 
neuronal survival and differentiation.  In the adult brain, it is associated with neurogenesis, 
neuroprotection, and plasticity (Gustafsson, Lindvall, & Kokaia, 2003).  Downstream effects of 
BDNF activation, such as those on synapsin 1 and CREB are linked to the regulation of synaptic 
vesicles and, in so doing, neurotransmitter release and the induction of LTP respectively are also 
linked to cognitive enhancing processes (Griesbach, Hovda, & Gomez-Pinilla, 2009; Silva et al., 
1998).  Several studies have reported that BDNF alone administered prior to brain injury or 
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insult is protective against injury-induced neuronal cell loss and cognitive deficits (Almli et al., 
2000).  Additionally, a recent study by Griesbach (2009) showed that following lateral FPI, 
exercise-induced increases in BDNF expression were correlated with markedly improved 
performance in the MWM over injured-vehicle treated animals.  The improvement in MWM 
performance was blocked in animals treated with TrkB-IgG, an immunoadhesin chimera of the 
TrkB receptor that prevented activation of this receptor by BDNF (Griesbach et al., 2009) .  Our 
hypothesis that BDNF might underlie the protective effect of lithium was based on the 
observation chronic lithium administration is associated with significant increases in BDNF 
expression in the rat hippocampus (Fukumoto et al., 2001).   
Both injury- and lithium-treatment have each been shown to increase levels of BDNF 
mRNA and protein in several brain regions, including the hippocampus (Hicks et al., 1996; 
Hicks et al., 1999).  In a previous study, using the lateral FPI model, significant increases in 
BDNF mRNA levels were detected bilaterally in the DG (1 hr – 3 day) and CA3 (1 – 6 hr) 
regions of the hippocampus (Hicks et al., 1997).  Injury-induced changes in BDNF mRNA occur 
within hours of the injury (Hicks et al., 1999) whereas it takes several days to detect significant 
changes in hippocampal BDNF protein levels (Griesbach, Hovda, Molteni, & Gomez-Pinilla, 
2002).  Our data show that BDNF protein levels on PID 1 were not significantly altered 
following lateral FPI.  The delay between the expression of BDNF mRNA and the appearance of 
BDNF protein may account for the lack of a significant increase in the relative abundance of 
BDNF protein in the TBI-Vehicle and TBI-Lithium groups on PID 1.     
On PID 7, both the TBI-groups showed a modest but non-significant increase in the 
relative abundance of BDNF protein compared with Sham-Vehicle.  The delayed increase in 
BDNF protein, relative to the early increases in BDNF mRNA seen during the early postinjury 
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period (Hicks et al., 1997), in both TBI groups could be indicative of the innate plasticity 
response of the brain to injury.  Following brain injury induced by intracerebroventricular 
administration of kainic acid, Shetty, Rao, Hattiangady, Zaman and Shetty (2004) reported an 
injury-induced increase in BDNF levels in the hippocampus 4-days postinjury. 
In the present study, we found that the relative abundance of BDNF protein in the 
ipsilateral hippocampus was significantly reduced in both injured groups relative to sham.  Our 
hypothesis that BDNF protein levels in the TBI-Vehicle group would be significantly decreased 
relative to Sham-Vehicle on PID 21 is supported by our findings.  Further support for the 
observed TBI-induced reductions in BDNF protein on PID 21 comes from a previous study that 
showed BDNF mRNA levels were significantly reduced in the ipsilateral hippocampus on PID 
21 following CCI (Griesbach, Sutton, Hovda, Ying, & Gomez-Pinilla, 2009).  Fukumoto (2001), 
had reported that chronic lithium-treatment, for 14 and 28 days, resulted in a significant increase 
in hippocampal BDNF expression.  We hypothesized that increased BDNF levels associated with 
chronic lithium treatment (Fukumoto et al., 2001) would outweigh the TBI-induced deficits in 
BDNF expression (Griesbach et al., 2009).  Based on our data, chronic post-TBI lithium was 
associated with a trend suggesting increased BDNF protein levels over TBI-Vehicle.  However, 
the amount of BDNF protein detected in the TBI-Lithium group was significantly less than 
Sham-Vehicle.  It is interesting that on PID 7 and PID 21, both TBI groups showed similar 
trends in the relative abundance of BDNF protein that was detected.  Specifically, in both injured 
groups the levels of this protein were elevated on PID 7 and significantly decreased on PID 21.  
The parallel effects on these days could reflect neurochemical alterations in this neurotrophic 
factor that are purely the result of injury-induced processes and not an effect of lithium 
treatment.  However, due to the sample size in our treatment groups and the large volume of 
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tissue (whole hippocampus) used for the western blot analysis, subtle changes in BDNF protein 
levels may have been masked.  Additional studies with increased sample sizes in addition to 
immunohistochemistry techniques would be needed to confirm the observed effects of post-TBI 
lithium administration on BDNF levels in the hippocampus. 
Caspase-3.  One of the reported mechanisms through which lithium exerts 
neuroprotective effects is the prevention of apoptosis by blocking the activation of caspase-3.  
However, there was no detectable expression of the activated form of caspase-3 on either PID 1 
or 7.  Expression of the proform of caspase-3 was detectable in all the treatment groups at both 
postinjury time points; however, there was no significant difference in proform caspase-3 levels 
between any of the treatment groups on either PID 1 or PID 7.  These findings do not support our 
hypothesis that activated caspase-3 expression will be increased on PID 1 and 7 in the TBI-
Vehicle groups.   
The presence of apoptotic cells following TBI was reported in the DG and CA3 regions 
of the hippocampus 24 hr after mild or moderate severity lateral FPI, in vehicle-treated rats (Rink 
et al., 1995).  Additionally, significant increases in caspase-3 have been reported following CCI 
in rats (Clark et al., 2000; Springer, 2002; Tweedie et al., 2007).  In contrast to these studies, the 
17-kDa band, corresponding to the activated caspase-3 protein, was absent in our TBI groups.  
To rule out any technical problems, we used a positive control that contained normal cell lysate, 
with and without staurosporine, and ran them on a separate blot with selected samples from PID 
1.  Analysis of these data confirmed the presence of activated caspase-3 in the positive control 
samples only, thus supporting our initial findings that there was no activated caspase-3 in our 
experimental samples.   
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The findings from the present study do not support the hypothesis that activated caspase-
3 would be elevated in the ipsilateral hippocampus following injury.  A possible explanation is 
that activated caspase-3 levels had peaked and declined by the time the animals were sacrificed.  
Indeed, Rink et al. (1995) reported that cells undergoing necrosis and apoptosis can be 
eliminated within a few hours.  Conti et al. (1998) reported prominent, but non-significant, 
increase in the number of cells with apoptotic morphologies in the ipsilateral hippocampus at 12 
and 48 hr following lateral FPI.  The increase in apoptosis reported by Conti (1998) temporally 
coincides with the decrease in proform caspase-3 on PID 1 observed in the TBI-Vehicle group, 
relative to the TBI-Lithium and Sham-Vehicle groups, in the present study.  The decrease in 
proform caspase-3 could be attributed to its conversion to an activated state.  Alternately, it is 
possible that that the cell death in the ipsilateral hilus and CA3 regions of the hippocampus, 
observed in injured rats from Experiment 3, was primarily due to necrosis.      
 Another possibility is that the hippocampal subregions affected by apoptosis at the 
selected postinjury time points were disproportionally small, and when compared to the entire 
hippocampus, the presence of this protein was masked.  It was reported that following lateral 
FPI, the presence of apoptotic cells was not localized to any one area of the hippocampus.  
Instead, these cells were scattered throughout the structure (Conti et al., 1998).  Furthermore, 
Conti (1998) identified larger numbers of cells with apoptotic appearance in the cortex.  It is 
possible that the lithium-induced neuroprotective effects that were observed in Experiments 1 & 
2 were produced, in part, by lithium’s effects in other brain regions.  Further study is needed to 
evaluate the effects of post-TBI lithium-treatment on other brain regions, particularly those 
regions important in learning and memory that are also known to be vulnerable to TBI-induced 
pathology (e.g., prelimbic cortex). 
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General Discussion 
 
Our experiments have provided strong evidence to support the neuroprotective effects of 
lithium and its use as a therapeutic agent in the treatment of the sequelae associated with TBI.  
The present study indicates that (i) low doses of lithium chloride initiated 30 min after lateral FPI 
and administered daily are effective in reducing TBI-induced deficits in vestibulomotor and 
cognitive function; (ii) treatment with the selected dose of lithium can be delayed up to 8 hr post-
TBI and still provide similar beneficial effects associated with the 30 min treatment; (iii) chronic 
low-dose lithium is associated with significant cell survival in the CA3 but not in the hilar region 
of the hippocampus of the injured rats. 
Dose of lithium and time window for neuroprotection after TBI  
Previous research in animal models of stroke have shown that pre- or post-injury 
administration of lithium, at doses equal to or below those used in the clinical setting for the 
treatment of BAD, achieves neuroprotection (Nonaka & Chuang, 1998; Ren et al., 2003; Xu et 
al., 2003; Yan et al., 2007; Yan et al., 2007).  The current study, which assessed the effect of 
postinjury administration of lithium in a rat model of lateral FPI, provides further evidence in 
support of the neuroprotective role of this agent.  Among the four doses of lithium that we tested 
(1.00, 0.50, 0.25, 0.125 mmol/kg, ip), only the 0.125 and 0.25 mmol/kg doses, administered 30 
min after injury, significantly ameliorated TBI-induced cognitive deficits, as assessed by 
performance in the MWM.  To date, only one other study, employing a rat model of ischemic 
injury, has reported on the beneficial effects of postinjury administration of lithium (Ren et al., 
2003).  The aforementioned study focused on the lithium-promoted recovery of neurological 
functioning, assessed by performance on tests evaluating motor, sensory, and reflex abilities.  
The authors of the study found that lithium treatment with doses ranging from 0.50 – 3.00 
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mmol/kg, initiated up to 3 hr after the onset of MCAO, significantly improved 
injury/reperfusion-induced neurological deficits, evaluated at 24 hr, 7 and 14 days post-ischemic 
injury (Ren et al., 2003).  Similarly, in our study we detected improvements in the motor 
performance on the BW task (PID 1, 3, 7) of our injured-lithium treated animals.  However, we 
observed that the 1.00, 0.25 and 0.125 mmol/kg doses improved BW performance whereas the 
0.50 mmol/kg dose did not.  This phenomenon of varying physiologic response to different 
dosages of a neuroprotective agent has been previously described in various models of brain 
injury (Calabrese, 2008).  Dawson et al. (2001) found that the most effective dose for reducing 
infarct volume in a MCAO mouse model for ischemic injury did not always improve motor 
performance, and in some cases significantly impaired it (Dawson, Wadsworth, & Palmer, 
2001).   
In Experiment 1, the two most effective doses were 0.25 and 0.125 mmol/kg.  Although 
both doses improved MWM performance in TBI-Lithium animals over the TBI-Vehicle treated 
group, the 0.25 mmol/kg dose was selected for use in Experiment 2, as the degree of cognitive 
improvement achieved with this dose was higher (although not significantly) than that observed 
with the lower 0.125 mmol/kg dose.  
Based on the results from Experiment 2, lithium appears to provide neuroprotection even 
when its administration is delayed up to 8 hr (but not 24 hr), postinjury.  This finding makes 
lithium a good candidate for evaluation in TBI clinical trials, as the elapsed time between the 
occurrence of a traumatic event and the administration of a test drug in humans is estimated to be 
4 hours, which takes into account the arrival of the patient at the hospital and the subsequent 
acquisition of an informed consent for study enrollment.  
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Mechanism of the neuroprotective effects of lithium           
In vitro studies have shown that lithium is effective in preventing cell death induced by a 
variety of cellular insults (Chen et al., 2003; Hennion et al., 2002; Hongisto et al., 2003; Nonaka 
et al., 1998; Rametti, Esclaire, Yardin, Cogne, & Terro, 2008; Senatorov, Ren, Kanai, Wei, & 
Chuang, 2004).  Similarly, cell death reduction with lithium treatment has been documented by 
in vivo studies showing decreased infarct volume following ischemic brain injury (Ren et al., 
2003; Yan et al., 2007; Yan et al., 2007), and reduced TUNEL staining following exposure to 
neurotoxins (Ghribi, Herman, Spaulding, & Savory, 2002) or radiation (Yazlovitskaya et al., 
2006).   
In the present study, we sought to investigate potential mechanisms of action for the 
observed lithium-induced neuroprotective effects observed in Experiments 1 – 3.  Specifically, 
we assessed the neuroprotective properties of lithium by means of western blot analysis of the 
relative abundance of the proteins GAP-43 and BDNF, selected as measures of postinjury 
structural reorganization and plasticity (Hashimoto et al., 2002) , and by measurement of 
proform and activated caspase 3, markers of apoptosis.   
BDNF expression has been associated with improved outcome in TBI (Griesbach et al., 
2009) and previous research has shown that lithium alone increases the expression of BDNF in 
the hippocampus and cortex of rats, as well as the overall brain expression of BDNF mRNA.  In 
particular, lithium-induced neuroprotection has been correlated, in several models of injury, with 
increased expression of BDNF and its primary receptor TrkB, and a study by Hashimoto et al. 
(2002) provides strong evidence in support of this interaction.  These authors demonstrated that 
the protective effects of lithium-treatment against glutamate induced neurotoxicity in cortical 
cells could be blocked by treatment with either an inhibitor of the TrkB receptor or a neutralizing 
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antibody specific to BDNF.  Additionally, cortical neurons from BDNF knockout mice were not 
protected by lithium, thus further supporting the important role of BDNF-TrkB interactions in 
lithium-induced neuroprotection (Hashimoto et al., 2002). 
Results from our Experiment 4 indicate that the amount of BDNF protein, assessed by 
western blot analysis, was appreciably higher in TBI-Lithium animals on PID 1.  This increase, 
however, was only transient, and on PID 21 BDNF levels were significantly decreased as 
compared to Sham-Vehicle.  This finding was unexpected, given the plethora of data in the 
literature pointing at the significance of the BDNF-TrkB interaction in mediating the 
neuroprotective effects associated with lithium (Chuang, 2004; Chuang, 2005; D'Mello et al., 
1994; Ghribi et al., 2002; Manji & Duman, 2001; Mora et al., 1999; Xu et al., 2003).  It must be 
noted, however, that our study is the first to investigate the effects of this drug in an experimental 
model of TBI.  
We also performed analysis of GAP-43, a neural-specific calmodulin binding protein, 
which is a major protein kinase C substrate found in developing and regenerating neurons.  We 
found that on PID 1, the relative abundance of GAP-43 was noticeably elevated in the TBI-
Lithium group as compared to the TBI-Vehicle group.  This suggests that post-TBI lithium-
treatment not only protects against the observed injury-induced decrease in GAP-43, it elevates 
levels of this protein relative to Sham-Vehicle.  The small sample size and greater variability in 
the relative abundance of GAP-43 protein levels among animals in the TBI-Vehicle and Sham-
Vehicle groups on PID 1 could have masked the effect of postinjury lithium treatment on GAP-
43.  In addition to increasing the sample size, immunohistochemical analysis the levels of GAP-
43 protein in specific regions of the hippocampus or quantification of mRNA using ELISA 
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would provide additional, more specific, information regarding the effects of post-TBI lithium 
administration on GAP-43 levels in the hippocampus.  
On PID 7 we found that the relative abundance of GAP-43 was significantly decreased in 
the TBI-Vehicle group as compared to both the Sham-Vehicle and TBI-Lithium groups.  This 
finding suggests that, relative to the Sham-Vehicle group, the abundance of GAP-43 protein in 
animals in the TBI-Vehicle is lessened on PID 1 and significantly reduced on PID 7.  
Additionally, these data indicate that, in the injured brain, lithium-treatment continues to protect 
against TBI-induced decline in GAP-43 for up to 7 days postinjury, maintaining the relative 
abundance of this protein at Sham-Vehicle levels.  However, by PID 21, we observed that the 
levels of GAP-43 in the TBI-lithium group significantly rebounded to Sham-Vehicle levels.  This 
is in contrast to the significant decrease in the relative abundance of GAP-43 protein in the TBI-
Lithium group as compared to both the Sham-Vehicle and TBI-Vehicle groups.  Based on the 
study by Emery et al. (2000) the postinjury timeframe associated with increased GAP-43 levels 
is between 48 -72 hrs; later postinjury assessment time points including 1, 2, and 4 weeks 
postinjury were not associated with changes in GAP-43 abundance relative to sham controls 
(Emery et al., 2000; Hulsebosch et al., 1998).  We interpret these data to indicate that the most 
likely timeframe for postinjury lithium-induced effects on neuronal remodeling most likely occur 
within the first 7-days after injury.  
It is believed that the inhibition of post-TBI activation of pro-apoptotic caspases 
improves outcome by preventing secondary injury-induced cell loss.  In agreement with this, 
several studies have linked the neuroprotective effects of chronic lithium treatment with the 
inhibition of apoptotic pathways.  Specifically, it has been shown that  lithium treatment prevents 
injury-triggered pro-apoptotic events such as cytochrome c translocation, decreases in anti-
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apoptotic Bcl-2, and increases in pro-apoptotic Bax, GSK-3β, and tau (Chen et al., 1999; 
D'Mello et al., 1994; Ghribi, Herman, & Savory, 2003; Li et al., 2002; Manji et al., 1999; Manji, 
Moore, & Chen, 2000b; Mora et al., 1999; Rametti et al., 2008; Xu et al., 2003).  Nevertheless, 
the results of our western blot analysis indicate that only the proform of caspase-3 was present at 
PID 1 and 7, with no significant between-group differences in protein expression.  Activated 
caspase-3 was not present in any of the experimental groups. 
Taken together, our findings indicate that postinjury lithium treatment is significantly 
effective in reducing injury-induced motor and cognitive deficits, and that this treatment is 
effective in reducing post injury cognitive and motor dysfunction even when delayed up to 8-
hours following TBI.  Treatment with this drug is also associated with a marked reduction in cell 
death in the CA3 region of the hippocampus, a structure that is critical to memory formation and 
retrieval.  Although lithium has a very narrow therapeutic range, the dose that was most effective 
in our study is well within that limit.  These encouraging findings support further testing of 
lithium in clinical TBI studies. 
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Appendix A 
 
 
 
 
 
 
 
Figure A1.  Comparison of motor performance pre- and post-TBI.  Lines represent the 
mean latency for each treatment group (n = 10/group) across days, ± SEM.  A split-plot 
ANOVA showed that there was a significant effect of group.  A Fisher LSD analysis 
revealed that the two sham groups had significantly shorter latencies to reach the goal 
box as compared to the TBI-0.50 and TBI-Vehicle groups.  There was no significant 
difference between the sham groups and the TBI-1.00, TBI-0.25, and TBI-0.125 groups.  
All the doses of lithium are mmol/kg.  Vehicle treated animals received 0.9% sterile 
saline.  All treatments were administered in a volume of 1 mg/kg.  (*) indicate significant 
differences as compared to Sham-Vehicle.  (†) indicate comparisons made to the Sham-
1.00 group.  *p ≤ .05.  **,†† p ≤ .01.  ***p ≤ .001.  Specific statistical information is 
provided in the text.   
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Figure A2.  MWM data from Experiment 1.  This graph shows the daily average latency 
to reach the goal platform for each treatment group (n = 10/group), ± SEM.  A split-plot 
ANOVA and Fisher LSD post hoc revealed that the TBI-Vehicle group had significantly 
longer latencies to reach the goal platform as compared to the TBI-0.125, TBI-0.25, 
Sham-Vehicle, and Sham-1.00 groups.  None of the groups performed as well as the 
Sham-Vehicle group.  All doses of lithium are in mmol/kg.  (*) indicate comparisons to 
Sham-Vehicle.  (†) indicate comparisons to Sham-1.00.  (‡) show comparisons made to 
TBI-30 min.  (•) indicate comparisons to TBI-8 hr.  *p < .05.  **, ††, ‡‡, ••p < .01.  ***, †††p < 
.001.  
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Figure A3.  Proximity score from MWM hidden platform testing in Experiment 1.  This 
graph shows the daily average proximity score for all treatment groups (n = 10/group) 
during MWM testing, ± SEM.  All doses of lithium are in mmol/kg.  Vertical lines 
represent SEM.  A repeated measure ANOVA revealed a significant difference among 
the average daily proximity scores of the treatment groups.  A Fisher LSD post hoc 
found that the two sham groups had significantly lower proximity scores (indicating 
better performance) as compared to the TBI-Vehicle group.  The two injured groups that 
had significantly shorter latencies to reach the goal platform as compared to the TBI-
Vehicle group during the hidden platform testing, TBI-0.25 and TBI-0.125, had 
significantly higher proximity scores as compared to the Sham-Vehicle group, however, 
they did not significantly differ from the Sham-1.00 group.  There was no appreciable 
difference in the proximity scores of the TBI-Vehicle group and the TBI lithium-treated 
groups.  (*) indicate comparisons to the Sham-Vehicle group.  (†) indicate comparisons 
made to the Sham-1.00 group.  **, ††p < .01.  ***p < .001. 
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Figure A4.  Analysis of the proximity score for each group during the probe trial in 
Experiment 1.  The data are expressed as the mean, ± SEM.  An ANOVA found 
significant differences between the treatment groups.  A Fisher LSD post hoc revealed 
that the Sham-Vehicle group had a significantly lower proximity score as compared to 
all other treatment groups.  *p < .05.  **p < .01.  ***p < .001.   
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Appendix B 
 
 
 
          
 
Figure B1.  Comparison of performance on beam walk task across groups in 
Experiment 2.  These data represent the mean latency to reach the goal box, ± SEM.  
TBI-Vehicle (n = 10), TBI-30 min (n = 10), TBI-8 hr (n = 10), TBI-24 hr (n = 9), Sham-24 
hr (n = 9), Sham-Vehicle (n = 10).  The TBI-30 min group data is the TBI-0.25 from 
Experiment 1 and is included in the data analysis as a basis for comparing the 
effectiveness of the selected dose of lithium when the initiation of treatment is delayed.  
The TBI-8 hr and TBI-30 min had significantly shorter latencies to reach the goal box as 
compared to the TBI-Vehicle and TBI-24 hr groups.  (*) indicate comparisons to Sham-
Vehicle.  (†) indicate comparisons to Sham-1.00.  (‡) compare to TBI-30 min.  (•) indicate 
comparisons to the TBI-8 hr.  ‡,• p < .05.  **, ††, ‡‡ p < .01.  ***, †††p < .001.  
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Figure B2.  Comparison of MWM performance across groups in Experiment 2.  Data are 
the mean latency for each treatment group, TBI-Vehicle (n = 10), TBI-24 hr (n = 9), TBI-
8 hr (n = 10), TBI-30 min (n = 10), Sham-Vehicle (n = 10), Sham-24 hr (n = 9), ± SEM.  
The TBI-30 min group data is identical to the TBI-0.25 from Experiment 1 and is 
included in the data analysis as a basis for comparing the effectiveness of the selected 
dose of lithium when the initiation of treatment is delayed.  An ANOVA, followed by a 
Fisher LSD post hoc analysis, showed that the Sham-Vehicle, Sham-24 hr, TBI-8 hr and 
TBI-30 min groups had significantly faster latencies to reach the goal as compared to 
the TBI-Vehicle andTBI-24 hr groups.  The TBI-8 hr and TBI-30 min groups had longer 
latencies to the goal platform as compared to the Sham-Vehicle group.  There was no 
significant difference in MWM performance between the two sham groups.  (*) indicate 
comparisons to Sham-Vehicle.  (†) indicate comparisons to Sham-24 hr.  (‡) denote 
comparisons to the TBI-30 min group.  (•) indicate comparisons to the TBI-8 hr.  *, ‡, •p < 
.05.  **, ††, ‡‡p < .01.  ***, †††p < .001. 
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Figure B3.  Proximity score during hidden platform testing in the MWM from Experiment 
2.  The average proximity score for each treatment group TBI-Vehicle (n = 10), TBI-24 
hr (n = 9), TBI-8 hr (n = 10), TBI-30 min (n = 10), Sham-Vehicle (n = 10), Sham-24 hr (n 
= 9) over the four days in the MWM was compared using a split-plot [6 (group) x 4 (day)] 
ANOVA.  A Fisher LSD was used to compare individual differences among the groups.  
The TBI-30 min group data is the TBI-0.25 from Experiment 1 and is included in the 
data analysis as a basis for comparing the effectiveness of the selected dose of lithium 
when the initiation of treatment is delayed.  The TBI-30 min (p = .031), TBI-8 hr (p = 
.03), Sham-Vehicle and Sham-24 hr (p < .001) groups had significantly lower proximity 
scores, indicating a more direct route to the hidden platform location, as compared to 
the TBI-Vehicle group.  The TBI-24 hr group had significantly higher proximity scores as 
compared to the Sham-Vehicle (p = .001) and Sham-24 hr (p = .008) groups.  The 
proximity scores for the TBI-30 min and TBI-8 hr groups were significantly higher than 
Sham-Vehicle (p = .034 and .036 respectively) but did not differ from the Sham-24 hr 
group (p = .122 and .128 respectively).  (*) indicate comparisons made to the Sham-
Vehicle group.  (†) indicate comparisons made to the Sham-24 hr group.  (#) indicate 
comparisons made to the TBI-Vehicle group.  *, #p < .05.  ††p < .01.  ***, †††p < .001.  
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Figure B4.  Proximity score from probe trial in Experiment 2.  The mean proximity score 
for each treatment group, obtained from the 60 s probe trial (no platform in MWM) on 
postinjury day (PID) 15.  The TBI-30 min group data is the TBI-0.25 from Experiment 1 
and is included in the data analysis as a basis for comparing the effectiveness of the 
selected dose of lithium when the initiation of treatment is delayed.  The bars represent 
the mean ± SEM.  A Fisher LSD post hoc analysis revealed that the Sham-Vehicle (p = 
.039) and Sham-24 hr (p = .009) groups had significantly lower scores (i.e., took the 
most direct route and remained closest to the previous location of the hidden goal 
platform) as compared to the TBI-Vehicle group.  Neither the TBI-30 min (p = .07) nor 
the TBI-8 hr (p = .314) significantly differed from the Sham-Vehicle group.  (*) indicate 
comparisons made to Sham-Vehicle.  (†) indicate comparisons made to the Sham-24 hr 
group, *, †p < .05.  ††p < .01. 
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Appendix C 
 
 
 
The Sham-Lithium group was included in the western blots to determine if lithium alone had any 
effect on the relative abundance levels of the proteins of interest, GAP-43, BDNF, and caspase-3.  
The raw values from the relative optical density from each subject were divided by the 
corresponding value from the analysis the β-actin, and the resulting value was converted to the 
percent of Sham-Vehicle.   
 
 
Figure C1.  Comparison of β-actin levels between sham groups.  Lithium is associated 
with a relative abundance of β-actin at multiple time points after injury.  Data are 
expressed as mean ± SEM.  The analysis of the β-actin protein levels were not 
consistent across all treatment groups and blots, indicating that there were differences 
in the total concentration of proteins loaded on the gel.  However, β-actin, a cytoskeletal 
protein, appears to be differentially affected by lithium-treatment and injury.  The levels 
of β-actin protein in the Sham-Lithium group show a significant increase in this protein 
as compared to other treatment groups, suggesting that lithium treatment may affect β-
actin.  *p < .05.  ***p < .001.  
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Table C1. 
 
Comparison of GAP-43 levels between Sham-Vehicle and Sham-Lithium groups in the 
ipsilateral hippocampus for each postinjury time point  
Note.  An independent samples t-test was used to compare the raw data (relative 
optical density) and data normalized to β-actin between Sham-Vehicle and Sham-
Lithium groups at each postinjury time point.  All data are expressed as the % Sham-
Vehicle. PID = postinjury day. 
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Table C2. 
 
Comparison of BDNF levels between Sham-Vehicle and Sham-Lithium groups in the 
ipsilateral hippocampus at each postinjury time point 
Note.  An independent samples t-test was used to compare the raw data (relative 
optical density) and data normalized to β-actin between Sham-Vehicle and Sham-
Lithium groups at each postinjury time point.  All data are expressed as the % Sham-
Vehicle.  PID = postinjury day. 
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Table C3. 
 
Comparison of proform caspase-3 levels between Sham-Vehicle and Sham-Lithium 
groups in the ipsilateral hippocampus at each postinjury time point. 
 
Note.  An independent samples t-test was used to compare the raw data (relative 
optical density) and data normalized to β-actin between Sham-Vehicle and Sham-
Lithium groups on PID 1 & 7.  All data are expressed as the % Sham-Vehicle.  PID = 
postinjury day. 
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